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SYNOPSIS of PhD Project
Multicellular organisms have evolved a number of highly regulated barriers to
oncogenic and stressful stimuli, including apoptosis, autophagy and senescence. The
tumor suppressor p53 plays a pivotal and pervasive role in setting and executing such
failsafe programs. During the last years three negative regulators of p53 functions,
which are often deregulated in cancer cells have been identified in Claudio Schneider
laboratory at LNCIB, Trieste. These include: calpain, hGTSE-1 (Monte et al., 2003;
Monte et al., 2004) (Bublik in preparation) and MAGE-A tumor antigens, (Monte et al.,
2006). In particular calpain was shown to inhibit susceptibility to p53-dependent
apoptosis (Benetti et al., 2001), to regulate the transcription competent β-catenin pool
(Benetti et al., 2005; manuscript attached), to activate specific NF-kB survival pathways
(Demarchi et al., 2005), and more recently to be involved in the regulation of the
autophagy-apoptosis switch (Demarchi et al., 2006; Demarchi et al., 2007; manuscripts
attached).
The research project described in this thesis stems from these previous findings and it is
part of a broader project aimed to dissect the calpain/calpastatin network interference in
autophagic signalling. The ultimate scope of the project is to understand the molecular
basis by which these pathways can enhance cancer cell survival through the analysis of
novel targets involved in the regulation of the specific failsafe programs.
In particular, in this work we focused on the transcriptional regulation of autophagic
signalling. To this aim, using bioinformatic tools, we performed an in silico analysis of
a set of autophagic genes promoters and identified beclin 1 as a novel NF-kB
transcriptional target. Notably, three NF-kB binding sites with different scores emerged
from the in silico analysis of a region located around 1100 bp upstream of the ATG
sequence of beclin 1. By means of luciferase reporter assays, we demonstrated that p65
overexpression enhances beclin 1 promoter activity, while its depletion leads to a
decrease of transcriptional activity.
Upon induction of autophagy by ceramide and tamoxifen, previously reported to induce
beclin 1 transcription, p65 depletion didn’t show any significant effect on beclin 1
promoter driven transcription, possibly due to the interference of other transcription
factors.
4Indeed, a 380bp 3’ region of beclin 1 promoter encompassing the NF-kB putative
binding site with highest stringency, was responsive both to ceramide and tamoxifen
treatment.
A significant decrease of beclin 1 mRNA levels was observed after p65 depletion by
means of qPCR experiments, clearly demonstrating that p65 is involved in the
regulation of beclin 1 transcription. Moreover, data obtained by semi-quantitative RT
PCR experiments, highlighted the existence of alternatively spliced forms of beclin 1
and suggest that a complex and finely tuned regulation of beclin 1 transcription might
occur and lead to different autophagic outcomes (survival/death).
Furthermore, induction of p65 expression led to increased beclin 1 protein steady state
levels in an inducible p65 cell line system. Consistently, a net decrease of beclin 1
protein levels was observed both in an inducible IkBα  cell line and in an adeno-
associated virus (AAV) encoding IkBSR infected cell system.
Accordingly, we found that p65 is required for autophagy induction both in basal
conditions and following ceramide and tamoxifen treatment. Indeed, p65 depletion or
IkBSR (super repressor) overexpression, are coupled to a clear reduction of LC3I to
LC3II processing and autophagosome formation.
In the light of the data presented in this thesis, it is likely that NF-kB transcription factor
activity is required for the proper regulation and for determining the final outcome of
the autophagic process. Indeed, preliminary ChIP data suggest p65 binding to beclin 1
promoter. Other NF-kB target genes have been demonstrated to regulate autophagy
showing both negative (e.g. Bcl-2, Bcl-XL and IL-13) and positive (e.g. IL-2, HIF-1,
BNIP3, PTEN and IFNγ) autophagy induction abilities. Given that NF-kB transcription
factor activation is a complex event that triggers waves of transcription, we suggest that
it could be required for proper autophagy regulation in different cellular contexts and
following different autophagic stimuli, in such a way to maintain both cellular
homeostasis and to regulate cell stress responses.
In the light of the obtained evidences, proper understanding of the relationship between
NF-kB and autopahgy is thought to be fundamental to clarify the basic molecular
mechanisms that determine cell death and survival during tumor progression.
5INTRODUCTION TO NF-kB FAMILY OF TRANSCRIPTION FACTORS
Nuclear factor-kappa B (NF-kB) transcription factor family consists of a series of
proteins conserved from the phylum Cnidaria to humans and absent in yeast and in
Caenorhabditis elegans in which NF-kB genes have been probably lost.  The Rel/NF-kB
family is comprised of the vertebrate NF-kB1 (p50/p100), NF-kB2 (p52/p100), Rel A
(p65), c-Rel and Rel B, the viral oncoprotein v-Rel, Xenopus X-Rel1 and the
Drosophila Dorsal, Dif and Relish factors. Usually, the diction NF-kB indicates homo-
and heterodimers formed by the five members of this family; the ability of these
members to form a variety of homo- and heterodimers is responsible for the subsequent
differential control of gene expression. Along with NF-kB other regulatory proteins
namely IKK (IkB kinase) and IkB are fundamental for the proper activation and
termination of NF-kB signaling.
NF-kB transcription factors and the pathways controlling NF-kB activation are best
characterized in immune and inflammatory response (Hayden et al., 2006), but they also
represent the nuclear effectors of an intricated cellular pathway activated in response to
a large number of extracellular stimuli in many cells; indeed, it plays important roles in
a myriad of physiological and pathological scenarios in the organisms and at the cellular
level regulating the expression of hundreds of human genes that are involved in diverse
and key cellular and organismal processes including cell proliferation, cell survival, the
cellular stress response, inflammation, innate and adaptive immune responses,
secondary lymphoid organ development, osteoclastogenesis and oncogenesis.
Targeted genes responsive to the activated form of NF-kB in immune response can be
grouped into those encoding cytokines, cell surface receptors, acute phase proteins and
viral genomes including HIV-1. Genes involved in cell cycle adjustment, apoptotic
response and different kinases are also linked with NF-kB activation. Because of the
ability of NF-kB to regulate a diverse set of genes, specific gene expression pattern
induced by NF-kB should be expected to have a profound effect in determining
different cellular phenotypes, such as differentiation or transformation and cell death or
survival.
6Structural domains of the NF-kB family of transcritpion factors and of their
regulatory proteins IKK and IkB
NF-kB family of transcription factors
NF-kB family of transcription factors is composed of two subfamilies that differ for
their structural organization at the C-terminal domain: the ‘Rel’ and the ‘NF-kB’
subfamilies that can either homo- or hetero-dimerize for determining gene expression
specificity.
 NF-kB transcripion factors subfamilies dimers recognize 9-10 base pair DNA sites
called ‘kB sites’ which are characterized of great variability (5’-GGGRNWYYCC-3’;
R, denotes a purine; N, denotes any base; W, denotes an adenine or thymine and Y
denotes a pyrimidine base) and both these subfamilies share a highly conserved 300-
amino acid N-terminal domain called Rel Homology Domain (RHD) (Baldwin, 1996;
Huxford et al., 1998), responsible for dimerization, interaction with the IkB family of
NF-kB inhibitors, nuclear translocation and DNA binding. The C-terminal end of the
RHD each protein bears a nuclear localization signal (NLS) (Latimer et al., 1998).
Crystallographic determination of RHD structure of several NF-kB family members
shed light on the Ig-like structure of 100 amino acids located in the C-terminal of the
RHD, and demonstrated that this subdomain is fully responsible for dimerization; for
this reason it is referred to as DimD (Huang et al., 2001). In the formation of most of the
dimers, each monomer contributes symmetrical β-strands that pack against each other to
form a β-sheet dimer interface. The amino acid residues constituting the dimer interface
are highly conserved across the whole NF-kB family. Nonetheless, the interactions
occurring at the dimer interface are not the only contributors for dimerization selectivity
in that amino-acid sequences located outside of the dimer interface are also thought to
be crucial, especially when considering RelB that is unable to homodimerize and in
vivo gives rise to a swapped, interwined domain (Huang and Ghosh, 2005).
The N-terminal subdomain (NTD) of the RHD is resulted to be crucial for NF-kB
contacting the DNA. Just as the DimD, it folds into an Ig-like domain making both
specific and aspecific contacts with DNA, while DimD domain can give rise only to
sequence non-specific interactions; the linker peptide connecting the two subdomains,
that is the DimD and the NTD, also makes both specific and non specific contacts with
DNA (Hoffmann et al., 2006).
7The Rel subfamily includes RelA (p65), RelB and c-Rel proteins which contain, besides
the N-terminal RHD, a C-terminal transactivation domain that doesn’t seem to be
conserved across the species at the sequence level but that retains the ability of
activating transcription in many species including yeast.
The NF-kB subfamily consists of NF-kB1 (p105) and NF-kB2 (p100) genes, which
contain the N-terminal RHD and are distinguished by long C-terminal domains that
contain multiple copies of ankyrin repeats (ARD/ANK) and that can function like IkB
proteins to sequester NF-kB dimers in an inactive state in the cytoplasm. NF-kB
proteins are synthesized as long precursors, and their C-terminal processing corresponds
to the activation of NF-kB pathway, in order to generate two shorter active DNA-
binding subunits, p50 and p52 respectively, that are finally able to regulate gene
expression by homo- or heterodimerizing with members of Rel subfamily (Perkins,
2007).
Processing of p100 and p105 can occur through several machanisms depending on the
upstream activation of the pathway; p105 infact, is activated both in the absence of cell
stimulation and subsequently to the activation of the so called ‘canonical pathway’ (see
below): in these settings, p50 generation depends on a co-translational mechanism as a
consequence of proteolysis of the p105 nascent polypeptide by the 26S proteasome
(Cohen et al., 2004). Finally, p105 calpain–mediated processing has been demonstrated
to occur in response to ceramide treatment (Demarchi et al., 2005). Instead, p100
processing depends on the ‘non canonical pathway’ activation (see below), where p52
formation is the result of phosphorylation-induced, ubiquitin-dependent processing of
p100 by the 26S proteasome (Bonizzi et al., 2004).
IkB Kinases: the IKK complex
Most of the diverse NF-kB activation signalling pathways converge on serine/threonine
IkB specific kinases (IKK) which are essential in signal transmission since they are able
to phosphorylate IkB inhibitory proteins and target them to proteasomal degradation.
Two major types of pathways leading to NF-kB activation have been described: the
canonical pathway and the non canonical one, both of which require IKKs activity for
NF-kB activation.
In the canonical pathway, the major player in IkB phosphorylation is a large 700-900
kDa complex with high specificity for serine residues in the destruction box of IkBα
(Chen et al., 1996) and requiring ubiquitination for its full activation.
8Figure 1: Mammalian members of the NF-kB, IkB and IKK families: members of each family and
domains involved in their regulation are shown. (Perkins N.D., 2007; Nature)
.
The basic components of this complex are IKKα, IKKβ active kinases and IKKγ/
NEMO (NF-kB essential modifier) regulatory subunit (DiDonato et al., 1997; Mercurio
et al., 1997; Woronicz et al., 1997).
Both IKKα, and IKKβ contain an N-terminal kinase domain (KD) characterized by
similar, but functionally different activation loops (T-loop): IKKβ is the primary target
for proinflammatory stimuli and shows a higher catalytic activity towards IkBα than
IKKα in the canonical pathway; in turn, IKKα is a more proficient kinase for p100 and
plays a pivotal role in the activation of the non canonical pathway.
Of note, only IKKα KD bears a functional NLS (nuclear localization signal, aa 233-
240) (Sil et al., 2004), while a ULD (Ubiquitin Like Domain, aa 307-384) is present
within the IKKβ KD and it has been demonstrated to be crucial for its functional
activity (May et al., 2004).
Other structural components of IKKα and IKKβ are the more C-terminal leucine zipper
(LZ) and putative helix-loop-helix (HLH) motifs and the NEMO binding domain
(NBD). LZ domain mediates dimerization of the kinases that is required for their
activity (Karin, 1999). HLH domain intramolecular association with KD switches on
IKK kinase activity and seems to be important in the postinductive downregulation of
9the kinase itself (Hayden and Ghosh, 2004); finally, both IKKα and IKKβ bind to
NEMO regulatory subunit via a short conserved sequence referred to as NEMO binding
domain (NBD) and located at distal C-terminal.
The third core component of the IKK complex is the non-catalytic regulatory protein
NEMO (IKKγ, IKKAP1, or Fip3). NEMO protein is highly conserved and represents an
absolute requirement for IKKα and IKKβ activity: cells lacking NEMO cannot be
activated by any of the classical NF-kB stimuli (TNFα, IL-1 or LPS). At the structural
level, NEMO contains three coiled-coil regions (CC1-3), a leucine zipper (LZ) motif, a
ubiquitin binding domain (UBD) located within the minimal oligomerization domain
(MOD), and a C-terminal zinc finger (ZF) required for NEMO activation in response to
genotoxic stress (Huang et al., 2002). NEMO oligomerization is necessary for IKK
complex activation, in that once in an oligomeric state, NEMO can act as a scaffold
allowing the cross-phosphorylation of the kinase dimers. N-terminal specific sequences
of NEMO are then important for its interaction with IKKα and IKKβ (aa 1-196 and aa
65-196 for IKKα  and IKKβ binding, respectively) and represent NEMO’s kinase
binding domain (KBD) (Tegethoff et al, 2003).
IkB proteins
IkB family members are characterized by the presence of five to seven ankyrin repeats
(ARD/ANK) that assemble into elongated cylinders that bind the NF-kBs dimerization
domain, such that their nuclear localization signal (NLS) is masked leading to
cytoplasmic retention of the complex (Perkins, 2007). ARD domains seem to mediate
also IkBs nuclear localization (Turpin et al., 1999). C-terminal and N-terminal regions
of IkBs also contain leucine-rich nuclear export sequences (NES) (C-term aa 265–277;
N-term aa 42-54) that are recognized by CRM1 receprtor and promote IkB nuclear
export (Henderson and Eleftheriou, 2000).
There are seven IkB family members: IkBα, IkBβ, IkBε, IkBγ and BCL-3; p100 and
p105 (p52 and p50 precursors respectively) also belong to this family, in that they
present ARD/ANK domain in their C-terminal that inhibits NF-kB signalling.
Conversely, BCL-3 IkB family member is distinguishable for its ability to interact with
p50 and p52 and function as a nuclear co-activator rather than as a repressor of NF-kB
signalling (Zhang et al., 2007).
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IkBα, IkBβ, IkBε contain a conserved motif at the N-terminus consisting of two serine
residues susceptible to phosphorylation by IKKβ , and one or two inducibly
ubiquitinated lysine residues; both the phosphorylation and ubiquitination events are
crucial for IkB targeting to proteasomal degradation.
Besides the ARD/ANK domain and the N-terminal motif previously described, IkBα
and IkBβ  proteins present in their C-terminal a motif associated with protein
degradation termed PEST (domain rich in Proline); serine and threonine residues within
this domain are phosphorylated by Casein Kinase II (CK2) that is activated by atypical
NF-kB pathways and this event seems to trigger calpain mediated proteolysis of IkBα
(Romieu-Mourez et al., 2002). Furthermore, it has been reported that following serum
starvation and consequent increase of reactive oxygen species (ROS), an IkB long-lived
pool underwent to selective lysosomal proteolysis. This degradation event seemed to
require lgp96 (lysosomal glycoprotein-96 protein) and binding of hsc-73 (heat shock
protein-73) to a KFERQ motif of IkB. This alternative IkB degradation mechanism is
phosphorylation and ubiquitination independent, suggesting that, during cell starvation,
chaperone mediated autophagy rather than the proteasome, might trigger IkB
degradation (Cuervo et al., 1998).
Signaling Pathways to NF-kB: the ‘canonical’, the ‘non-canonical’ and the
‘atypical’ pathways
As discussed above, IKK ser/thr kinases act as a bottleneck for all the pathways that
converge on NF-kB. IKK kinases phosphorylate and trigger the degradation of IkB
family members, then enhancing NF-kB transactivation of target genes. Nonetheless
these pathways are characterized by significant differences for the great variability
among the selectivity and kinetics of IkB degradation, the different IKK and adaptor
proteins and NF-kB dimers involved, leading to consequent different persistences of
NF-kB activation. Indeed, all these aspects confer to individual NF-kB responses the
ability to generate waves of activation and inactivation of various NF-kB family
members that can influence the nature of the transcriptional response to a given stimulus
(Hayden and Ghosh, 2004).
Further complexity to NF-kB signalling has emerged recently, with the characterization
of atypical pathways involving IKK-independent mechanisms of activation as well as
different utilization of IKK activity.
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The canonical NF-kB pathway
The canonical or classical NF-kB pathway is the most frequently observed, it occurs
ubiquitously and is induced in response to a variety of stimuli such as TNFα (Tumor
necrosis Factor alpha), IL-1 (Interleukin 1), engagement of the T-cell receptor (TCR)
and of B-cell receptor (BCR), bacterial infection, stimulation with lipopolysaccaride
(LPS) etc.
Consequently to the engagement of the receptor, the signal is transduced through
adaptor molecules to the IKK complex that phosphorylates IkBα , targeting it for
proteasomal degradation. The whole process occurs within minutes and is finely
regulated at each level.
TNFR engagement represents the more explicative model of activation of NF-kB
classical pathway and results in NF-kB, p38, JNK and caspase activation.
Consequently to trimeric TNFα binding, TNFR oligomerizes, dissociates from SODD
(Silencer of death Domain) endogenous inhibitor of TNFR, and becomes active. This
receptor family lacks intrinsic enzymatic activity and needs to recruit adaptor molecules
for transducing the signal through its cytoplasmic TNFR-associated death domain
(TRADD) (Perkins and Gilmore, 2006). TRADD, consequently, directly recruits
downstream TNF-receptor associated factor (TRAF) family of adapter molecules. In
particular, TRAF2 and TRAF5 seem to be required specifically for NF-kB signalling
via TNFR, in that TRAF2/5 double knockout cells show impaired TNF-induced IKK
activation (Tada et al., 2001). Following TNFα stimulation, TRAF2 directly recruits
IKKα and IKKβ by binding to the relative LZ domains (Devin et al., 2001). TRAF2 is
also responsible for Receptor Interacting Protein 1 (RIP1) kinase recruitment that in this
setting works as a scaffold molecule becoming K-63 ubiquitinated due to the E3-ligase
actitvity of TRAF. Consequently RIP1 can nucleate the assembly of a signaling
complex that leads to IKK activation. Notably, TRAFs E3 ligase activity is also
fundamental for K-63 ubiquitination of NEMO; polyubiquitin binding domains (UBDs)
of these proteins mediate their recruitment in a signaling complex where activation of
IKK by trans-auto-phosphrylation can occur (Hayden and Gosh 2004; Scheidereit,
2006) thereby activating IKKβ. Activated IKKβ then phosphorylates IkBα at serines 32
and 36, which causes IkBα to become a substrate for the Skp1, Cdc53/Cullin1, F-box
protein βtransducin repeat containing protein (SCFβTrCP) E3 ligase complex, and to be targeted to
proteasomal destruction. This event causes the release of p50-, p65- and c-Rel
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containing heterodimers and allows them to relocate to the nucleus. Once in the nucleus
p50/p65, and p50/c-Rel heterodimers can bind and transactivate antiapoptotic genes
among which Bcl-XL, cIAP-1 and 2, FHC (Ferritin Heavy chain), MnSOD (Manganese
Superoxide Dismutase), IkBα and many others.
The canonical NF-kB pathway can be terminated in several ways, the more striking of
which occurs through a negative feedback: being the induction of IkBα transcription
activated by NF-kB, newly synthesized IkBα can enter the nucleus, bind NF-kB
heterodimers and relocalize them into the cytoplasm. Two other IkB family members
that are not regulated by NF-kB, IkBβ and IkBε can inhibit this signaling. Other
negative feedback loops also exist, in that genes encoding de-ubiquitinating enzymes
such as Cylindromatosis protein (CYLD) and A20, which can degrade ubiquitinated
K63 chains of TRAF and NEMO and counteract NF-kB activation process, are both
RelA/c-Rel/p50 transcriptional targets. Conversely, positive feedback loops can also
occur: c-Rel and Rel-B genes, together with the precursor proteins NF-kB1 (p105/p50)
and NF-kB2 (p100/p52), contain kB elements in their promoter and this implies that the
composition of NF-kB complex can change over time resulting in temporal changes in
the spectrum of genes that will be induced and repressed (Saccani et al., 2003). Another
positive feedback loop leading to fine regulation of NF-kB signalling, has been
demonstrated to occur consequently to serum starvation: in this setting, an increase in
ROS intracellular levels leads to NF-kB activation; contemporarily, a long-lived IkB
pool undergoes a selective pathway of lysosomal proteolysis. This long-lived pool of
IkB might allow cells to increase NF-kB transactivation potential more slowly than the
proteasome pathway regulating in this manner long-lasting NF-kB signalling (Cuervo et
al., 1998).
The non canonical NF-kB pathway
Non canonical or alternative NF-kB pathway is activated in response to a limited
number of stimuli such as stimulation of CD40, lymphotoxin-β receptor (LTβ), B-cell
activating factor of the TNF pathway (BAFF), and some viruses Human T-cell
Leukaemia virus (HTLV-1), latent membrane protein-1 (LMP-1) of Epstein-Barr virus
(EBV), Tax Kaposi’s sarcoma-associated Herpes Virus (KSHV), viral FADD-like
interleukin-1-β-converting enzyme (FLICE/ caspase8)-inhibitory protein (vFLIP) and
specific engagement of members of TNF receptor associated factor (TRAF)-binding
receptors of TNF receptor superfamily (Hauer, et al, 2005).
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Of note, activation of non canonical pathway does not require the formation of IKKα,
IKKβ and IKKγ complex, rather proceeds through IKKα homodimer formation and
activation. Actually there is no direct evidence supporting the involvement of a separate
IKK complex composed exclusively by IKKα homodimers in the non canonical
pathway. Nevertheless a major role for IKKα emerges from the analysis of IKKβ and
IKKγ knockout cells in which these two subunits seem to be dispensable for this
alternative pathway activation (Bonizzi and Karin, 2004).
Activation of the non canonical pathway proceeds via NF-kB inducing kinase (NIK)
which phosphorylates the T-loop serines of IKKα , leading to its activation and
dimerization. NIK activated IKKα dimer, in turn, phosphorylates p100 within its C-
terminal domain at Ser-866 and Ser-870 (Senftleben et al., 2001, Perkins, 2006). These
phosphorylations create an SCFβTrCP
 
binding site on p100 and trigger K48-linked
ubiquitination at K-856 of p100, then inducing its processing to p52. In most of the
circumstances the final outcome of this process is p52 association with RelB (Bonizzi
and Karin, 2004). p52/RelB heterodimer then shuttles into the nucleus, and binds with
higher affinity to distinct kB elements, resulting in the regulation of a specific subset of
genes (Hoffman et al., 2006).
Interestingly, activation of non canonical pathway by viral Tax and vFLIP proteins
again occurs through a physical recruitment of IKKα to p100, but does not require NIK
for p100 processing (Xiao et al., 2001).
A feature of the alternative pathway is the slow kinetic of the onset of p100 to p52
conversion, that requires several hours compared to the fast IkBα processing that occurs
within minutes. The alternative pathway also results in long-lasting NF-kB activation
and de novo synthesis is required, while in the canonical pathway it is not. It is very well
estabilished that non canonical signaling induced by both CD40 or BAFF receptor
induces TRAF3 degradation and concomitant enhancement of NIK expression and this
event requires de novo synthesis. In this context, TRAF3 acts as an inhibitor of the
pathway, interacting directly with NIK and targeting it for proteasomal degradation
(Liao et al., 2004).
Interestingly, recent data indicate that autophagic pathway may represent an alternative
to proteasomal TRAF3 targeted NIK degradation. Infact, inhibition of Hsp90 by
Geldanamycin treatment induces NIK degradation through an autophagic process and in
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this settings, it may suppress NIK induced p100 processing, typical of the NF-kB
alternative pathway (Qing et al., 2007).
Atypical pathways of NF-kB activation
Although the canonical and alternative pathways account for most of the physiological
inducers of NF-kB, there is growing evidence that different physiological and not-
physiological stimuli trigger NF-kB nuclear localization and DNA binding. These
alternative mechanisms of NF-kB activation can be both IKK-dependent or -
independent.
Concerning IKK-independent mechanisms, it has been demonstarted that short
wavelength ultraviolet (UV-C) light or expression of Her2/ erbB-2/Neu oncogene can
lead to casein kinase II (CK2) dependent phosphorylation and to subsequent
degradation of IkBα  (Kato et al, 2003; Ramieu–Mourez et al., 2002). In these
circumstances, IkBα phosphorylation by CK2 occurs at serine residues within its C-
terminal PEST domain instead of at classical N-terminal serines 32/36. UV-C light CK2
dependent phosphorylation of IkBα also depends on p38 MAP kinase pathway (Kato
Fig 2: Pathways leading to NF-kB activation: canonical, non-canonical and atypical pathways (ND
Pekins and TD Gilmore, 2006; Cell Death Diff.)
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et al., 2003), while with Her2/erbB-2/Neu, IkBα degradation results from calpain
activity rather than from the proteasome.
Other IKK-independent mechanism of NF-kB activation have been proposed to be
activated in response to UV-C, hypoxia/reoxigenation, hydrogen peroxide or
pervanadate treatment and nerve growth factor (NGF) stimulation. In these
circumstances, IkBα phosphorylation occurs at tyrosine-42 and probably requires C-
terminal PEST sequence for IkBα degradation to take place (Schoonbroodt et al., 2000;
Perkins, 2007). However, in other settings, thyrosine-42 phosphorylation of IkBα does
not target it for degradation and rather enhances Ikbα dissociation from NF-kB
complexes (Perkins, 2007). Interestingly, as activated IKKα  and IKKβ  also
phosphorylate RelA, these IKK-independent pathways have the potential to induce
differentially modified forms of NF-kB subunits with distinct functions.
Some atypical mechanisms of NF-kB induction can be IKK dependent, but exhibit
functional differences to classical and alternative IKK-dependent activation pathways.
Genotoxic stimuli such as ionizing radiations or chemotherapeutic drugs (e.g.
camptothecin and etoposide), lead to an NF-kB induction that requires IKKγ-dependent
IKKβ activation. Here, NEMO translocates into the nucleus where it is first sumoylated
on Lys-277and Lys 309 and then phosphorylated by the ataxia telangiectasia mutated
checkpoint kinase (ATM) on Ser-85; sumoylation on NEMO is then replaced by mono-
ubiquitination that causes NEMO to leave the nucleus as a complex with ATM (Perkins,
2007). The NEMO-ATM complex, once in the cytoplasm, can activate IKKβ through a
process requiring IKK-associated protein ELKS (a protein rich in E, L, K and S
residues) (Wu, et al., 2006). However, it remains to be determined whether this atypical
pathway is engaged by all genotoxic stimuli and in all cell types.
The existence of these alternative NF-kB pathways underlines the heterogeneity of the
mechanisms leading to NF-kB activation; indeed some stimuli such as UV-C, are able
to activate both IKK-dependent and -independent alternative pathways.
Post-translational modifications regulating NF-kB activity and function
The enormous complexity that characterizes NF-kB, IkB and IKK post-translational
modifications has been elucidated in recent years and has shed light on their
contribution in enabling the fine control of NF-kB function. These regulatory
modifications which include phosphorylation, ubiquitination, acetylation, sumoylation
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and nitrosylation, determine the specificity of NF-kB regulated gene expression and its
functionality as a regulator of critical cellular pathways such as cell growth, cytokine
and chemokine secretion and apoptosis.
IKK complex
Induction of NF-kB by many stimuli requires activation of IKK through different
postranslational modifications.
The first step in IKK complex activation involves IKKγ modification through K-63
linked ubiquitination. In the case of NEMO, different sites of ubiquitination and
different E3 ubiquitin ligases are involved in its K-63 ubiquitination, depending on the
activating upstream stimulus: TCR activation resullts in Bcl-10/MALT1-mediated and
TRAF-6 dependent K63 ubiquitination at lysine 399, while TNFα and IL-1 require
TRAF2 and TRAF5. By contrast, bacterial infection seems to require nucleotide binding
oligomerization domain (NOD2/CARD15) and receptor interacting protein 2 (RIP-2)
for K-63 ubiquitination of NEMO at lysine 285. In the classical pathway K-63 linked
ubiquitinated IKKγ behaves as a K-63 linked polyubiquitin binding protein and binds
polybiquitinated RIP-1. Ubiquitination removal is due to CYLD or A20 activation and
is required for terminating NF-kB response (Perkins, 2006).
This cascade of modifications, therefore, serves to oligomerize and activate the
pathway. Polyubiquitination of adapter and signalling proteins allows, for example,
TAK1 K-63 ubiqutinated kinase targeting to IKK complex in response to TNFα, IL-1,
TLR and TCR mediated activation of NF-kB. TAK, in turn, phosphorylates IKKβ
within the serine loop at Ser-177 and 181 and renders it competent for IkBα
phosphorylation response (Perkins, 2006).
Other kinases involved in IKKβ activation have been described, such as PDK1, SGK
and MEKK3 (Perkins, 2006; Tanaka et al., 2005), although the mechanism by which
these kinases are targeted to IKK complex is not known. Moreover, c-Src-dependent
phosphorylation at Tyr-188 and Tyr 199 in response to TPA (12-O-
tetradecanoyilphorbol-13-acetate) and TNFα has also been reported. In addition to all
these kinases, autophosphorylation of IKKβ is catalysed by oligomerization of the
whole complex and requires IKKβ mono-ubiquitination at Lys-163 (Carter et al., 2005).
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IKKβ is also subjectected to S-nitrosylation at Cys-179 within the activation loop, and
this modification inhibits IKKβ activity (Reynaert et al., 2004); interestingly, the same
nitrosylation is required for some natural product-mediated inhibition of IKKβ (Chen et
al., 2006; Perkins, 2006).
A further regulatory post-translational event is represented by IKKβ-mediated IKKγ
phosphorylation at Ser-31, Ser-43 and Ser-376, and might serve to potentiate IKK
complex activation (Perkins, 2006).
Different IKKγ modifications are then induced by genotoxic stress. As already reported
in these circumstances IKKγ is first sumoylated on Lys-277 and Lys-309, then
phosphorylated by ATM on Ser-85 and finally initial sumoylation is replaced by mono-
ubiquitination (See Atypical Pathways).
Alternative IKKα modifications take place in response to activation of NF-kB non
canonical pathway. Here, NIK-mediated activation of IKKα  occurs through
phosphorylation at IKKα Ser-176 and Ser-180 and in some cell types Akt/Protein
Kinase B dependent phosphorylation of IKKα at Thr-23 has been reported (Hacker and
Karin 2006).
Modifications of IkB proteins
IKKβ principal role in activating NF-kB signalling is phosphorylation of IkBα (Hayden
and Gosh, 2004) that represents the major NF-kB inhibitor. IkBα, β  or ε proteins,
contain N-terminal IKKβ target serine residues that, once phosphorylated, trigger their
own SCF-βTrCP E3 mediated K-48-linked ubiquitination and proteasomal degradation
with different kinetics. Other kinases than IKKβ can phosphorylate IkBα: as already
discussed, CK2 engagement following UV-C light exposure or overexpression of Her2
oncogene, allows IkBα phorsphorylation at Ser-283, Ser-289 and Ser-293 or at Thr-291,
and Thr-299 residues inside the PEST C-terminal domain, and these modifications
target IkBα for degradation. Conversely, CK2-mediated IkBβ phosphorylations at
Serines 313 and 315 can block its NF-kB inhibitory activity. IkBα has also been
reported to be inhibited by p56-lck, Syk and c-Src tyrosine kinases following
hypoxia/reoxygenation, hydrogen peroxide exposure and NGF treatment by direct
phosphorylation on Tyr-42 residue.
Another post-translational modification affecting IkBα activity is sumoylation at Lys-21
by SUMO-1 (small ubiquitin-like modifier 1), which counteracts IkBα ubiquitination at
18
the same residue. This event renders IkBα refractory to proteasomal degradation.
Interestingly, IkBα  sumoylation seems to be inhibited by IkBα N-terminal
phosphorylation (Perkins et al., 2006).
Bcl-3 IkB family member is also highly susceptible to phosphorylation, but little is
known about the sites and the kinases involved, and only GSK3β kinase has been
demonstrated to induce Bcl-3 degradation by phosphorylating it at Ser-394 and –398 in
unstimulated cells. Furthermore, K-63-linked polyubiquitination of Bcl-3 has been
demonstrated to regulate its nuclear localization (Viatour et al., 2004).
Modifications of NF-kB subunits
As already discussed, non canonical and canonical pathways activation occur through
different post-translational modifications of NF-kB subunits. Processing of p105 to p50
in the canonical pathway takes constitutively place in a co-translational manner, and
inducible degradation of p105 can also occur without p50 generation (Perkins, 2007).
Ikkβ has been shown to phosphorylate p105 at Ser-927 and Ser-932, and this event
targets p105 to SCF-βTrCP-mediated ubiquitination and subsequent proteasomal complete
degradation. Interestingly, IKKβ can also induce SCF-βTrCP independent processing of
p105, that in this case leads to p50 generation (Perkins, 2006).
Fig.3: Modulation of the transcriptional activity of p65 phosphorylation (Viatour P., Merville M-P.,
Bours V. and Chariot A; TiBS, 2005)
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In resting cells, p105 is phosphorylated by GSK3β at Ser-903 and Ser-907, causing
p105 stabilization and p105 processing in response to TNFα stimulation (Demarchi et
al., 2003). p105 processing  has also a regulatory role, indeed it seems to be required for
Tpl2/COT kinase release and MAP kinase pathway signalling. When physically
associated with p105, Tpl2 kinase is unable to phosphorylate MEK1 substrate (Babu et
al., 2006), but it retains the ability to phosphorylate p105, indicating that its kinase
activity is not impaired by the association with p105.
Processing of p100 involves IKKα activity: phosphorylation occurs at Ser-866 and Ser-
870 of p100 and results in SCF-βTrCP-mediated K-48 linked polyubiquitination of p100
on Lys 855 (Amir et al., 2004). Following this initial phosphorylation events, IKKα
further phosphorylates p100 at additional serine residues within the Rel Homology
Domain, in order to ensure correct p100 to p52 processing or in order to regulate proper
p52 dimerization or DNA binding (Perkins, 2006).
Rel members need also to undergo cytoplasmic modifications for efficient and specific
signaling. RelA is phosphorylated by PKA (protin kinase A) at a highly conserved Ser-
276; also p50 and c-Rel undergo PKA-mediated phosphorylation at equivalent sites of
RelA Ser-276 (Guan et al., 2005). In the nucleus, the same Ser-276 residue of RelA
(and the equivalent residue of c-Rel) undergoes MSK1 kinase mediated phosphorylation
and this modification seems to disrupt intramolecular interactions between RelA N-and
C-termini, allowing DNA binding and p300/CBP co-activators recruitment (Perkins,
2006). Thr-254 RelA phosphorylation by an unknown kinase is thought to be necessary
for pThr-254Pro motif generation in RelA. This motif allows peptidyl-prolyl isomerase
(Pin1) binding, favouring disruption of RelA/IkBs interactions and RelA translocation
into the nucleus. Pin-1 also protects RelA from SOCS-1-mediated ubiquitination and
degradation (Ryo et al., 2003). As Thr-254 is within RelA RHD Pin-1 could also be
expected to affect RelA DNA binding and transcriptional activity.
Multiple RelA phosphorylation sites and candidate kinases have been reported to have a
modulatory role on its transcriptional activity. Phosphorylation at Ser-536 and Ser-529
residues within the TA1 subdomain can stimulate RelA transactivation (Viatour et al.,
2005) and have been detected in response to many inflammatory stimuli. Multiple Ser-
536 kinases have been described: IKKβ, IKKα , IKKε, NF-kB activating kinase
(NAK/TBK1/TANK-binding kinase-1), and RSK1 (Perkins, 2006). By contrast, only
CK2 has been demonstrated to phosphorylate Ser-529. TA1 contains many other
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phosphorylable residues, suggesting that other regulatory events might occur in this
region. Other phosphorylation sites within the TA2 subdomain of RelA have been
recently characterized. Ser-468 is a target for GSK3β, IKKε and IKKβ phosphorylation
in response to TNF, IL-1β and T-cell stimulation. These modifications can both activate
or inhibit NF-kB signalling and occur in different cellular compartments. Thr-505
phosphorylation within TA2 inhibits RelA transactivation by inducing increased
association with HDAC1 and requires ARF mediated Chk1 checkpoint kinase activation
(Rocha et al., 2003; Campbell et al., 2006). Phosphorylation on Thr-435 by an unknown
kinase has also been reported to inhibit RelA activation (Perkins, 2006). It is noteworthy
that these phosphorylations occur within evolutionarily conserved TA subdomains,
suggesting that they regulate RelA association with co-activators and corepressors.
RelA is also inducibly acetylated at a number of sites, and these modifications have
different effects on its activity. CBP and p300 co-activators acetylate RelA at Lys-218, -
221 and-310 and enhance RelA DNA binding and transcriptional activity. Of note,
RelA Ser-276 and –536 phosphorylation results in an increased p300 binding and
therefore in enhanced RelA acetylation at Lys-310 (Perkins, 2006).
With regard to the other NF-kB subunits, PKCζ , NIK and IKKε  inducible
phosphorylation of c-Rel occurs at different serine residues and generally stimulates c-
Rel activity. RelB Ser-368 (Ser-276 equivalent of RelA) phosphorylation regulates its
dimerization with p52. p50 DNA binding activity is enhanced by Lys-431, -440 and
–441 acetylation. p52 acetylation leads to different outcomes: it is, infact, thought to
either induce p100 to p52 processing or to increase its DNA-binding activity (Deng et
al., 2006).
Biological roles of NF-kB and IkB proteins
The signaling pathways that regulate life and death of a cell are the subject of intense
biological studies, since mutations or misregulation of components of these pathways
often give rise to defects in apoptosis and are implicated in a large number of diseases,
such as neurodegeneration and cancer.
NF-kB family of transcription factors can be found in all cell types and has revealed a
great diversity of functions and context in which it becomes activated. NF-kB proteins,
infact, are regulators of the immune, inflammatory, stress, proliferative and apoptotic
responses of a cell to a very large number of stimuli. Moreover, many reports suggest
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apparently opposing or contradictory functions for NF-kB. Furthermore, NF-kB
response is integrated with important pathways in the cell, such as p53 tumour
suppressor pathway, JNK pathway and others (Dutta et al., 2006; Hoffman et al., 2006;
Tergaonkar and Perkins, 2007).
NF-kB was first identified as a regulator of the expression of the kappa light chain gene
in murine B-lymphocytes, and most of initial research had focused on understanding its
function in the innate and adaptive immune responses. The importance of the NF-kB
family members in the regulation of various aspects of immune system development,
immune response and inflammation as well as in regulating apoptosis in the immune
system, in the liver, nervous system, hair follicles and epidermal appendages, has been
very well unveiled by studies on transgenic or knockout NF-kB mice (Tripathi and
Agarwal, 2006).
Concerning the innate immune response an essential involvement of classical NF-kB
pathway has been demonstrated, in that its activation is associated with increased
transcription of a number of genes coding for chemokines, adhesion molecules and
cytokines, all of which are required for migration of inflammatory and phagocytic cells
to tissues and for pathogen destruction (Kucharczak et al., 2003). In these settings
different Toll-like receptor (TLRs) isotypes are competent for specific pathogen pattern
recognition, and activate NF-kB transactivation of a plethora of genes encoding
inflammatory molecules and enzymes (IFNγ, IL-12 and iNOS). For example, TLR4 is
the receptor for LPS component of Gram-negative bacteria and for some viruses; TLR2
recognizes a larger variety of microbial products (peptidoglycans and lipoproteins) and
TLR5 recognizes bacterial falgellin; TLR3 and TLR9 recognize bacterial DNA or
double-stranded RNA, respectively. Cellular types involved in innate immunity
response are monocytes and macrophages, but also non-immune cells such as
fibroblasts, endothelial and epithelial cells (Tripathi and Aggarwal, 2006).
Many of the events involved in innate immune response are also critical to subsequent
adaptive immune response. In this context, survival of peripheral blood cells in response
to antigens depends on BCR-mediated activation of NF-kB and induction of
antiapoptotic target genes. c-Rel knockout primary B cells undergo apoptosis upon
mitogenic stimulation; lack of p50 demonstrated that this member of NF-kB family is
important for the survival of quiescent B-cells; similar impairments in B-cell
proliferation and survival has emerged from IKK-β and IKK-γ knockouts. Furthermore,
c-Rel and RelA double knockout caused B cell failure to mature IgM(lo) and IgD(hi).
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Attenuation of apoptosis in response to BAFF-R engagement has been found to be
necessary for B-cell development. All these phenotypes have shed light on a protective
role of NF-kB in B-cell survival, due to the ability of these transcription factors to
transactivate antiapoptotic genes such as Bcl-2, Bcl-XL and Bfl1/A1 (Tripathi and
Aggarwal, 2006). B-cell activation and effector function of NF-kB has been clearly
demonstrated by studies performed on mice deficient in NF-kB1, NF-kB2, RelA, c-Rel
or BCL-3 genes and in all these models a compromised humoral response was observed
due to defects in B-cell maturation and proliferation or to defective immunoglobulin
class switching. NF-kB2, RelB and c-Rel have also important functions in
hematopoietic and non-hematopoietic lineages and regulate second limphoyd organs
development and architecture.
NF-kB family members are also directly involved in regulating T-cell functions, since
an adaptive T-cell response is balanced by proliferation and expansion of antigen-
specific T-cell during the initiation of the response and the loss of excess T-cells as the
response resolves. In this case TCR engagement and co-stimulatory signalling by CD28
is required for full activation of naive T-cells. This event triggers NF-kB activation and
subsequent cell survival via NF-kB mediated induction of antiapoptotic genes Bcl-2 and
Bcl-XL (Zheng et al., 2003). Analysis of activated CD4+ or CD8+ T cells indicates that
while NF-kB mediated induction of Bcl-XL and Bfl1/A1 is transient, Bcl-2 activation is
delayed and IL-2 dependent (Verschelde et al., 2003). It has also been reported that
E2F1 and p73 are involved in induction of apoptosis in mature T cells (Green, 2003),
and in these settings a NF-kB dependent mechanism might antagonize cell death.
Indeed, the identification of a kB site in the vicinity of p73 first exon suggested that NF-
kB might interfere with E2F mediated transactivation of p73, counteracting, in this way,
cell death (Kucharczak et al., 2003). All these evidences reveal a mechanism underlying
the protective effects of inflammation and innate immunity towards T-cell apoptosis in
the adaptive immune response (Gerondakis and Strasser, 2001). In contrast, NF-kB
contribution to apoptosis has also been reported in mature T cells during activation-
induced cell death (AICD) and it is imputable to NF-kB induction of FasL expression
and subsequent activation Fas-death cascade (Zheng et al., 2001).
As illustrated, NF-kB represents a key player of the inflammatory response for its
ability to increase the expression of many cytokines, enzymes and adhesion molecules,
and its deregulation has been found to be involved in many inflammatory chronic
diseases such as asthma, rheumatoid arthritis, psoriasis, inflammatory bowel disease and
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allergic diseases. All chronic inflammatory pathologies show an increased production of
IL-1β, TNF-α , IL-5, IL-6, GM-CSF and iNOS enzyme and many therapeutic
intervention is then oriented in trying to suppress NF-kB activation. NF-kB is, indeed,
the target of many anti-inflammatory drugs, such as nonsteroidal anti-inflammatory
drugs (NSAIDs), glucocorticoids and immunosuppressant drugs, and several natural
products (Gilmore and Herscovitch, 2006).
NF-kB, as previously discussed, represents a key player in the development and
selection of T- and B-lymphocytes and it is critical for maintainance of immunological
homeostasis through its ability to regulate apoptosis.
Other in vivo studies on RelA-/- mice provided clear evidence for NF-kB role in
preventing apoptosis in different contexts. In fact, RelA deficient mice die as embryos
manifesting massive liver apoptosis as a consequence of circulating TNF stimulation
(Beg and Baltimore, 1996; Alcamo et al., 2001), a phenotype observed also in IKKβ
deficient mice. Further studies demonstrated that RelA cytoprotective function in
response to TNFα and other pro-inflammatory molecules was due to its ability to induce
several survival genes, such as TRAF-1, TRAF-2, c-IAP1, c-IAP2, IEX-IL, Bcl-XL and
BfI-1/A1. On the other hand, kB binding sites have been found also in the promoters of
IL-1β converting enzyme protease, c-myc and TNF-α genes, which are commonly
involved in signal-induced programmed cell death. Studies in hepatocytes treated with
TGF-β (transforming growth factor-β) unveiled again a protective role for NF-kB, as
TGF-β induces apoptosis by stabilizing IkBα and inactivating NF-kB (Kucharczak et
al., 2003).
NF-kB has been demonstrated to have an essential role in the development, survival and
homeostasis of hair follicles and epidermal appendages (skin, teeth and eyes) and this
has been very well illustrated by mice expressing a degradation-deficient IkBα and in
heterozygous NEMO females, both of which manifest epidermal diseases resembling
human anhydrotic ectodermal dysplasia (HED) and incontinentia pigmenti (IP),
respectively (Fusco et al., 2004; Kucharczak et al., 2003).
Although most studies link NF-kB with prosurvival functions and prevention of
apoptosis, several studies have clearly demonstrated a pro-apoptotic role of NF-kB
because, along with AP-1, it can induce FasL expression and in some circumstances
such as long term treatment of chronic inflammatory diseases, its continuous
suppression could manifest itself in squamous cell carcinoma (Lind et al., 2004).
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Notably, in the nervous system NF-kB represents a double-edged sword, inducing both
anti- and pro-apoptotic processes. All cell types of the nervous system express
functional p50/p65 heterodimer that can be induced by several stimuli such as
membrane depolarization, nerve growth factor (NGF), activity-dependent neurotrophic
factor (ADNF), opioids, the secreted form of β-amyloid protein, TNF, adhesion
molecules and glutamate (Mattson and Meffert, 2006). Several mechanisms of
activation and inhibition of NF-kB are known to affect neuronal survival in the context
of developmental cell death and neurodegenerative disorders. Environmental insults
such as oxidative and metabolic stress, neurotoxins and physical trauma trigger NF-kB
activation whereas intracellular signals such as calcium, ROS and ceramide mediate
stress- induced modulation of NF-kB activity. These intracellular signals are linked to
specific receptors at the plasma membrane and use several pathways to activate NF-kB,
including calcium/calmodulin-dependent kinase II, Akt and PKC. Target genes of NF-
kB that promote neuron survival encode BDNF, Bcl-2, Bcl-XL, N-methyl-D-aspartate
receptor subunits, MnSOD and IAPs. NF-kB has been implicated in NGF-mediated
protection of developing sensory neurons to cytokines (Mattson and Meffert, 2006); in
neurons, NF-kB becomes activated by binding of NGF to either p75NTR or TrkA
receptors. TRAF6 mediates signaling downstream of p75NTR leading to activation of
both NF-kB and JNK, and is linked to both pro-survival and pro-death functions. TrkA-
linked p62 scaffold protein binds to atypical PkC and TRAF6 and acts as a platform for
crosstalk between p75NTR and TrkA. Selective stimulation of these receptors and
consequent NF-kB activation results in induction of sets of genes with significant
overlap, suggesting that temporarily different waves of response can occur consequently
to receptors stimulation by neurotrophins.
RelA-/- neurons show decreased survival compared to the wild type counterpart
(Hamanoue et al., 1999). Moreover, NF-kB-mediated protective role against
neurodegeneration in cortical neurons exposed to the amyloid β-peptide associated with
Alzheimer’s disease has also been reported. In this context, increased levels of IkBα
and decreased NF-kB prosurvival activity lead to neurodegeneration (Bales et al., 1998).
Surprisingly, an increased NF-kB activity has been observed in Parkinson’s and ALS
(amyotrophic lateral sclerosis) neurodegenerative diseaseses. However, in these settings
NF-kB activity might activate an early defense mechanism against oxidative stress and
mytochondrial disfunction (Mattson and Meffert, 2006). By contrast, proapoptotic
effects for NF-kB have also been described in some models of neuronal cell injury, and
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most of them seem to converge on p53 tumor suppressor. p53 is a detrimental factor for
neuronal viability in response to ischemia/reperfusion and excitotoxic stress. For
example, NMDA receptor activation in rat striatum activates NF-kB and leads to a
concomitant increase of p53 and c-myc expression, inducing cell death (Kucharczak et
al., 2001). Although it is well documented that in certain settings NF-kB promotes the
expression of proapoptotic genes, an alternative mechanism is represented by the
cellular milieu of the central nervous system: NF-kB-mediated production of
proinflammatory cytokines, ROS, excitotoxins and induction of nitric oxide synthase in
glial cells might indirectly promote cell death, resulting in glia-mediated neurotoxicity.
A unifying hypotesis concerning the role of NF-kB in neurons is that activation of NF-
kB in neurons could promote cell survival, while its activation in glial cells may induce
the production of neurotoxins (Mattson and Meffert, 2006).
Another important context in which NF-kB activation leads to contradictory biological
outcomes is viral infection. For many viruses, activation of NF-kB has been linked to
their transforming activity. The first identified member of the Rel/NF-kB family has
been v-Rel, the oncogene from avian Rev-T virus, derived from the cellular gene c-Rel
that induces fatal lymphoma/leukemia in young birds (Gilmore, 1999). Oncogenic
potential of v-Rel and of the other members of Rel/NF-kB family arises from their
ability to suppress apoptosis from a variety of signals by upregulating antiapoptotic
proteins. Many other viruses have utilized multifunctional proteins to hijack and
stimulate NF-kB pathway. Tax oncoprotein of human T-cell leukaemiua virus type-1
(HLTV-1) that causes adult T-cell leukaemia (ATL) immortalizes T-cells by inducing
NF-kB mediated upregulation of antiapoptotic genes. LMP-1 protein of human
herpesvirus Epstein-Barr virus implicated in Burkitt’s lymphoma also induces NF-kB
signalling and increases expression of Bfl1/A1. Interestingly, this increase confers
protection against apoptosis induced by growth factor deprivation in EBV-positive cell
line (D’Souza et al., 2000). v-FLIP protein of human herpesvirus 8 (that causes
Kaposi’s sarcoma) also suppresses apoptosis triggered by growth factor deprivation by
constitutive inducing IKK activity and Bcl-2 expression (Liu et al., 2000). Consistent
with these evidences, many other viral proteins such as Tat, Vpr, Nef, X4 and gp120 of
HIV virus (Choe et al., 2001; Fakruddin et al., 2004), A224L protein of African swine
fever virus (ASFV) etc (Hiscott et al., 2006), affect NF-kB signalling to counteract
apoptosis and to enhance viral replication and pathogenesis.
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HIV infection leads to the progressive loss of CD4+ T cells and the almost complete
destruction of the immune system in the majority of infected individuals. The earlier
step in this viral infection is mediated by envelope glycoproteins, which bind to CD4
and to the coreceptors CCR5 or CXCR4. Interestingly, binding of X4 Env expressed on
cells to CXCR4, besides triggering apoptosis of uninfected CD4+ T, can also induce
autophagy and accumulation of Beclin 1 via CXCR4 (Espert et al., 2006; Espert et al.,
2007).
Some viral proteins exploit NF-kB signaling to induce cell death. This is the case of
Dengue, Sindbis and reovirus that promote cell death in infected cells; another example
is E1A human adenovirus protein that has been reported to block IKK activity
(Kucharczak et al., 2001).
Interestingly, when considering Sindbis virus, NF-kB seems to behave in a
contradictory manner. In Sindbis virus infection, Bcl-2 induction decreases Sindbis
virus replication in mouse brains, resulting in protection against lethal encephalitis. In
the same context, the Bcl-2 interacting protein Beclin 1 has also been reported to
increase mice survival. The mechanisms by which Beclin 1, in cooperation with Bcl-2-
like proteins, functions to inhibit Sindbis virus replication and Sindbis virus-induced
neuronal death are unknown, but it has been suggested that binding to Beclin somehow
might protect Bcl-2 (or Bcl-XL) from cleavage by caspases, thereby preventing Sindbis
virus-induced cell death (Liang et al., 1998). This is, probably, another example in
which the contradictory role of NF-kB in regulating both apoptosis and cell survival is
determined by the death stimulus, by the cellular context and by the timing of
modulating NF-kB activity relative to the death stimulus.
Overproduction of NF-kB antiapoptotic target genes has confirmed an undisputed pro-
survival and pro-oncogenic role of this transcription factor; moreover, through its
antiapoptotic activity NF-kB can also reduce the effectiveness of many common target
therapies, which themselves activate NF-kB (Luo et al., 2005).
Nevertheless, NF-kB in some settings seems to behave as a tumor suppressor. For
example, RelA has been shown to oppose epidermal proliferation driven by TNFR1 and
JNK, and keratinocytes from mice lacking RelA are hyperproliferative in vitro. (Zhang
et al., 2004). Also in this context contradictory NF-kB behaviour has been observed.
Concerning with another example of NF-kB tumor suppressor function, some studies
have shed in light that p53 tumor suppressor can activate NF-kB via MEK1 and pp90rsk
mediated Ser-536 phosphorylation, and that NF-kB plays a crucial role in p53 mediated
27
apoptosis (Ryan et al., 2000). Moreover, it has been reported that loss of p65 can cause
resistance to different agents that signal death through p53; this loss is able to enhance
tumorigenesis induced by E1a and Ras (Ryan et al., 2004). In addition to p53, ARF can
regulate also RelA activity through activation of ATM-and Rad3-related (ATR)/Chk1
checkpoint kinases, but in this case ARF signalling is thought to lead to Thr-505
phosphorylation of RelA and to repress the induction of Bcl-XL sensitizing cells to
TNF-induced apoptosis (Basseres and Baldwin, 2006).
    
Fig.4: Different abilities of NF-kb in either promoting or suppressing tumor formation. (Perkins N.D. and
Gilmore T.D., 2006; Cell Death Diff.)
It is then well established that, by regulating gene expression, NF-kB can promote a
plethora of oncogenic processes: tumor cell proliferation through its ability to induce
proto-oncogens such as cyclin D1 and c-myc; metastasis through its mediated induction
of cellular adhesion molecules and metalloproteinases; angiogenesis through regulation
of vascular endothelial growth factor and cell immortality through regulating telomerase
(Luo et al., 2005). Furthermore, other pathways can influence NF-kB transcriptional
activity adding a major level of regulation to NF-kB pro-oncogenic potential. Notably,
NF-kB can further contribute to the tumorigenic process through its effect on infiltrating
and non-cancerous macrophages; indeed, the secretion of NF-kB-regulated cytokines
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and growth factors from these cells, helps to drive tumor cell proliferation and size
(Greten et al., 2004).
With regard to the links of NF-kB to other pathways, a crosstalk between p53 tumor
suppressor pathway and NF-kB has been demonstrated. In contrast to what discussed
previously, NF-kB can also contribute to suppression of p53 activity through the
induction of hdm2 expression, an inhibitor of p53 (Basseres and Baldwin, 2006).
Finally, direct proapoptotic function of NF-kB rely on its ability to directly transactivate
apoptosis-inducing genes, such as Fas, Fas-ligand and death receptors 4 and 5, TNFα,
Bcl-XS, p53 and death receptor (DR) ligand TRAIL (Kucharczak et al., 2003).
Interestingly, one study demonstrated that c-Rel-induced expression of TRAIL
receptors DR4 and DR5 along with Bcl-XS was able to sensitize cells to TRAIL-
induced apoptosis (Chen et al., 2003). It has to be noted that in a model of lumen
formation in mammary gland acini, TRAIL induction has been demonstrated to be
required both for apoptosis and autophagic process to occur (Mills et al., 2004).
Another important basis for NF-kB tumor activity is its ability to prevent reactive
oxygen species (ROS) induced apoptosis and in this context NF-kB crosstalk with JNK
pathway is thought to be fundamental. Several mechanisms have evidenced that NF-kB
activation results in suppression of JNK activity. These include induction of Gadd45β
expression, which functions as an inhibitor of the upstream MKK7 kinase and induction
of XIAP, which, in addition to inhibit caspase-3 and –7 activities, can inhibit JNK. As
discussed above, RelA-/- mice die for massive liver TNF-α induced apoptosis. TNF-α
stimulation leads to increased ROS intracellular levels and, in this circumstance, JNK
pathway and caspase activation trigger cell death. NF-kB activation directly counteracts
both caspases and JNK effects, leading to cell survival (Bubici et al., 2006). Another
interesting feature of NF-kB is that it can be directly activated by ROS and counteract
ROS signalling through the transactivation of several genes such as ferritin heavy chain
(FHC), manganese superoxide dismutase, metallothionein and glutathione S-transferase.
In various tumors, NF-kB and ROS/JNK signaling appear therefore to have opposing
effects. Infact, inducers of JNK cascade (MKK4, BRCA-1, JunB and JunC) have been
implicated in tumor suppression, and both ROS and JNK can mediate tumor cell killing
inflicted by radiation and some anticancer drugs. Conversely, NF-kB activation
promotes cell viability during oncogenic transformation and survival of late-stage
tumors (Bubici et al., 2006).
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Recent work suggested a novel antiapoptotic function of NF-kB activation. NF-kB has
been proposed to negatively regulate autophagy consequently to TNFα treatment using
Ewing sarcoma stably expressing IkBα and in MCF-7 cells (a breast cancer cell line
haploinsufficient for Beclin 1 one of the key players proteins of the autophagic process).
It has been observed that consequently to TNFα treatment, an increase in ROS was
implicated in autophagic vacuole formation. In these settings NF-kB has been proposed
either to counteract ROS formation or to engage mTOR kinase, indeed reducing the
overall autophagic activity of the cells (Djavaheri-Mergny et al., 2006). This work
agrees with previous data linking ROS to autophagy and describing a death-related
pathway, referred to as type II PCD, which is induced by high levels of ROS (Yu et al.,
2004; Kiffin et al., 2006). Interestingly, a more recent work demonstrates that under
starvation conditions, a consequent increase of ROS levels takes place and is both local
and reversible (Shertz-Shouval et al., 2007). Data presented by the authors argue for a
biphasic role of ROS in autophagy induction: an initial rapid increase in ROS levels
occurs consequently to starvation, requires both PI3K class III kinase and Beclin 1 and
favours early steps of the autophagic process; after this initial steps, the need of ROS
buffering is required for the cells to complete the autophagic response, since a
prolonged oxidizing environment inhibits the activity of Atg4 redox-sensitive enzyme
that is necessary during the late steps of the autophagic process. Altogether, data
presented in this work suggest that an unrestrained increase in ROS levels inhibits
autophagy. Moreover, this study argued for an involvement of ROS in starvation-
induced autophagy as signaling molecules of a survival pathway rather than of a death
one.
INTRODUCTION TO THE AUTOPHAGIC PROCESS
Normal cellular development and growth require a well regulated balance between
protein synthesis and degradation. Eukaryotic cells have two major avenues for
degradation, the proteasome and autophagy. Autophagy, which literally means “self
eating”, is a major mechanism for degrading long-lived cytosolic proteins and cellular
organelles, such as peroxisomes, mitochondria and endoplasmic reticulum and, unlike
the proteasome, terminates at the lysosome/vacuole, whereas the ubiquitin-proteasome
system degrades specific short-lived proteins (Yorimitsu et al., 2005).
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The autophagic process is evolutionarily conserved from yeast to mammals, and it was
initially characterized in yeast as a mechanism used to promote survival under
metabolic stress. In fact, consequently to nutrient starvation high levels of autophagy
are induced in order to allow unneeded proteins to be degraded by the lysosome and the
amino acids to be recycled for the synthesis of proteins essential for survival. Akin to
yeast, in higher eukaryotes autophagy is induced in response to nutrient depletion that
occurs in animals at birth after severing of the trans-placental food-supply, as well as in
nutrient starved cultured cells and tissues (Kuma et al., 2004). Besides nutrient
starvation, autophagy can be activated by many other forms of stress, including energy
starvation (Lum et al., 2005), oxidative stress (Droge et al., 2007), mitochondrial
dysfunction (Jin S., 2007), endoplasmic reticulum stress (Yorimitsu and Klionsky,
2007) and infections (Espert et al., 2007), playing an essential role in cell survival, in
many phisiological cellular processes such as lifespan extention (Massey et al., 2006;
Cuervo et al., 2005), and during development and differentiation (Levine and Klionsky,
2004). Due to the large spectrum of functions in which it is involved, an impairment of
autophagy is thought to be detrimental in many pathological conditions, among which
cancer, muscolar disorders and neurodegenerative diseases (Levine and Klionsky, 2004;
Cuervo, 2006; Martinez-Vincente and Cuervo, 2007). In addition, autophagy has a very
well estabilished role in the intracellular resistance to pathogens, contributing to
endogenous MHC class II antigen processing and presentation of viral, bacterial, self-
and tumor antigens (Münz, 2006; Menéndez-Benito and Neefjes, 2007). Conversely,
there is evidence that autophagy is involved in type II programmed cell death (PCD)
and might contribute to the pathology of some diseases (Bursch, 2004).
Three different types of autophagy have been described in mammalian cells:
macroautophagy, microautophagy and chaperone-mediated autophagy (CMA) (Shintani
et al., 2004; Cuervo, 2004). These three pathways differ in the procedures of delivering
substrates to lysosomes, in the nature of these substrates and in the mechanisms
involved in their regulation. Both micro- and macroautopahgy involve dynamic
membrane rearrangements: microautophagy consists in the direct engulfment of
cytosolic regions by the lysosome membrane (Reggiori and Klionsky, 2002), while
macroautophagy involves the sequestration of cytoplasm into a double-membrane
cytosolic vescicle, termed autophagosome, before delivering to lysosomes. CMA
process allows degradation of specific cytosolic proteins that contain a penta-peptide
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consensus motif, indeed being more selective and having a limited degradative capacity
(Cuervo et al., 2005; Massey et al., 2006).
Autophagy was morphologically identified at first in the 1960s in mammalian cells;
however, the molecular mechanism for this process has only recently begun to be
elucidated. One breakthrough for studying the molecular basis of autophagy was
achieved in S.cerevisiae strain defective in proteinases A and B and in carboxipeptidase
Y (CPY). Infact, shifting of this yeast strain from vegetative to nutrient-deficient
conditions induced the formation of vescicles that were called autophagic bodies.
Electron microscopy analysis of the autophagic bodies revealed that their content
appeared morphologically indistinguishable from cytoplasm. Subsequent examination
of yeast strains that failed to accumulate autophagic bodies led to the identification of
several genes involved in this process (Tsukada and Ohsumi, 1993; Thumm et al.,
1994), which were termed autophagy-related genes (ATG) (Klionsky et al., 2003).
Besides micro- and macro-autophagy in yeast, an additional lysosomal pathway has
been characterized, which involves most of ATG genes products and is referred to as
‘cytoplasm-to-vacuole’ (Cvt) pathway. This additional lysosomal pathway differs from
autophagy for it has a biosynthetic function, leading to the transport of specific resident
vacuolar hydrolases (aminopeptidase I [ApeI] and α-mannosidase [Asm1]) into the
vacuole (Kim and Klionsky, 2000). The study of both autophagy and Cvt pathways
allowed the identification of the ATG genes. Currently, more than 25 ATG genes have
been identified in yeast, and the relative protein products seem to be specific to the
autophagic process. Additionally, orthologs of the ATG genes have been recently
identified and functionally characterized in higher eukaryotes such as mammals, insects,
worms and plants; they all have been shown to play essential roles in autophagic
cellular functions (Kim and Klionsky, 2000). These findings have revealed that the
molecular machineries of autophagy found in yeast are also commonly utilized in
several others eukaryotic cells, underlying the high conservation of this process also at
the molecular level.
Induction and regulation of autophagy
Autophagy occurs at basal levels in normal growing conditions to perform homeostatic
functions. Nonetheless, it is rapidly upregulated in response to some environmental
stress and developmental transitions. In yeast, one of the major players in the
autophagic regulation is the evolutionarily conserved target-of-rapamycin protein
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(TOR) that specifically responds to nitrogen levels and behaves as a negative regulator
of autophagy. In mammalian cells, the nutritional status and other cues such as
temperature, oxigen concentrations and hormonal factors, are fundamental in the control
of autophagy and such conditions tightly regulate mTOR activity.
Downstream of TOR kinase, several genes essential for autophagy and yeast related
pathways have been characterized, although the nutrient sensor upstream of TOR
remains unknown (Noda and Ohsumi, 1998). Under nutrient-rich conditions, active Tor
kinase switches on protein translation and synthesis and inhibits autophagy whereas, in
the absence of an adequate supply of nutrients, Tor becomes inactive and autophagic
catabolism provides amino-acids and other components necessary for cell survival. The
mammalian Tor protein (mTOR) also senses environmental changes in order to
modulate autophagy, but the mechanism of regulation may be more complicated than in
yeast. In yeast TOR controls the phophorylation state of Atg13, one of the proteins
required for autophagy. In nutrient-rich conditions, mTOR mediated phosphorylation of
Atg13 confers lower affinity for Atg1, a kinase involved in autophagic induction, and in
this condition autophagy is repressed. In contrast, under starvation conditions or
following treatment with the Tor inhibitor rapamycin or rapalogs, Atg13 is rapidly and
partially dephosphorylated and interacts with Atg1 with higher affinity (Matsuura et al.,
1997); the net result of this interaction is an increase of autophagic activity. Atg1 is the
sole serine/threonine protein kinase identified among the Atg proteins, and it is essential
both for the Cvt pathway and for autophagy (Harding et al., 1996). The role of Atg1
activity still remains arguable. However, the Atg1 kinase complex might be crucial for
the induction and regulation of the autophagic process, possibly by swithcing between
the Cvt pathway and autophagy in response to environmental changes.
The Atg1-Atg13 complex also interacts with several proteins, such as Vac8, Atg11 and
Atg17. Atg11 and Vac8 are also phosphorylated independently of the Atg1-Atg13
complex, although the role of such phosphorylation is currently unknown (Scott et al.,
2000). Atg17 is required for autophagy under starvation conditions, while it is not
needed for the Cvt pathway under nutrient-rich conditions. The interaction of the Atg1-
Atg13 complex with Atg17 is thought to have a major role in the regulation of
autophagosome biogenesis in that Atg17 mutants that are not able to interact with Atg1-
Atg13 complex show reduced autophagic capacity. These results suggest that the Atg1-
Atg13-Atg17 complex might play a role in autophagy which is likely to be different
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from induction, and might be involved in autophagosome formation, by specifically
determining the ultimate size of vescicle. Although Atg1 is conserved in mammals, it
remains to be estabilished how the Atg1 hortholog acts in mammalian autophagic
system. In contrast, Atg13 and Atg17 horthologs have not been identified in mammals
yet.
In yeast there are two TOR genes, TOR1 and TOR2 that give rise to two different
complexes which share several functions such as regulation of translation, ribosome
biogenesis, amino-acid transport and autophagy; unlike TOR1, TOR2 has additional
functions on cytoskeleton regulation that cannot be inhibited by rapamycin (Loewith et
al., 2002; Jacinto et al., 2004).
In mammals, a unique TOR gene exists that gives rise to two TOR complexes: mTOR
Complex1 (containing mTOR, GβL, and raptor) which is rapamycin sensitive and
mTOR Complex2 (containing mTOR, GβL, and rictor) that is rapamycin insensitive.
Early studies in mammalian cells established that the regulatory cascade upstream of
mTor includes a class I phosphatidylinositol (PtdIns) 3-kinase (PI3K class I), PDK1 and
Akt/PKB, while the phophatase PTEN acts antagonistically to the PI3K class I to induce
autophagy. Amino acids are the most powerful inhibitors of autophagic sequestration
activating the mTOR and S6K signalling cascade through a mechanism that is still
unknown (Oldham et al., 2003). Besides amino acids, also hormones have a role in
modulating autophagy; in fact, in mammals, hormones such as insulin or glucagon act
antagonistically in modulating autophagy in the liver, but only at intermediate amino
acid concentrations (Cuervo et al., 2005). Insulin alone, in fact, is not able to induce
S6K phosphorylation and activation and actually, high levels of amino acids do not
require the presence of insulin; on the other hand, glucagon inhibits S6K and stimulates
proteolysis at intermediate levels of amino acids (Bugnet et al., 2003). In any condition,
a linear relationship has been observed between the percentage of inhibition of
autophagic proteolysis and the phosphorylation status of S6K, indicating the importance
of this event in the regulation of autophagy (Blommaart et al., 1995). Also the inhibition
of mTOR kinase with rapamycin reduces the phosphorylation of S6K, consequently
inducing the autophagic pathway independently of aminoacids. Rapamycin not only
induces protein degradation, but also partially reduces protein synthesis, indicating a
coordinate control of opposing processes by the same signaling pathway aimed to the
mantainance of cellular homeostasis (Blommaart et al., 1995).
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The kinase mTOR seems to be the main regulator of the autophagic pathway where
signals derived from both energetic and nutritional status, hormones and cytokines
convey. Earlier studies demonstrated that growth factors and hormones, such as insulin,
regulate mTOR Complex 1/S6K1 activation via calss 1 PI3K. These kinase resides near
to the plasma membrane and its products are the lipids phosphatidylinositol-3,4-
biphosphate (PI(3,4)P2) and phosphatidylinositol-3,4,5-triphosphate (PI(3,4,5)P3) that
have been demonstrated to have an inhibitory effect on autophagy (Petiot et al., 2000;
Criollo et al., 2007). Insulin and growth factors receptors engagement lead to the
recruitment of adaptor molecules that bring class I-PI3K lipid kinase closer to the
membrane and favour the transient production of (PI(3,4,5)P3). Indeed, (PI(3,4,5)P3)
binds to PKB/Akt, recruiting it to the membrane where it is phosphorylated by
phosphoinositide-dependent  kinase 1 (PDK1) (Stokoe et al., 1997) and mTOR
complex2 (Sarbassov et al., 2005). Activated Akt/PKB, in turn, phosphorylates TSC2
(Tuberous sclerosis complex 2) inactivates its GAP activity towards Rheb (Ras
homolog enriched in brain) and targets it for degradation, subsequently leading to mTor
activation (Corradetti and Guan, 2006), elevated protein synthesis, increased cell growth
and inhibiton of autophagy. Downregulation of both class I-PI3K and mTor leads to
autophagy activation as well as overexpression of the phosphatase PTEN (phosphatase
and tensin homolog deleted from chromosome ten), which removes the phosphate from
the 3-position of PI(3,4)P2 and PI(3,4,5)P3 avoiding downstream signalling (Arico et al.,
2001).
At present it is not clear whether aminoacids regulate mTOR directly or through the
TSC1/2 complex, or simply reducing Rheb GTPase activity. It has been recently
suggested that aminoacids can inhibit autophagy independently of mTor based on the
observation that in myotubes rapamycin was unable to abolish the stimulation of
proteolysis by leucine starvation (Mordier et al., 2000). Interestingly recent studies
established a link between human vacuolar protein sorting 34 (hVps34, a class3 PI3K
that uses phosphoinositide as a substrate to produce PtdIns(3)P, and is required for
autophagic induction), and mTOR Complex1. A mechanism by which nutrients and
glucose could lead to its activation was recently shown. In fact, it was demonstrated that
in the absence of TSC1/TSC2, although mTOR Complex1/S6K1 activation was
elevated and refractive to stimulation by insulin, it was still regulated by amino acids
(Nobukuni et al., 2005). It was also demonstrated that overexpression of hVps34 drives
S6K1 activation in the presence, but not in the absence of amino acids (Byfield et al.,
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2005) and stimulation of cells with amino acids increases hVps34 activity. Of note,
hVps34 is the only PI3K found in yeast. Indeed this suggests that the rise of systemic
hormonal regulation during evolution has led to the insulin PI3K class I signalling
pathway in order to control the growth and development of organisms (Nobukuni et al.,
2007). The suggestion that hVps34 is a positive mediator in both autophagy and mTOR
Complex1/S6K1 signalling appears contradictory and the mechanism by PtdIns(3)P
signals to mTOR/Complex1/S6K is unknown. Nonetheless, given the role of PtdIns(3)P
in recruiting proteins containing either FYVE or PX domains, it is possible that hVps34
is involved in forming a signalling complex that includes mTOR Complex1 and S6K.
Moreover, glucose depletion has been reported to inhibit hVps34 activity, suggesting
that amino acids and glucose are converging through a common mechanism to activate
this signalling. Finally, it has recently been found that mTOR co-immunoprecipitates
with hVps34 (Nobukuni et al., 2007).
Another possible explanation for the inability of rapamycin to reverse aminoacid-
induced inhibition of autophagy in some cell types is that mTOR is present in the two
distinct complexes mTOR Complex1 that is rapamycin sensitive and mTOR Complex2
that is not inhibited by this drug (Sarbassov et al., 2005). Raptor of mTOR Complex1
phosphorylates S6K1 and is involved in controlling cell growth, whereas rictor in the
mTOR Complex2 is required for Ser473 phosphorylation of PKB and controls cell
proliferation and survival. Indeed, the relative amount of mTOR sequestered in each of
these two complexes might determine whether or not autophagy can be accelerated by
rapamycin (Codogno and Meijer, 2005).
Other growth regulatory pathways can affect mTOR and TSC1/2 and mTOR signalling:
Rsk1 and Erk can activate mTOR Complex1 in response to growth stimuli such as
phorbol esthers and EGF by phosphorylating and inhibiting TSC2 (Corradetti and Guan,
2006) even if in some cellular contexts Erk has been shown to activate autophagy
(Meijer and Codogno, 2004). Osmotic stress  (hypertonic stress induced by sorbitol and
mannitol) has been shown to reduce mTOR activity and S6K phosphorylation,
independently of TSC2 and Rheb (Corradetti and Guan, 2006).
Along with the mainteinance of osmotic neutrality, translation and ribosome biogenesis
are energetically expensive processes and low nutrient conditions strongly reduce
mTOR activity, and couple to an increase in AMP concentration enhancing the
autophagic process. Small decreases in ATP content are transmitted to mTOR by AMP-
activated protein kinase (AMPK) which then phosphorylates and inactivates mTor
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signalling and leads to the inhibition of protein synthesis (Corradetti and Guan, 2006).
Interestingly, in murine myotubes, amino acid deprivation or AMPK activation lead to
mTOR Thr2446 phosphorylation, while Ser2448 of mTOR is phosphorylated in response
to amino acids and growth factors. These two phosphorylation sites are mutually
exclusive because phosphorylation of one site inhibits phosphorylation of the other and
vice versa. They may be viewed as switches, which integrate the counteracting signals
of growth factors and nutrient deprivation (Cheng et al., 2004).
Autophagy is induced also in response to death inducing stimuli. For example,
consequently to genotoxic stress, p53 is activated and triggers starvation-like responses
by inhibiting mTOR. Thus a crosstalk between p53 and mTOR pathway was
demonstrated and the means by which p53 is able to inhibit mTOR has been shown to
require AMPK activation and functional TSC1/2 complex. In these ways etoposide
treated cells switch from an anabolic to a catabolic state, and cell growth is halted;
indeed, p53 induced activation of starvation response can represent a rapid damage-
control mechanism that can temporarily prevent transmission of altered genetic material
from mother to daughter cell (Zhaohui et al., 2005). Moreover, it has been found that
PTEN expression can be driven by the p53 transcription factor, underlying again an
important role for p53 in regulating mTOR pathway (Stambolic et al., 2001).
Intriguingly, PTEN has been shown to be upregulated also after TNFα treatment via
NF-kB in human leukemic cells; this effect seems to be cell context dependent (Lee et
al., 2007; Kim et al., 2004).
Another exemple of autophagy induction in response to death inducing stimuli, is
related to the expression of activated forms of death-associated protein kinase (DAPK)
and death-associated related protein kinase-1 (DRP-1). These kinases are positive
effectors of cell death in response to stimuli such as INFγ and TNFα, and trigger
autophagy and cell death independently of caspase activity in carcinoma cells with non-
functional p53 (Shohat et al., 2002; Inbal et al., 2002); moreover the expression of a
dominant-negative form of DRP-1 blocked the induction of autophagy in MCF-7 in
response to tamoxifen treatment (Codogno and Meijer 2005). Also TNF-related
apoptosis-inducing factor (TRAIL) and Fas-associated death domain (FADD) have a
role in promoting both apoptosis and autophagy (Mills et al., 2004; Thorburn et al.,
2005). The ability of FADD to interact with the autophagic protein Atg5 has been
shown to play a crucial role in death induction by INFγ, independently of caspase-8
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activation (Pyo et al., 2005). Induction of autophagy has been observed in fibroblasts
and monocytoid cells in response to the inhibition of caspase-8 (Yu et al., 2004). In this
experimental setting the accumulation of autophagic vacuoles was dependent on
receptor-interacting protein (RIP), a protein associated with the cytoplasmic domain of
the death receptor, and on the activation of JNK and its upstream kinase MKK-7. RIP is
a substrate of caspase-8, which cleaves and inactivates it, indicating that this caspase
plays a role in processes other than apoptosis. Overexpression of hypoxia-inducible
BH3-like domain containing protein (BNIP3) leads to autophagic type II cell death in
cancer cell lines by opening of the mitochondrial permeability transition pore (Daido et
al., 2004). Hypoxia inducible factor (HIF-1) expression has been demonstrated to be
driven by mTOR, and HIF-1, in turn, is able to transactivate RTP801/Redd1 protein and
inhibit mTOR (Corradetti and Guan, 2006). These data seem to be at odds with each
other, but actually, hypoxia has been demonstrated to positively regulate the autophagic
process in different contexts. Moreover, it is possible that hypoxia-mediated inhibition
of mTOR by RTP801/Redd1 occurs at different time points. Of note, RTP801/Redd1 is
also induced in response to energy stress, arsenic and hydrogen peroxide, glucocorticoid
treatment and DNA damaging agents (Corradetti and Guan, 2006).
                         
                         Figure 6: Tor kinase signalling in mammals (Corradetti and Guan 2006)
Also the accumulation of Atg proteins has been observed in mammalian cells
undergoing autophagic cell death, and is dependent on the expression of Bcl-2 family
members (Bcl-2 and Bcl-XL) (Shimizu et al., 2004); moreover an accumulation of
Beclin 1 has been described in ceramide and tamoxifen-induced autophagic death in
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MCF-7 cells (Scarlatti et al., 2004). The upregulation of Atg proteins is probably
important in determining the amplitude of the autophagic response. Indeed, the
accumulation of Atg proteins is not a common trait during starvation-induced
autophagy, the initiation of autophagy not requiring protein synthesis (Gozuacik et al.
2004). On the other hand, autophagic cell death requires protein synthesis (Codogno
and Meijer 2005).
Molecular mechanism of autophagosome formation
Macroautophagy consists in the sequestration of portions of the cytoplasm into double
membrane vescicles that fuse with the lysosomes, leading to the degradation of the
inner membrane along with the content of the autophagosome. One of the first questions
that arise is which is the origin of autophagosomes. It seems that in yeast there is a
putative site called PAS (Pre-Autophagosomal-Structure) where these vesicles appear to
be formed de novo, characterized by the presence of several Atg proteins, that constitute
the machinery required for the formation of autophagosomes (Suzuki et al., 2001; Kim
et al., 2002). In contrast to vesicles that generate by budding, an initial membrane must
be formed in autophagy: this is the nucleation step of vesicle formation. The origin of
this membrane is unknown. There is a general, although not universal, consensus that
the endoplasmic reticulum (ER) is a source of the membrane for forming the vesicle. It
has been reported that ER function and machinery of the early secretory pathway are
required for autophagy and the Cvt pathway in yeast, although further studies are
required for understanding this relationship (Ishihara et al., 2001; Hamasaki et al., 2003;
Reggiori et al., 2004). The absence of conditional mutants in higher eukaryotes has
prevented the analysis of the molecular machinery involved in autophagosome
formation, and, as a consequence, all the studies have been performed mainly at
cytological and morfological level. The existence of autophagosomes precursors in
mammalian cells arose from some electron microscopy studies made in isolated rat
hepatocytes where some thick, osmiophilic membrane multilayer was observed (Seglen,
1987; Fengsrud et al., 1995). These structures were termed phagophores or isolation
membranes and their existence was confirmed by other studies of in vivo visualization
of autophagosome formation using GFP-Atg5. These studies demonstrated that
autophagosomes were generated by elongation of a small membrane structure, indeed
from an autophagosome precursor. Formation of these structures didn’t occur after
tratment of cells with 3-MA or wortmannin, which are known inhibitors of PI3Ks that
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are required at early steps of autophagosome formation (Mizushima et al., 2001).
Furthermore, the same studies demonstrated that autophagosomes maturate from small
cup-shaped cisternae, not simply derived from large pre-existing membranes, even if it
was not clarified whether these small compartments were formed de novo or derived
from some membrane source. These cisternae membranes, indeed, elongate, bend, and
form spherical autophagosomes (Mizushima et al., 2001).
Elongation of the isolation membrane and biogenesis of autophagic vesicles involves
two ubiquitin-like systems: Atg12–Atg5 and Atg8-phosphatidylethanolamine (Atg8-PE)
protein conjugation systems (Ohsumi, 2001; Reggiori and Klionsky, 2002; Levine and
Klionsky, 2004). The Atg12–Atg5 conjugation system, originally discovered in yeast, is
widely conserved among eukaryotes. As in yeast cells, in mammalian cells Atg5 is
mostly present as conjugated with Atg12. The initial step of the conjugation reaction
results from the activity of Atg7 E1-like enzyme, which activates C-terminal glycine
residue of mammalian Atg12. Such an activation results in the formation of an Atg12-
Atg7 thioester intermediate (Tanida et al., 2004). Atg12 is subsequently transferred to
mammalian Atg10 E2-like protein to form Atg12-Atg10 thioester intermediate
(Mizushima et al., 2001). The last step consists in the attachment of C-terminal glycine
of Atg12 to lysine 130 of Atg5 through an isopeptide bond (Mizushima et al., 1998).
Mammalian Atg12-Atg5 conjugate is contained in large complex that contains also the
Atg16L WD protein (Mitsushima et al., 1999). Atg16L, infact, can form homo-
oligomers and mediates the formation of high multimeric structures of tetramers and
octamers Atg12, Atg5, and Atg16L complexes. (Kuma et al., 2002; Mizushima et al.,
2003). Although most of these complexes are cytosolic, small fractions localize on the
isolation membrane during the elongation process being associated to its outer side.
Interestingly Atg12-Atg5-Atg16L complexes dissociate from the membrane upon
autophagosome completion, underlying their requirement to be fundamental during the
elongation step. This requirement has been further confirmed by the expression of an
Atg5 K130R mutant in Atg5 null embryonic stem (ES) cells: such a mutant is no longer
conjugated to Atg12 but, all the same, it localizes at the autophagosome precursor with
Atg16L. However, in this situation, no isolation membrane formation occurs
(Mizushima et al., 2001).
The Atg12-Atg5 system is closely linked to the LC3 (MAP-LC3 microtubule-associated
protein 1 light chain 3) ubiquitin-like system. LC3 is the mammalian orthologue of
yeast Atg8; it is the first protein identified on the autophagosome membrane (Kabeya et
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al., 2000) and requires several postranslational modifications before targeting to
autophagosomes.
Similarly to yeast Atg8 conjugation, C-terminal region of LC3 is cleaved soon after its
synthesis, and this processing is catalyzed by Atg4 cysteine protease (Mizushima et al.,
1998). The resulting processed form, called LC3-I exposes then a glycine residue that
becomes accessible to the E1-like Atg7, the same enzyme used in the Atg12-Atg5
conjugation system (Tanida et al., 2004). Activated LC3 is transferred to Atg3 E2-like
enzyme which is then transferred to Aut1/Atg3 E2-like enzyme (Tanida et al., 2002)
and is finally conjugated to phosphatidylethanolamine (PE). LC3 PE-conjugated form,
called LC3-II, is tightly associated with the autophagosome on both the inner and the
outer membrane bilayer. Unlike the Atg12-Atg5 conjugation, modification of LC3 with
PE is a reversible event, indeed Atg4 can again cleave LC3 after the glycine residue to
remove it from the lipid (Sherz-Shouval et al., 2007; Tanida et al., 2004). LC3-PE
conjugation appears to be regulated in a complex manner in vivo because depletion of
the Atg12-Atg5 conjugate causes instability of LC3-PE. Infact, Atg5 null cells
overexpressing AtgK130R cannot target LC3 to the membrane. In this situation,
autophagy is severely impaired and LC3 shows a diffuse cytosolic staining (Mizushima
et al., 2001). LC3 autophagosomal localization is very well induced by different
autophagic stimuli; for this reason, LC3 is considered one of the best markers for
monitoring the autophagic process. Besides MAP1-LC3, other two Atg8 homologs have
been found in mammalian cells: GATE-16 (Golgi-associate ATPase enhancer of 16
kDa), GABARAP (GABA receptor-associated protein) (Kabeya et al., 2000; Kabeya et
al., 2004). All these proteins appear to be modified with lipids in the same manner and
have been shown to localize to the autophagosome (Kabeya et al., 2004; Sherz-Shouval
et al., 2007).
Indeed, during the membrane formation stage, the Atg12-Atg5-Atg16 complex drives
the expansion and/or curvature of the membrane envelope and finally dissociates from
the vesicle just before, or immediately after completion. On the other hand, LC3-PE is
detected on both the forming intermediate vesicle and the completed autophagosome
(Tanida et al., 2004; Ferraro and Cecconi, 2007).
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Role of PI3-Kinase in autophagosome formation
Among the Atg components, PtdIns 3-kinase is class III has been proposed to play some
role in membrane nucleation. Phosphatidylinositol 3-phosphate (PtdIns(3)P) is known
to have an important role in various cellular functions. There is only one PtdIns 3-
kinase, Vps34, identified in yeast. Vps34 is involved in forming two distinct PtdIns 3-
kinase complexes (Kihara et al., 2001). Complex I is composed of Vps34, Vps15,
Vps30/Atg6, and Atg14, while complex II contains the same proteins, except that Atg14
is replaced by Vps38. Notably, complex I disruption in yeast results in loss of
autophagy and Cvt pathway.
              
Figure 7: Two ubiquitin conjugation systems are involved in vescicle espansion during autophagosome
formation. The result of these conjugations is the translocation of the structural component Atg8 (LC3 in
mammals) to autophagosomal membrane. (Ferraro and Cecconi, 2007)
On the other hand, complex II depletion allows normal progression of autophagy and
the Cvt pathway. PtdIns(3)P is known to be bound by proteins that have PtdIns(3)P-
binding sites such as the PX and FYVE domains. Different yeast proteins, either
containing or lacking PX or FYVE domains, have been found to interact with
PtdIns(3)P and to be involved in either the autophagic process  or in the Cvt pathway:
Atg20 and Atg24, have PX domains, bind to PtdIns(3)P (Nice et al., 2002, Hettema et
al., 2003) and seem to be involved only in the Cvt pathway, although they have been
observed also at the PAS; Atg18, Atg21, and Atg27 also bind to PtdIns(3)P, even if
none of them has known binding domains, and are then recruited to the PAS in a
manner that is dependent on the PtdIns 3-kinase complex I (Guan et al., 2001; Wurmser
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et al., 2002; Stromhaug et al., 2004). Atg18 is required for both the Cvt and autophagy
pathways, whereas Atg21 and Atg27 are primarily required for the Cvt pathway.
During autophagy PtdIns(3)P might mediate the recruitment of some Atg components to
the PAS to enable them to allow their involvement in the vesicle-forming machinery.
Nonetheless further studies are required, because there is no direct evidence that
PtdIns(3)P exists in the putative membrane of the PAS. In contrast to yeast, mammalian
cells regulate autophagy via two PtdIns 3-kinase complexes, namely class I and class III
(Codogno and Meijer., 2005). As discussed above, class I complex has a negative
regulatory role on autophagy induction. This inhibitor effect is mainly due to mTOR
hyperphosphorylation of the regulatory Atg13 protein. Atg13 forms a complex with
Atg17 and Atg1 serine/threonine kinase proteins. Consequently to nutrient rich
conditions, Atg13 m-TOR hyperphosphorylation inhibits its association with Atg1, and
blocks autophagosome formation. On the contrary, nutrient starvation triggers Atg13
dephosphorylation and subsequent association with Agt1, favouring generation of the
autophagosomes. Of note, Atg1 human homologues have been recently characterized,
namely ULK1 and ULK2 (Yang YP et al., 2005; Ferraro and Cecconi, 2007). mTOR
inhibition also enhances Atg8 and Atg14 gene expression. Infact, mTOR activation of
Tap42 leads to PP2A inhibition and PP2A is required to activate some transcription
factors that trigger the transcription of Atg8 and Atg14 genes (Ferraro and Cecconi,
2007).
In mammals, a complex similar to the yeast complex I has been described that involves
the Apg6/Vps30 ortholog Beclin 1 and the Vps34 PI3K class III association and is
required for autophagosome formation. Vps34 PI3K is localized on the trans-Golgi
network and on endosomes and generates PtdIns(3)P; Beclin 1/Atg6 was observed on
trans-Golgi network, complexed to Vps 34 (Kihara et al., 2001), and recently it was
detected also on the endoplasmic reticulum and on mitochondria (Pattingre et al., 2005).
Similarly to yeast, the production of PtdIns(3)P is required to allow the localization of
other autophagic proteins to the pre-autophagosomal membrane (Kihara et al 2001). The
yeast strains lacking APG6 gene are defective in autophagy induction upon nutrient
starvation, and this function can be complemented by the ortholog Beclin 1 from higher
eukaryotes, indicating the involvement of this gene in autophagy (Liu et al., 2005). Also
in mammalian cells the requirement of Beclin 1 in autophagy induction has been
assessed, indeed both beclin 1 deficient ES cells and Beclin 1 -/- mice showed reduced
autophagic activity (Yue et al., 2003; Qu et al., 2003). Overexpression of Beclin1 in
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MCF7 breast cancer cells increased autophagic vacuoles induction and protein
degradation upon nutrients starvation in a 3-MA sensitive manner, further underlying
the importance of a functional PI3K complex in this process (Liang et al., 1999).
Recently, a new regulatory mechanism of autophagy has been proposed that involves
modulation of Beclin 1/Vps34 complex activity by the anti-apoptotic protein Bcl-2.
According to this mechanism, ER localized Bcl-2 sequesters Beclin 1 preventing the
formation of Beclin 1/Vps 34 complex, and thus inhibiting its PI3K activity and
autophagy induction. These studies showed that overexpression of Bcl-2 inhibited
autophagic vacuole formation and protein degradation in breast carcinoma and colon
carcinoma cell lines. Moreover the expression of Bcl-2 in Apg6-deficient yeast mutants
prevented the rescue of autophagy induced by Beclin 1 under nutrient starvation
condition. The inhibitory action of Bcl-2 towards autophagy has indeed been proposed
to function as a rheostat that prevents autophagy to occur at elevated levels that could
promote cell death; indeed, the relative amounts of Beclin1 and Bcl-2 complexed with
each other within a cell might govern the threshold for transition from cell homeostasis
to cell death (Pattingre et al., 2005).  Interestingly, some recent reports showed that the
ability of Bcl-2 to counteract autophagy induction is probably cell type and context
dependent, indeed under ischemic condition, immortalized iBMK and MMEC beclin
competent cells stably expressing Bcl-2 undergo autophagosome formation (Mathew et
al., 2007; Karantza-Wadsworth et al., 2007). The same results were obtained in HeLa
cells overexpressing Bcl-2 under ER stress stimuli (Criollo et al. 2007).
Vesicle formation
In yeast PI3K complex I might generate PtdIns(3)P at the PAS and facilitate the
recruitment of certain Atg components, such as the vesicle-forming machinery. The
Atg12-Atg5-Atg16 complex and Atg8-PE conjugate are included in this machinery, and
their localization to the PAS also requires Atg9 integral membrane protein (Suzuki et
al., 2001). The PtdIns 3- kinase complex I may function before Atg12-Atg5-Atg16 and
Atg8-PE, since it is required for their proper localization at the PAS, while Atg9 might
have a role prior the closure of the vesicle double layer (Ferraro and Cecconi, 2007).
Atg9 also interacts with Atg2, and their association is required for autophagosome
formation. Atg1 kinase and Atg 18 determine Atg2 proper localization on PAS.
Mammalian orthologues of Atg9 and Atg2 have been already discovered in the human
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genome, even if they have not been characterized yet (Ferraro and Cecconi, 2007). As
already discusssed, Atg12-Atg5-Atg16 complex and Atg8-PE conjugate are proposed to
be first located at the initial nucleation membrane and then to function in vesicle
expansion.
Expansion of the vesicle presumably requires the delivery of lipids, possibly in the form
of lipid bilayers present in transport vesicles; however, the origin of these lipids is not
entirely known. Atg9 localizes at the PAS and mitochondria as multiple dots, and may
cycle between these structures (Reggiori et al., 2004; Reggiori et al., 2005). It is not
clear how Atg9 cycling functions. One hypothesis is that Atg9 marks the membrane
source of the autophagosome. Atg9 may mediate the delivery of lipids/membrane by
recycling from the donor (the mitochondria) to the acceptor membrane
(autophagosome). This proposed lipid flow mediated by Atg9 cycling could be
regulated via the Atg1-Atg13 complex and the PtdIns 3-kinase complex I in a manner
that includes Atg2 and Atg18. The Atg9 protein is required for the recruitment of the
Atg12-Atg5-Atg16 complex and Atg8-PE to the PAS (Suzuki et al., 2001) Atg9 cycling
might then help the vesicle expansion in concert with the Atg12-Atg5-Atg16 complex
and Atg8-PE. The presence of Atg5-Atg12 during the elongation process probably
regulates the transport of additional membrane or lipids from somewhere to the
isolation membrane, and recruits LC3 to the membrane. The mature autophagosome is
therefore characterized only by the presence of LC3 as a specific marker. After Atg5
uncoating, presumed fusion machinery present on the vesicle would become exposed to
drive the fusion of the autophagosome with the lysosome or vacuole. Thus, coating
could act in part to prevent premature fusion of the forming intermediate vesicle with
the vacuole.
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Fig. 8: Proposed mechanism of autophagosome formation (Yorimitsu and Klionsky, 2005)
In mammals, autophagosomes undergo a stepwise maturation process including fusion
events with endosomal and/or lysosomal vescicles. Autophagosomes have been
reported to fuse with early (Liou et al., 1997) and late endosomes (Berg et al., 1998), as
well as lysosomes (Dunn et al., 1990; Gordon et al., 1992). The SKD1 AAA ATPase
was recently shown to be necessary for autophagosome maturation (Nara et al., 2002).
Early autophagosomes accumulated in cells expressing dominant negative forms of
SKD1, indicating that fewer fusion events with endo/lysosomes took place. Hepatocytes
derived from Vti1b SNARE protein deficient mice showed a delayed fusion between
autophagosomes and multivescicular endosomes, suggesting that this protein
participates to autophagosome fusion events both in yeast and in mammalian cells.
Recently the small GTPase Rab7 has been identified on late autophagosomes (Jager et
al., 2004). Rab7 is probably required for the final maturation of late autophagic
vacuoles, and for the fusion with lysosomes Infact, it is needed for the formation of
large perinuclear vescicular aggregates where the autophagosome marker LC3
colocalizes with the late endosomal and lysosomal markers Lysobiphosphatidic acid, a
lipid present on these vescicles, and with Lamp1 (lysosome associated membrane
protein 1), a membrane molecule associated with late endosomal/lysosomal
compartment. Moreover, cells expressing Rab7 RNA interfering or a dominant negative
form of Rab7 displayed improper accumulation of late autophagic vacuoles (Jager et al.,
2004), suggesting a role for Rab7 in the final maturation of autophagic vescicles, most
probably in the fusion with lysosomes. It appears that Rab7 plays a similar role in the
late steps of both autophagosome and phagosome maturation, consequently it is
possible for other molecules to be shared between the two pathways.  RILP, Rab7
interacting ligand protein, is a molecule present on late endosome and lysosomes and it
is known to mediate the movement of phagosomes from the periphery to the perinuclear
region where they fuse with lysosomes. Therefore RILP requirement for
autophagosome movements has been suggested. The late endosomal/lysosomal markers
Lamp-1 and Lamp-2 (Lysosome assiciated membrane protein-1 and 2) have been
detected on late autophagosomes (Eskelinen et al., 2002; Tanaka et al., 2000).
Interestingly Lamp-2 deficient mice die at the age of 20-40 days (Tanaka et al., 2000),
and show an accumulation of autophagic vacuoles in several tissues, while Lamp-1
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deficient mice are normal (Andrejewski et al., 1999), suggesting that the lack of Lamp-1
is compensated by Lamp-2. The accumulation of autophagic vacuoles in Lamp-2
deficient mice correlates with an impared degradation of autophagosomes. Interestingly
Lamp1 and Lamp2 accelerate the recruitment of Rab7 on autophagosomes, as
Lamp1/Lamp2 double deficient cells show an accumulation of late autophagic vacuoles
compared to wild type, while the early autophagosomes appear similar in both lines
(Eskelinen et al., 2004).
Beclin 1 and autophagy
Beclin1 was originally identified in a yeast two-hybrid screen performed for the
identification of Bcl2-interacting proteins. In this study Bcl2 interaction with Beclin 1
was demonstrated to be fundamental for the antiviral, antiapoptotic and survival
promoting effects of beclin 1 on CNS Sindbis virus infection, suggesting that Beclin 1,
via interactions with Bcl-2, can function in vivo in the CNS as an antiviral host defense
mechanism (Liang et al., 1998). Human beclin 1 is a coiled-coil protein and shares
structural similarities to the yeast autophagy gene Atg6/vps30. The beclin1 gene maps
to a tumor susceptibility locus on human chromosome 17q21 and is monoallelically
deleted in 40-75% of human breast, ovarian and prostate cancers (Aita et al., 1999).
Its involvement in the autophagic process protein was initially demonstrated by gene
transfer sudies: human beclin when expressed in Apg6 null yeast strain was able to
induce autophgy under nitrogen deprivation conditions. Moreover, when overexpressed
in MFC7 cells (human breast carcinoma cells that present haploinsufficiency for Beclin
1 gene and display impaired ability to engage autophagic pathway) it increases basal
levels of autophagy and nutrient deprivation-induced autophagy. In this context MCF7
enforced overexpression of Beclin 1 results in the loss of malignant morphological
properties, decreased rates of proliferation, impaired clonogenity in vitro, and impaired
ability to form tumors in nude mice (Liang et al., 1999). Beclin 1 was shown to localize
at the trans-golgi network where it interacts with of PI3K class III presumably binding
to C2 N-terminal domain of PI3K class III (Liang et al., 2007). Beclin 1-bound PI3K is
functionally active and PtdIns(3)P might be essential for autophagosome formation due
to their ability to recruit other Atg genes (Kihara et al., 2001). PI3K class III binding
domain on Beclin 1 has been characterized and is located at aa 244-337 downstream the
coiled-coil region and is referred to as ECD domain (Furuya et al., 2005). Interestingly
Beclin 1 mutant lacking ECD shows impaired ability to activate autophagy, suggesting
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that this mutant might act as a dominant negative protein. Beclin 1 has been found to
localize also into mitochondria, ER and perinuclear membrane. A Beclin 1 NES (aa
180-189, downstream to Bcl2 binding site aa 88-150) has been characterized and
enables Beclin 1 shuttling between nucleus and cytoplasm in a CRM1 dependent
manner. Interestingly, nuclear localization of Beclin 1 impairs its ability to induce
autophagy under nutrient starvation conditions (Liang et al., 2001). Beclin 1 null mice
dye early in embryogenesis, demonstrating that autophagy is required during
embryogenesis and for the mantainance of tissue homeostasis in vivo. Beclin 1+/-
mutant mice develop wide spectra of tumors that seem to express decreased levels of
Beclin 1 protein (Qu et al., 2003). Beclin 1 null ES cells show severely altered
autophagic response, whereas their apoptotic response to serum starvation and UV
treatment is identical to the wild type counterpart, establishing a role for autophagy and
Beclin 1 in tumor suppression (Yue et all., 2003). Interestingly, Beclin 1 null ES cells
failed to form embryoid bodies when cultured in the absence of LIF; this was
attributable to a failure of autophagy beclin-dependent clearance of apoptotic cells
during embryoid development that in the absence of Beclin1 failed to cavitate (Qu et al.,
2007). Further evidences argue for a general involvement of Beclin 1 during embryonic
development: in C.elegans, short interfering siRNA suppression of Beclin 1 inhibits
autophagy and interferes with morphogenesis of the developmental stage known as the
dauer diapause (Melendez et al., 2003). Beclin 1 expression and Atg genes upregulation
are sporadically seen under nutrient starvation, while their protein levels are increased
consequently to ceramide, tamoxifen, vitamin D analogues, radiations TNFα and other
stimuli treatment (Scarlatti et al., 2004; Hoyer-Hansen et al., 2005). Bcl-2 binding to
Beclin 1 has been demonstrated to negatively regulate Beclin 1 association with PI3K
classIII and to inhibit Beclin 1-induced autophagy under starvation. Interestingly,
Beclin 1 mutants lacking Bcl-2 binding domain enhance basal autophagosome
formation and cell death in normal growth conditions (Pattingre et al., 2005).
Nonetheless, in other studies performed in different cellular systems and under different
autophagy stimulation conditions, Bcl-2 seems to be dispensable in Beclin 1-mediated
autophagy regulation (Zeng et al., 2006; Karantza-Wadsworth et al., 2007; Matthew et
al., 2007). For example, overexpression of Bcl-2 and Bcl-XL in mouse wt embryonic
fibroblasts (MEFs) treated with etoposide appears to stimulate, rather than inhibit,
Beclin 1-dependent autophagic cell death (Shimizu et al., 2004). Besides Bcl-2, Beclin
1 also binds Bcl-XL but not Bax (Liang et al., 1998; Furuya et al., 2005). Two recent
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independent studies demonstrated that Beclin 1 binds both Bcl-2 and Bcl-XL through a
BH3-like amphipatic α-helix located inside the previously characterized Bcl-2 binding
domain at aa107-135 (Oberstein et al., 2007; Maiuri et al., 2007), thus demonstrating
that beclin1 is a new member of the BH3-only protein family. Interaction between
Beclin 1 and Bcl-XL is phisiologically relevant, as its inhibition by the BH3-only Bad
protein can stimulate autophagy.
Fig. 9: Model for cross-regulatory mechanism of beclin 1 mediated modulation of autophagy ([modified
figure] original: Liang et al., 2006, Nature Cell Biol.)
Moreover it suggests new modes of crosstalk between autophagic and apoptotic
pathways. Recently, two novel Beclin 1 binding proteins, UVRAG and Ambra1, have
been identified and have been demonstrated to positively regulate Beclin 1-mediated
autophagy probably by facilitating its interaction with PI3K class III either in basal or in
stress conditions (Fimia et al., 2007; Liang C. et al., 2007). Altogether, these data
demonstrate that fine tuning of Beclin 1 interactions are determinant in the autophagic
or apoptotic responses in different physiological contexts such as cell growth,
tumorigenesis, host defense and development.
Biological outcome of autophagy induction
Besides its role in the turnover of proteins and organelles, autophagy has multiple
physiological and pathological functions. When cells encounter environmental stressors
such as nutrient starvation and pathogen infection, autophagy takes place, resulting in
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either adaptation and survival, or death (Kondo et al., 2005).  The observation of
autophagic vacuoles in dying cells has suggested the existence of an alternative form of
programmed cell death depending on autophagy induction and referred to as autophagic
cell death or type II programmed cell death. Accumulating evidences are now indicating
that in many conditions, in particular when cells have an intact apoptotic machinery,
autophagy has a protective rather than a pro-death function (Levine and Yuan, 2005). It
is therefore crucial to understand the mechanism regulating autophagy and in particular
which molecular players differentiate the protective autophagy from autophagic death,
in order to utilize them as a therapeutic strategy.
Autophagy as a cell death mechanism
The term “autophagic cell death” describes a form of programmed cell death
morphologically distinct from apoptosis and presumed to result from excessive levels of
cellular autophagy (Schweichel and Merker, 1973); in contrast to necrosis, both
apoptotic and autophagic cell death are characterized by the lack of a tissue
inflammatory response (Levine and Yuan, 2005). Large numbers of autophagic
vacuoles have been observed in dying cells of animals of diverse taxa (Schweichel and
Merker, 1973; Bursch, 2001; Clarke, 1990; Lockshin and Zakeri 2004). According to
the consensus view, autophagic cell death occurs primarily when the developmental
program (e.g., insect metamorphosis) or homeostatic processes in adulthood (e.g.,
mammary gland postlactational involution) require massive cell elimination. Recent
studies have also described autophagic cell death in diseased mammalian tissue and in
tumor cell lines treated with chemotherapeutic agents. In many of these cases,
morphological features of autophagic and apoptotic cell death or of autophagic and
necrotic cell death are observed in the same cell, making it difficult to understand the
exact role of autophagy in cell demise.
In Drosophila autophagic cell death is observed during salivary gland regression, and is
prevented by mutations in the ecdysone-regulated transcription factors BR-C and E74A
(Lee and Baehrecke, 2001), but these mutations do not prevent autophagy in the same
cells. In Drosophila the caspase inhibitor p35 blocks metamorphic cell death, but not
autophagy, suggesting that cell death requires caspase-mediated apoptosis rather then
autophagic cell death (Lee and Baehrecke, 2001). These studies suggest that autophagy
is not required or sufficient to induce cell death in these experimental settings.
50
   
Figure 10: Comparison of autophagic cell death and apoptosis (Kondo et al., 2005).
However, there are also some experimental evidences where inhibitors of autophagy
such as 3MA, inhibit cell death. This drug retards or partially prevents cell death in
starved hepatocytes from carcinogen-treated rats (Schwarze and Seglen, 1985), in
tamoxifen-treated mammary carcinoma cells (Bursch et al., 1996), in chloroquine-
treated cortical neurons (Kaidi et al., 2001) in nerve growth factor (NGF)-deprived
sympathetic neurons (Xue et al., 1999), in serum and potassium-deprived cerebellar
granule cells (Canu et al., 2005), in serum deprived PC12 cells (Uchiyama, 2001), and
in TNF-treated human T lymphoblastic leukemia cells (Jia et al., 1997). It must be noted
that the use of 3MA pharmacological inhibitor can affect other pathways than
autophagy, so as class III PI3K itself might be required for other survival pathways.
Yu et al. (Yu et al., 2004) published the first genetic evidence showing that autophagic
cell death is dependent on ATG genes. The authors observed that inhibiting caspases
with zVAD, a caspase inhibitor with broad specificity, or by knocking down caspase 8,
surprisingly induced cell death in several cell lines. Morphologically, the cell death was
characterized by accumulation of autophagic vacuoles, without the hallmarks of
apoptosis. In these settings, 3MA and downregulation of beclin 1 and Atg7, inhibited
both the accumulation of autophagic vacuoles and the cell death, indicating that
classical autophagy induction was really needed for cell demise. Intriguingly, it was
shown that the signaling pathway triggering the death process included the activation of
RIP and JNK. These results, then, suggest that although the same autophagy genes are
required both for autophagic cell death and starvation-induced autophagy, there might
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be differences in the signal transduction pathways activating these two processes.
Further, this study suggests that caspase 8 might act as a suppressor of autophagic cell
death. It is possible that caspase 8 could act as a hub that regulates which death
pathway, apoptotic or autophagic, the cell takes. Thus, apoptosis and autophagy may
have complementary roles in cell death: if apoptosis fails, then cells have the option of
dying via autophagy. This mechanism might be of importance for instance during viral
infection, because many viruses have means to inhibit caspase activation (Eskelinen,
2005).
Another study demonstrating that autophagy genes are required for type II cell death
was performed in embryonic MEFs double deficient for Bax and Bak, which are
resistant to apoptotic death stimuli (Shimizu et al., 2004). When treated with apoptosis-
inducing drugs like etoposide or staurosporine, double-deficient cells still underwent a
cell death characterized by accumulation of autophagic vacuoles that could be inhibited
by downregulation of Atg5, beclin 1, and by 3-MA. Of note, this etoposide-induced
autophagic cell death was related to the deficiency of Bax and Bak, since it was not
detected in cells deficient in Apaf-1 or caspase 9, or in wild-type fibroblasts treated with
the caspase inhibitor zVAD. Interestingly, overexpression of Bcl-2 and Bcl-XL in wild
type cells triggered Atg5-mediated etoposide-induced autophagic death similar to that
observed in the Bax/Bak double-deficient cells. Overexpression of Bcl-2 or Bcl-XL in
Atg5-/- cells did not trigger cell death, demonstrating the requirement of the autophagy
protein Atg5 for cell death induction. Furthermore, silencing of Bcl-XL with RNA
interference in Bax/Bak-/- cells prevented the etoposide-induced accumulation of
autophagic vacuoles and cell death, indicating Bcl-XL was required for this death
pathway. Since Bcl-2 and Bcl-XL are known to interact with Beclin 1 (Liang et al.,
1998) the authors suggested that Bcl-XL might influence autophagosome formation at
least partly via regulation of Beclin 1.
These studies showed that apoptotic stimuli can induce an autophagic cell death in cells
where the apoptotic pathway is inhibited and that, under certain conditions, autophagic
cell death can act as a substitute for apoptosis. Infact, autophagic cell death has not been
observed in wild type cells treated with etoposide, it is not blocked by 3-MA and the
main route for this cell demise is apoptosis. One explanation might be that apoptosis is
faster than autophagic death; indeed the wild type cells are dying much more than the
Bax/Bak -/-. Another possible explanation is consistent with the theory of Lockshin and
Zakeri claiming that cells preferentially die by apoptosis, but will die by any alternative
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available route, including autophagy, if exposed to harsh enough stimuli (Lockshin and
Zakeri, 2004). Interestingly, such a role for Bcl-XL has not been demonstrated in
starvation-induced autophagy. Infact, it was shown that different cell lines
overexpressing a Beclin 1 lacking Bcl-2 binding domain died faster both in untreated
and under nutrient starvation conditions (Pattingre et al 2005).  Of note the recent
finding that Beclin 1 is a BH3-only protein suggests that it can have some apoptotic
functions by itself (Oberstein et al., 2007).
Other works demonstrated that downregulation of Atg5 expression suppressed both
autophagic vacuole formation and cell death in HeLa cells treated with interferon-γ. On
the other hand, overexpression of Atg5 or stimulation with interferon-γ induced 3-MA
sensitive autophagic cell death (Pyo et al., 2005). Intriguingly, the caspase inhibitor
zVAD inhibited cell death, but not the formation of autophagic vacuoles, suggesting
that caspases might be involved in the signaling or execution of the cell death
downstream of autophagic vacuole formation. Moreover, it was also shown that Atg5
interacted with the death domain of FADD (a component of the apoptosis-signaling
cascade initiated by death receptors). The Atg5-mediated cell death, but not the
accumulation of autophagic vacuoles, was blocked in FADD-deficient cells, suggesting
that FADD is a downstream effector of Atg5. This result has two implications: first, it
shows that the accumulation of autophagic vacuoles can be separated from cell death.
Second, it suggests that an autophagy protein (Atg5) can mediate a death signal to a
protein involved in apoptotic cell death (FADD). Of note, Yusefi et al. recently reported
that Atg5 is a calpain  (a non-lysosomal Ca++ dependent cysteine protease) substrate and
that the resulting processed form triggers apoptotic cell death (Yousefi et al., 2006).
The results aforementioned suggest that autophagic vacuoles can act as the initiator of
the death process, which then mediates the death signal to the apoptotic machinery that
finalizes the cell demise However further studies are required to clarify the relationship
between apoptosis and autophagic cell death and the role of Bcl2 family proteins in
regulating auophagy and its crosstalk with apoptosis. Recent work performed in our
laboratory further sustains these observations. We demonstrated that calpain is needed
to trigger macroautophagy: cells lacking calpain activity show impaired autophagy and
result more sensitive to apoptosis induced by different autophagic stimuli such as
ceramide, etoposide and starvation (Demarchi et al., 2006). Accordingly, recent studies
demonstrate that calcium mobilizing agents such as ionomycin and thapsigargin (that
can also act as calpain inducers) are potent inducers of macroautophagy (Hoyer-Hansen
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et al, 2007). Furthermore in this work it was demonstrated that calcium induces
autophagy via a signaling pathway involving the Ca++ activate kinase CaMKKβ that is a
direct activator of AMPK. As discussed in previous sections, AMPK inhibits mTOR
activation and leads to autophagy induction. Another in vivo model substantiates an
involvement of autophagy in the clearance and demise of specific cell types. In
atherosclerotic plaques, macrophage infiltration is involved in destabilization of the
plaque, whereas SMC (smooth muscle cells) contribute to plaque stability. Stent-based
delivery of rapamycin in rabbits has been demonstrated to cause selective macrophage
death while leaving SMC cells viable. Both cell lines showed equal mTOR inhibition
under rapamycin; nevertheless, only macrophages died consequently to the treatment.
This different behaviour has been attributed to the higher metabolic demand of
macrophages in respect to SMC cells, suggesting that autophagy can lead to cell demise
depending on the metabolic activity of specific cell lines (Verheye et al., 2007).
Autophagy as a cell survival mechanism
The pro-survival function of autophagic process is better documented than autophagic
cell death and even though autophagy genes act as mediators of cell death in some
experimental conditions, increasing evidence suggests that the accumulation of
autophagosomes in dying cells or tissues commonly represents a failed rescue effort in
response to external stress. Starvation induced autophagy is coupled to the survival of
unicellular organism such as yeast; mutants in autophagic essential genes are in fact
viable in normal growing medium, but die upon aminoacid withdrawal. In these
conditions, the activation of autophagic degradation allows the cell to eliminate the
structures and organelles in excess, and generates free fatty acids and amino acids
necessary to fuel mitochondrial ATP production and maintain protein synthesis (Levine,
2005). Also, multicellular organisms including mammals activate autophagy in nutrient
starvation conditions to sustain life. In C. elegans, silencing of the autophagy genes
unc-51, bec-1, atg8 and atg18 impair survival during the dauer phase of development,
indicating the importance of autophagy in recycling nutrients during starvation
(Melendez et al., 2003). In newborn mice, autophagy activation is essential to allow
survival during the severe starvation occurring after trans-placental nutrient supply is
interrupted, and before nutrients are restored by milk feeding. Mice deficient in the
essential autophagy gene Atg5 develop normally, but die within a day after birth,
demonstrating the importance of the autophagic process to maintain survival in
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starvation conditions (Kuma et al., 2004). Interestingly these Atg5-/- mice show signs of
energy depletion, in particular the myocardial ATP production is reduced; moreover,
they exibit low aminoacids concentration in plasma and tissues. Although death of
individual cells has not been observed in these mice, it is possible that the function of
tissues such as the heart and the diaphragm, which require high energy levels, is
impaired due to the inability to induce autophagy. Also Atg7 conditional knockout mice
show the same phenotype, moreover the cells of these mutants display multiple cellular
abnormalities, such as the appearance of concentric membranous structures, deformed
mitochondria and the accumulation of ubiquitin-positive aggregates, suggesting the
importance of autophagy also in the quality control of proteins and organelles in
quiescent cells (Komatsu et al., 2005).
Autophagy appears to be important also for maintaining cellular bioenergetics and
survival when cells are unable to take up external nutrients, like for example during
growth factor deprivation. In the absence of growth factors there is a decreased surface
expression of nutrient transporters, decreased nutrient uptake and an intracellular
deficiency of factors such as interleukin-3 (IL-3), cells undergo rapid apoptosis, but the
inactivation of the apoptotic genes BAK and BAX prevents this death allowing the cells
to survive (Lum et al., 2005). Immortalized interleukin-3 (IL-3) dependent cells derived
from bone marrow of Bak-Bax double deficient mice survive in culture for weeks after
IL-3 deprivation. The expression levels of the major glucose transporter GLUT-1
declined rapidly following IL-3 withdrawal; correspondingly, mitochondria membrane
potential decreased and also ATP content fell, and these cells displayed the hallmarks of
autophagy. Autophagy induction triggers progressive destruction of organelles in order
to keep ATP at levels sufficiently high to allow cell survival, untill the occurrence of
atrophy that finally degenerates into death. Notably readdition of IL-3 within six weeks
recovers cell survival and proliferation. Treatment with 3-MA and Atg5 or Atg7
depletion increase cell death in IL-3 deprived cells, demonstrating autophagy
requirement for the mantainance of the bioenergetic balance within the cell and survival
(Boya et al., 2005). Furthermore, it was demonstrated that autophagy inhibition with
chemical inhibitors (hydroxychloroquine, monensin, bafilomycin A1 and 3-MA) or by
knocking-down autophagy essential genes such as ATG5, ATG12, ATG10 and
BECLIN-1 in nutrient starved HeLa cells leads to apoptotic cell death, indicating that
autophagy plays a pro-survival function during nutrient deprivation. Indeed, cell death
triggered by autophagy inhibition is reduced by stabilization of mitochondrial
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membranes with Bcl-2, and by caspase inhibitors. Interestingly, when fusion between
autophagosomes and lysosomes is inhibited with lysosomotropic agents
(hydroxychloroquine, monensin) or by LAMP-2 depletion, the nutrient starved cells
undergo autophagic cell death. Also in this case, readdition of nutrients and removal of
the drug rescues the normal viability of the cell, but if starvation is too long the cells
reach the point-of-no-return, undergoing apoptosis. (Boya et al., 2005).
The pro-survival function of autophagy is not only restricted to nutrient starvation, but
plays an important role also in cellular homeostasis in response to stressors, through the
removal of damaged mitochondria and other organelles, in degrading intracellular
pathogens, and in degrading protein aggregates too large to be removed by the
ubiquitin-proteasome system (Levine and Yuan, 2005). It has been reported that
autophagy protects mammary carcinoma, colon adenocarcinoma prostate carcinoma and
malignant glioma cell line U373-MG from radiation induced cell death, and addition of
inhibitors of the autophagic pathway restored sensitivity to radiation (Paglin et al.,
2001; Ito et al., 2005). Another in vivo investigation performed in pigs demonstrated
that autophagy is induced in chronically ischemic myocardium. Interestingly in this
model, apoptosis is initially engaged (e.g. after few ischemic episodes), while the
continuous exposure to the ischemic damage induces increased expression of
autophagic genes such as beclin1, cathepsins, LC3 and others, contemporarily a
decrease in apoptosis is observed. These data argue for a cytoprotective role of
autophagy in chronically ischemic myocardium, indeed autophagy allows full
functional recovery consequent to the removal of the ischemic injury (Yan et al., 2005).
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Autophagy and diseases
Figure 11: Possible outcomes of autophagy activation or inactivation in different pathologies.
Autophagy and cancer
Cancer results from the misregulation of pathways that govern cell differentiation, cell
proliferation, and cell survival. Autophagy may protect against cancer by sequestering
damaged organelles, permitting cellular differentiation, increasing protein catabolism,
and/or promoting autophagic death in order to mantain cellular homeostasis.
Alternatively, autophagy may contribute to cancer by promoting the survival of nutrient
starved cells. Recent data are most consistent with a model in which autophagy
contributes to tumor suppression and defects in autophagy contribute to oncogenesis.
Indeed, when baseline levels of autophagic degradation were compared, cancer cells
showed reduced protein degradation than their normal counterpart (Gozuacik and
Kimchi, 2004). The inhibition of a catabolic pathway could provide cancerous cell with
some developmental advantages: first, early stage of tumor development require a
higher level of protein synthesis than protein degradation and therefore inhibition of
autophagy could maintain continuous tumor growth. Second, autophagy could decrease
mutation rate and suppress oncogenesis by eliminating damaged organelles that could
produce genotoxic stresses such as free radicals (Kondo et al., 2005). In accordance
with this hypothesis, recent findings clearly demonstrate that autophagy limits
metabolic stress to protect genome integrity, and defective autophagy increases DNA
damage and genomic instability in different cell lines, facilitating cancer progression
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(Mathew et al., 2007; Karantza-Wadsworth et al., 2007). Furthermore, the mammalian
autophagy gene beclin-1 has tumor suppressor activity in breast carcinoma cells (Liang
et al., 1999), is commonly deleted in human breast ovarian and prostate cancer (Aita et
al., 1999), and is a haploinsufficient tumor suppressor gene in mice (Qu et al 2003; Yue
et al 2003). As seen with beclin1, UVRAG  is monoallelically deleted in various human
cancers. HCT116 cells bear a monoallelically frameshift mutation in UVRAG gene that
generates a premature stop codon; indeed, overexpression of UVRAG in HCT116 cells
has been demonstrated to decrease tumorigenesis of HCT116 in nude mice (Liang et al.,
2006). Similarly, dowregulation of AMBRA1 expression, leads to increased
proliferation rates (Fimia et al., 2007).
Several theories regarding the role of autophagy-dependent death and autophagy-
dependent survival in cancer biology have been proposed (Shintani and Klionsky, 2004;
Gozuacik and Kimchi, 2004). According to one theory, autophagy-dependent death is a
mechanism of tumor suppression. Although there are no direct data to support this
hypothesis, it is possible that autophagy is involved in the spontaneous or
chemotherapy-induced death of existing tumor cells. The role of autophagy in cell death
in apoptosis-competent cells is unclear; however, autophagy gene-dependent death in
cells crippled in apoptosis (e.g., zVAD-treated cells; bax-/-, bak-/- cells) may have
relevance for cancer biology and therapy, since human tumor cells frequently contain
mutations that render them resistant to apoptosis. One prediction is that such cells have
an increased dependency on autophagy pathways for self-destruction, and that the
impact of autophagy-dependent cell death on tumor progression may be greater in tumor
cells that are resistant to apoptosis. Another prediction is that the enhanced autophagy-
dependent death potential of apoptosis-resistant tumor cells might be exploited
therapeutically by the administration of autophagy inducing agents. Indeed, there are
examples of putative autophagic cell death in cancer cell lines treated with
chemotherapeutic agents.
During tamoxifen-induced death of MCF7 cells (a cell type that contains a mutation in
caspase-3), there is a marked upregulation of Beclin 1 expression (Scarlatti et al., 2004);
moreover, temozolomide (a DNA alkylating agent) induces autophagy, but not
apoptosis, in malignant glioma cells (Kanzawa et al., 2004). In both cases
chemotherapy-induced autophagic cell death is inhibited by 3-MA (Scarlatti et al.,
2004, Kanzawa et al., 2003) and also ceramide induces autophagic cell death in
malignant glioma (Daido et al., 2004).
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Figure 12: Potential strategies for treating cancer by manipulating the autophagic process (Kondo et al.,
2005).
In addition, arsenic trioxide induces autophagy in malignant glioma (Kanzawa et al.,
2003; Kanzawa et al., 2005), resveratrol induces autophagic cell death in ovarian cancer
cells (Opipari et al., 2004), and soybean derived saponins induce autophagy in colon
cancer cells (Ellington et al., 2005). However, direct evidence proving that autophagy is
a bona fide death pathway in chemotherapy-treated cancer cells is lacking. In addition,
rapamycin, an inhibitor of TOR kinase that has promising antitumor effects in human
clinical trials (Huang and Houghton, 2003), is one of the most potent known inducers of
autophagy, but is not known to induce autophagic cell death.
In contrast to potential pro-death effects, more clearly established pro-survival effects of
autophagy during nutrient starvation might speed up tumor initiation and/or progression
(Ogier-Denis and Codogno, 2003; Gozuacik and Kimchi 2004). As tumor cells grow
beyond their blood supply, they are exposed to nutrient-limiting conditions, and it is
possible that transformed cells use autophagy as a survival strategy in this setting.
Indeed, tumor cell lines of diverse origins, including colon carcer, breast cancer,
melanoma, hepatoma, and malignant glioma, switch on autophagy in response to
nutrient starvation (Kondo et al., 2005), leading to hypothesize the existence of a
positive selective pressure for the maintenance of autophagy in tumor progression.
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Accordingly, recent studies revealed that autophagy enables cell survival in vitro and in
vivo when apoptosis is inactivated (Degenhardt et al., 2006).
Autophagy and neurodegeneration
The accumulation of mutant or toxic proteins plays a major role in chronic
neurodegenerative diseases (Martinez-Vincente and Cuervo, 2007). Neurodegenerative
disordes are catalogued as protein conformational disorders, because they all originate
consequently to protein misfolding events. Cells continously check the quality of
proteins repairing or removing them when abnormalities are detected. Two major
systems are involved in this quality control: the proteasome system and autophagy. An
imbalance between efficiency of the quality control and the amount of altered proteins
can lead to conformational disorders, in which intracellular accumulation of abnormal
proteins occurs. For example deficits in the ubiquitine proteasome system are associated
with various neurodegenerative diseases, since ubiqutin-positive inclusions frequently
appear in neurons of animals or patients with neurodegenerative diseases. A direct
involvement of autophagy in neurodegenerative disorders has been recently
demonstrated: generation of neuron- specific autophagy Atg7 deficient mice showed
behavioural defects and ubiquitinated-positive proteinaceous aggregates accumulation
throughout the brain (Komatsu et al., 2006). Similar phenotypes were obtained in
neural-cell-specific Atg5-/- mice (Hara et al., 2006) and in mouse embryos bearing
Ambra1 functional deficiency (Fimia et al., 2007).
 Morphologic evidence of autophagy has been reported in neurodegenerative diseases
including Parkinson, Huntington, and Alzheimer diseases, and transmissible spongiform
encephalopathies (Qin et al., 2003; Anglade et al., 1997; Yu et al., 2004; Liberski et al.,
2004). Recent studies have provided insights regarding autophagy and
neurodegenerative disease. α-synuclein, the  major component of neuronal cytoplasmic
inclusions that characterize Parkinson and other neurodegenerative diseases (Maries et
al., 2003), is degraded both through the proteasome, and by chaperone-mediated
autophagy pathways (Webb et al., 2003). Interestingly, pathogenic α-synuclein mutants
associated with familial, autosomal-dominant forms of Parkinson disease
(Polymeropoulos et al., 1997; Kruger et al., 1998) are inefficiently degraded by
chaperone-mediated autophagy. Since the accumulation of wild-type α-synuclein in
neuronal inclusions is common in adult-onset neurodegenerative diseases, these
experiments suggest that defects in autophagy-related pathways may contribute to
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multiple neurodegenerative diseases. Consistent with this hypothesis, autophagy has
also been implicated in regulating the turnover of Huntingtin (Htt), the protein involved
in Huntington disease, an autosomal-dominant neurodegenerative disorder caused by
the expansion of a polyglutamine (polyQ) tract in Htt. The accumulation of expanded
polyQ-containing proteins in insoluble aggregates in affected neurons is a hallmark
feature of Huntington and other polyQ expansion diseases (DiFiglia et al., 1997).
Although neuronal Htt proteins in inclusions are highly ubiquitinated, polyQ is a poor
substrate for proteasomes (Venkatraman et al., 2004). Pharmacological evidences
suggest a role for autophagy in the degradation of the N-terminus of Htt: 3-MA
increases the aggregation of Htt with expanded polyQ in clonal striatal cells (Qin et al.,
2003), while Rapamycin, an inducer of autophagy, reduces the aggregation of expanded
polyQ in transfected cells (Ravikumar et al., 2002) and protects against
neurodegeneration in a fly model of Huntington disease. In addition, it improves
performance on behavioural tests and decreases aggregate formation in a mouse model
of Huntington disease (Ravikumar et al., 2004). As the disease progresses, the presence
of undigested materials accumulating inside autophagic vacuoles, the sustained
activation of macroautophagy to sequester the aggregates and the removal of crucial
cellular elements by autophagy along with the aggregates, could lead to a generalized
cellular failure. In this case, the cell can use autophagy to undergo autophagic cell death
(Cuervo 2004 et al.,). Other evidences implicating the involvement of autophagy in
neurodegeneration are the observation of increased beclin1 levels found consequently to
traumatic brain injury in mice near the injury site (Erlich et al., 2006). Moreover in
traumatic brain injury rapamycin has a cytoprotective effect (Erlich et al., 2007), further
confirming its fundamental role in the control of neurodegeneration.
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RESULTS
In silico analysis of beclin 1 promoter
Many cell types, such as stem cells, must be able to adjust their proliferation rate in
response to a wide variety of mitogenic stimuli. Checkpoint controls can cancel such
cell cycle progression by activating the barrier-program unless prosurvival signalling
raises the threshold required for entering such failsafe fate. Clear examples of such
prosurvival mechanisms are the activation of NF-kB and PI3K/Tor signalling cascades.
Autophagy is a program induced by damage/stress and nutrients/oxygen deprivation,
while it is negatively regulated by the PI3k/Tor pathway: it can, in fact serve as a
survival mechanism for cancer cells to avoid switching into apoptosis.
Recent work in our lab has focused on calpains, a family of sixteen intracellular
nonlysosomal Ca2+-regulated cystein proteases, mediating regulatory cleavage of
specific substrates involved in a number of processes.
In particular, we have shown that calpain inhibits susceptibility to p53-dependent
apoptosis (Benetti et al., 2001) and regulates the transcription competent β-catenin pool
(Benetti et al., 2005). In addition, we have shown that calpain is involved in NF-kB
activation and its relative prosurvival function in response to ceramide, where calpain
deficiency strengthens the proapoptotic effect of ceramide (Demarchi et al., 2005). Most
recently we further explored the involvement of calpain in the apoptotic switch and
found that, in calpain deficient cells, autophagy is impaired, resulting in a dramatic
increase in apoptotic cell death (Demarchi et al., 2006).
Many activators of NF-kB, such as TNFα, TRAIL, reactive oxygen species (ROS) and
ceramide, work also as potent macroautophagy inducers. However, the possible
crosstalk between these two signalling pathways is largely unknown.
The aim of this work was to investigate whether there was any relation between NF-kB
or other transcription factors and regulation of autophagy.
As a first approach, we performed in silico analyis using CONFAC (Karanam and
Moreno, 2004) in order to verify whether any transcription factor binding site (TFBS)
was conserved in the promoters of autophagic genes both in humans and mouse. An
input consisting of a list of autophagic genes was therefore submitted.
The CONFAC analysis of regions including 500bp upstream of the Trancription Start
Sites (TSS) and including up to 15kbp of the first intron revealed that no TFBS was
conserved between human and mouse.
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However, considering the single outputs relative to each gene, beclin 1 was reported to
bear 3 putative overlapping NF-kB binding sites inside the first intron.
Subsequently, a set of NF-kB target genes (together with beclin 1 (Figure 1A)) was
analyzed with CONFAC in order to verify the results obtained during the previous
analysis. Finally, a Mann-Whitney test was performed between the set of NF-kB target
genes and a set of 250 randomly selected genes from RefSeq (Figure 1B). Two
matrices, each containing the number of occurrences of every TFBS found by CONFAC
in the two datasets were genrated and compared to verify the statistical significance of
CONFAC results about NF-kB regulated genes.
The results corroborated the reliability of this analysis, confirming the significance of
NF-kB binding sites occurrence in the promoter regions investigated.
These in silico analysis, therefore, suggested that beclin 1 might indeed represent a new
NF-kB target gene.
Recent work from Farnham P.J. et al., focused on the identification of E2F regulated
promoters using ChIP experiments, led to the isolation of three genomic fragments, all
of which representing strong E2F binding sites (Weinmann et al., 2001). One of these
fragments, referred to as ChET4, was demonstrated to correspond to the promoter
region of beclin 1.
We therefore analyzed ChET4 sequence using Consite (Sandelin et al., 2004) tool.
Results obtained confirmed that the ChET4 fragment contained the NF-kB binding site
as expected (Figure 1C); moreover, the kB element was exactly positioned on ChET4
sequence. The kB site sequence on beclin 1 promoter, GGGACTTCCC, has been found
to be positioned at around –100bp upstream the ATG of beclin 1.
                     
Figure 1A
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Fig 1: A) Gene list submitted to CONFAC analysis (including beclin 1 and a set of other NF-kb target
genes). B) NF-kB binding site occurrence in the promoter regions investigated (blue) compared to its
occurrence in the promoter regions of 250 randomly selected control genes (red). CONFAC output was
submitted for subsequent statistical analysis using Mann-Whitney test. Parameters relative to the
statistical analysis are reported in the right table of figure 1B. C) ConSite analysis of ChET4 sequence
allowed exact kB site positioning on the first intron of beclin 1, at around –100 bp from beclin ATG.
Genomic organization of beclin 1 whit respect to ChET4 sequence is shown in the box, and table in figure
1C shows the exact position of kB site on beclin 1 sequence.
                                                           Figure 1B
Figure 1C
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NF-kB subunit p65 enhances the transcriptional activity of beclin 1 promoter
The data obtained from the in silico analysis of beclin 1 promoter, prompted us to
perform further investigations in order to clarify the role of NF-kB in the regulation of
beclin 1 promoter, using transativation luciferase reporter assays.
Thus, pUC19 ChET4 clone was obtained from P.J. Farnham’ laboratory. The region
corresponding to the beclin 1 promoter was cloned into pGL3 luciferase reporter vector
(Figure 2A) to perform transactivation luciferase reporter assays.
Figure 2 A) top of the figure represents beclin 1 genomic organization  according to Ensemble
ENSG00000126581: boxed region shows an enlarged view of beclin 1 5’ untranslated region, first intron
and second exon. In the middle box the same region is enlarged toghether with a piece of upstream
promoter region, and exact localization of ChET4 is reported. Lower image shows KpnI/SacI insertion of
ChET4 beclin 1 promoter region upstream to the luciferase gene.
pGL3ChET4 reporter was cotransfected into U2OS and HEK293T in combination with
expression vectors for the following transcription factors E2F, p65, p50, p65 together
with p50, with an empty vector as a negative control (Figures 2B and 2C). Data were
normalized by cotransfection with CMV renilla TK vector. As shown in Figure 2B and
2C, overexpression of p65 alone efficiently enhanced beclin 1 promoter activity when
compared to the empty vector. Notably, while both overexpressed E2F and p50 were
unable to increase beclin1 promoter activity, synergism between p65 and p50 towards
luciferase transactivation was observed, in particular in HEK293T (Figures 2B and 2C).
Figure 2A
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To address the role of constitutive p65 in the regulation of ChET4 beclin 1 promoter, a
small interference RNA was used to selectively knock down endogenous p65. A
scramble siRNA (SiCtrl) was used as a control. p65 expression was almost completely
abolished 48h after transfection of the specific p65 siRNA. pGL3ChET4 was
overexpressed in U2OS cells after p65 depletion or treatment with a scrambled siRNA
as control (Figure 2D).
Figure 2B and 2C: HEK293T and U2OS cells were cotransfected with pGL3ChET4 and E2F, p65, p50,
p65 and p50 or a control empty vector. Luciferase assays were performed 24h after transfection. Data
represent the means of at least four independent experiments and error bars represent standard deviations;
lower panels: Western blot analyses were carried out using the same lysates to monitor steady-state levels
of each overexpressed protein.
Interestingly, depletion of endogenous p65 significantly decreased ChET4
transactivation activity (Figure 2D).
Ceramide and Tamoxifen are two well established autophagy inducers in several cell
lines. Treatment with these drugs has been demonstrated to induce beclin 1 expression
(Scarlatti et al., 2005). Moreover, ceramide can also trigger p65 activation (Demarchi et
al., 2005; Boland and O’Neil, 1998). For these reasons, subsequently to p65 silencing
and to an overnight pGL3ChET4 overexpression, U2OS cells were treated with 25µM
Figure 2B Figure 2C
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ceramide or with 10µM tamoxifen for 5 hours. As shown in Figure 2D, we couldn’t see
any increase of ChET4 transactivation after treatment of the cells with both drugs.
Nonetheless, p65 depletion in all these experimental settings significantly decreases
beclin 1 promoter activity.
                   
Figure 2D: U2OS cells. p65 expression was selectively knocked down after 48h. Subsequent
overexpression of pGL3ChET4 was performed for 16h, followed by treatment with both 25µM ceramide
or 10µM tamoxifen for 5h. Cell lysates were prepared immediately after treatment for the luciferase
reporter assay. Data represent the means of at least three independent experiments and error bars
represent standard deviations; lower panels: Western blot analyses were carried out on the same lysates to
monitor steady-state levels of endogenous levels of p65.
Isolation of p65/RelA consensus on ChET4 beclin1 promoter
Preliminary in silico analysis of ChET4 beclin 1 promoter region with Consite tool,
carried out at 85% cut off stringency evidenced the presence of two other putative NF-
kB binding sites in a more upstream region, even if with a less significant score (Figure
3A).
In order to understand which of these three kB sites was actually required for the
observed p65-mediated enhancement of beclin1 promoter activity, we decided to
exclude the effect of the more upstream NF-kB binding sites. Analysis of ChET4
sequence showed that a unique site for SacI was present at 685bp. Therefore, SacI Hind
Figure 2D
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III region of CheET4 was excided and cloned it into pGL3 luciferase reporter vector.
Thereafter we will refer to this region as p65 consensus region.
pGL3 p65 consensus region was cotransfected in combination with E2F, p50, p65
                            
Figure 3A Output of p65 Consite Analysis of ChET4 sequence performed at 85% stringency cut
off: red circles indicate other two NF-kB binding sites on ChET4 beclin 1 promoter region.  At the
bottom of the table the third NF-kB binding site is reported.
expression vectors or a control empty vector both in HEK293T and U2OS cells.
As shown in Figures 3B and 3C, the effects of p65 on this shorter construct
encompassing p65 consensus were similar, if not more pronounced, to the ones
observed with ChET4 construct which covers a broader promoter region.
In light of these latest results it was likely that the kB site emerged with CONFAC
analysis should be the only one responsible for the effects seen on beclin 1 promoter
after p65 overexpression. To further confirming these data, again, we assessed the effect
of knocking down endogenous p65 using specific p65 siRNA and scrambled siRNA as
a control (SiCtrl). Also in this case, we tested the effect of both ceramide and tamoxifen
on p65 consensus region of ChET4. Silencing and treatment conditions were identical to
the ones previously used for monitoring the effect of specific p65 depletion on ChET4
promoter activity.
Notably, in these settings we could observe that both ceramide and tamoxifen
treatments enhanced the transcription driven by the p65 consensus binding region.
Figure 3A
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These data can be explained considering that the effect of p65 binding on a restricted
region is cleared from the possible interference due to the interaction of other
transcription factors that may mask p65 binding. Although both drugs, previously
shown to activate p65, clearly amplified the activity of the reporter driven by the p65
consensus binding region, this effect couldn’t be observed using ChET4. A possible
explanation for this discrepancy is that other endogenous transcription factors could
bind and regulate ChET4 activity in response to the drugs.
     
                      
Figure 3B Figure 3C
Figure 3D
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Figure 3: B) and C) HEK 293T cells and U2OS cells were cotransfected with pGL3ChET4 and E2F,
p65, p50, p65 and p50 or a control empty vector, respectively. Luciferase assays were performed 24h
after transfection. Data represent the means of at least five independent experiments and standard
deviations are shown; lower panels: Western blot analyses were carried out on the same lysates to
monitor steady-state levels of each overexpressed protein. D) U2OS cells. p65 expression was selectively
knocked down for 48h. Subsequent overexpression of pGL3ChET4 was performed for 16h, followed by
treatment with either 25µM ceramide or 10µM tamoxifen for 5h. Cell lysates were prepared immediately
after the treatment for subsequent luciferase reporter assay. Data represent the means of at least three
independent experiments; lower panels: Western blot analyses were carried out on the same lysates to
monitor steady-state levels of endogenous levels of p65.
p65 regulation of beclin 1 transcription
Data obtained from the previous experiment argued for an involvement of either p65 or
the p65/p50 dimer in the regulation of beclin 1 promoter. p50 has been reported to bind
kB elements on the promoters of NF-kB target genes through its RHD, but lacks C-
terminal transactivation domain, indeed cannot be responsible for any transactivation.
These pieces of evidence prompted us to investigate whether p65 could regulate beclin
1 mRNA levels.
HEK 293 cells were transfected with p65, E2F or with a control empty vector and
analyzed by semi-quantitative RT-PCR. The primers used for the amplification step
mapped at a central codifying region of beclin 1 and were previously demonstrated to
work properly in semi-quantitative RT-PCR experiments (Scarlatti et al., 2005). We
named these primers B5’ and B3’, B5’ being the primer on exon 4 while B3’ the one
positioned on exon 8.
                                    
Figure 4A: RT-PCR analysis of beclin 1 and GAPDH mRNA expression in HEK 293T. Cells were
transfected as indicated. RNAs were reverse-transcribed and amplified with specific primers for beclin 1
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and GAPDH as described under “Experimental Procedures.” The relative beclin 1 mRNA level was
normalized by reference to the GAPDH. Upper panel: the band about 500bp expected to be amplified
using B1 and B2 set of primers specific for beclin 1 region exon 4-8 (B1 and B2 primers) was
significantly increased following p65 overexpression with respect to a control empty vector. RT-PCR
analysis was repeated three times. A representative experiment is reported.
HEK 293T cells overexpressing p65 showed a significant enhancement of beclin 1
mRNA compared to transfection of either a control empty vector or of E2F transcription
factor (Figure 4A).
Thus, we went on trying to better elucidate the effect of specific p65 siRNA on beclin 1
transcription using RT-real time PCR experiments.
At genomic level, beclin 1 gene transcript consists of 12 exons. This genomic
organization suggests that alternative splicing of beclin 1 RNA is likely to occur. In
fact, besides beclin 1 full lenght transcript, EBI database reports the existence of several
clones coming from different libraries that seem to contain beclin 1 alternative spliced
forms in both human and mouse species. Therefore, we decided to perform some
preliminar analysis. Indeed, we divided beclin 1 region into three parts in order to
monitor the effect of specific p65 silencing on each region by semi-quantitative RT-
PCR. Three set of primers were designed: A5’/A3’, B5’/B3’ and C5’/C3’ as indicated in
Figure 4B.
As positive controls, two specific beclin1 siRNAs were used (indicated as SiB1 and
SiB2 in Figure 4B [red]) while a scrambled control siRNA was used as a negative
control (SiCtrl).
Thus, U2OS cells were transfected with p65 siRNA, SiB1, SiB2 and control siRNA
(SiCtrl). 72 hours later total RNA was extracted and subjected to reverse transcription.
PCR amplifications using the three different sets of primers were performed and the
relative beclin 1 mRNA level was normalized by reference to the GAPDH.
As shown in Figure 4C, selective silencing of p65 significantly decreased amplification
of beclin B5’-B3’ and C3’-C5’ fragments, with a more prominent effect on C3’-C5’
fragment. SiB1 was more efficient than SiB2 in decreasing the amplification of beclin1
B5’-B3’ and C3’-C5’ fragments. Notably, we couldn’t obtain any amplification using
A5’/A3’ set of primers (a 516bp amplificate was in fact expected). Other tests were
performed using B5’/A3’ and A5’/B3’sets of primers and demonstrated that A5’ primer
probably did not match any cDNA sequence (data not shown).
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Figure 4B: beclin1 transcript according to ENSEMBL ENSG00000126581. Sets of primers used for RT-
PCR analysis of beclin 1 transcript. Positions of both beclin1 siRNAs used as positive controls (SiB1 and
SiB2) are reported in red color
          
Figure 4C: RT-PCR analysis of beclin 1 mRNA fragments obtained using the three different sets of
primers reported in figure 4B and GAPDH mRNA expression in U2OS cells. Cells were tranfected as
indicated. RNAs were reverse-transcribed and amplified with the indicated set of primers for beclin 1 and
with GAPDH primers as described under “Experimental Procedures.” The relative beclin 1 mRNA level
was normalized by reference to the GAPDH. Left pannel: the major bands of around 500bp expected to
be amplified using B5’/B3’ and C3’/C5’sets of primers were significantly downregulated following
specific p65 siRNA, SiB1 or SiB2 tranfection with respect to a transfected scrambled control siRNA.
Note that no specific A5’-A3’ fragment has been amplified.
Figure 4B
Figure 4C
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Analysis of beclin 1 transcripts using different databases underlined that beclin 1 first
exon is poorly characterized and several annotated beclin1 transcripts were shown to
lack this exon. Notably, other three amplificates, besides the expected ones and with
lower molecular weight were amplified using B5’/B3’ and C5’/C3’ sets of primers, and
they seemed to be differentially regulated by the specific beclin 1 siRNAs used. This
suggests that actually other beclin1 transcripts, different from the full lenght one, might
exist.
Data from these preliminary assays prompted us to design a beclin 1 Taqman probe and
the relative primers on the twelfth beclin 1 exon for subsequent quantitative PCR
analysis. In fact, C5’-C3’ amplificate was efficiently silenced both with p65 siRNA and
SiB1. Moreover, p65 silencing efficiently decreased also the lower molecular weight
amplificates.
U2OS cells were then transfected with p65 siRNA, SiB1 and a scramble control siRNA
(SiC-). After 72 hours of transfection, total RNA was extracted and reverse transcribed
as explained in ‘Experimental procedures’ section. Real Time PCR reactions were
performed using the aforementioned specific Beclin 1 Taqman probe and a GAPDH
probe was used for subsequent data normalization. Calculation of the mRNA values was
performed using ∆∆Ct method. Specific p65 siRNA was demonstrated to decrease
beclin1 mRNA levels in a significant manner with respect to both control siRNA and
SiB1 in U2OS cells.
We could therefore conclude that constitutive p65 regulates beclin 1 transcription.
In attempt to further clarify whether, besides Beclin 1 mRNA, p65 could positively
regulate also beclin 1 protein steady state levels, p65 was overexpressed alone or
toghether with p50 in U2OS, HEK 293T or Hela cells and western blot analysis of
beclin 1 protein levels was performed. Unfortunately, in these settings, we were unable
to see any p65-mediated change in the regulation of beclin 1 steady state levels (data not
shown), and since we did not know whether the lack of such expected p65- mediated
effect on beclin 1 could be directly attributable to inefficient transfection or to
postranslational beclin 1 regulation, we decided to investigate p65 role in beclin 1-
mediated downstream effects.
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Figure 4D: qPCR analysis of beclin 1 mRNA in U2OS cells. Cells were transfected with siRNAs as
indicated. Equal amounts of total RNAs were reverse-transcribed and amplified with specific Taqman
beclin 1 FAM probe and with Taqman GAPDH VIC as described under “Experimental Procedures.”
Student’s t-test was used to assess the statistical significance of the observed beclin 1 mRNA differences
in qPCR experiments.
Production of anti-LC3 antibody
The clear effect of p65 on beclin 1 transactivation prompted us to investigate whether it
could regulate beclin 1–mediated autophagy induction.
The data reported in the previous sections demonstrated that p65 could regulate beclin1
transcription. In order to clarify whether p65 could have any effect also on autophagy,
we decided to produce an antibody against LC3, since commercially available
antibodies didn’t show appropriate immunoreactivity against LC3 protein. Indeed, in
our previous work (Demarchi F. et al., 2006) we used an αLC3 antibody kindly
provided by Yoshimori’s lab.
The strategy used for αLC3 antibody production was very similar to the one used by
Yoshimori (more specific information can be found in “experimental procedures”
section). We decided to produce two differently tagged RatLC3 recombinant proteins in
BL21 DE3 bacteria strain: a 6His GST tagged LC3 recombinant protein was used for
rabbit immunization and a 6His tagged LC3 recombinant protein was used for
subsequent rabbit serum purification. Proper induction of the expression of both
recombinant proteins was assessed (Figure. 5A).
Figure 4D
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Figure 5A: expression of recombinant proteins was tested. Left panel: Coomassie gel loaded with lysates
of BL21DE3 bacteria strain transformed with constructs codifying for 6His Rat LC3 or for another 6His
protein previously produced are shown. Right panel: Coomassie gel loaded with lysates of BL21DE3
bacteria strain transformed with constructs codifying for GST alone or GST Rat LC3. NI: not induced; I:
induced (0,5M IPTG, 37°C).
Recombinant proteins were further analyzed by western blot using specific αGST
antibody and Yoshimori’s αLC3 antibody. The recombinant proteins were efficiently
expressed and were recognized by both antibodies (Figure 5B). Proteins were
subsequently purified onto a nickel column. A rabbit was then immunized with the 6His
GST tagged LC3 recombinant protein.
                                    
Figure 5B: BL21 DE3 bacteria were transformed with constructs codifying 6His GST Rat LC3, 6His Rat
LC3 or for 6His CH and GST alone as controls. Upper panel: Western blot analysis of bacteria expressing
6His GST Rat LC3 using αGST antibody. Lower panel: Western blot analysis of bacteria expressing 6His
GST Rat LC3 and 6His rat LC3 using a specific αLC3 antibody provided by Yoshimori’s lab.
Figure 5A
Figure 5B
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Sera from immunized rabbit were subsequently purified using a column onto which
6His LC3 had been covalently crosslinked. Purified αLC3 antibody was then tested in
human cells overexpressing either human or rat LC3 proteins. In fact, high degree of
homology among rat, human and murine LC3 primary amino acid sequences exists,
indeed the antibody was expected to recognize also huaman and murine LC3.
As shown in Figure 5C, our purified αLC3 antibody efficiently recognized
overexpressed human and rat LC3.
Next, we tested the immunoreactivity of our antibody against endogenous murine LC3
in wild type murine embryo fibroblast (MEF) cells in which autophagy was induced by
ceramide and tamoxifen treatment. Figure 5D clearly shows that our αLC3 antibody
recognized murine LC3. Moreover, it efficiently recognized both LC3I and LC3II
forms. Thus, induction of autophagy can be easily followed using this antibody. We
performed the same analysis also using human cell lines and the same result was
obtained (data not shown, see below).
                             
Figure 5C: Lysates from U2OS cells overexpressing HA tagged human LC3, GFP tagged human LC3,
GFP tagged Rat LC3 or GFP alone were subjected to SDS-PAGE and subsequently analyzed by western
blot using our purified αLC3 antibody. αLC3 antibody showed good immunoreactivity against both
human and rat overexpressed LC3 proteins.
Figure 5C
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Figure 5D: wild type MEF cells were treated for 12h with 25µM ceramide or 10µM tamoxifen. Cell
lysates were then subjected to SDS-PAGE and subsequently analyzed by western blot using αLC3
antibody purified from different bleedings. αLC3 antibody produced in our lab efficiently recognized
both LC3I and LC3II forms in murine embryo fibroblast cell line. Autophagy induction is indicated by
the increase of LC3II band observed after treatment with both drugs and due to LC3I processing.
p65 positively regulates autophagy in different human cell lines
In the previous sections we brought to light that p65 positively regulates beclin 1
transcription, probably by directly binding to its promoter and inducing its expression.
These observations prompted us to perform further biochemical analysis in order to
clarify whether p65 was involved in the induction of the autophagic process.
U2OS, HEK 293T and HeLa cell lines were analyzed for their ability to undergo the
autophagic process consequently to ceramide or tamoxifen treatment and the effect of
p65 knock down or of overexpression of either p65 or of p65 inhibitor proteins was
monitored.
As shown in Figure 5A, p65 silencing was able to block LC3I to LC3II processing,
indicating that p65 could mediate autophagy induction. Notably, p65 silencing exerted
this kind of blockage also in not treated cells; indeed, it is likely that p65 might affect
cellular constitutive autophagy. We also asked whether the disappearance of LC3II band
following p65 silencing could be attributed to an induction of p65-mediated LC3II
lysosomal processing; nonetheless, it is unlikely that such a process occurred, since
accumulation LC3I was observed after p65 knockdown.
Effect of p65 and of p65 inhibitors (IkBSR [an IkB protein in which serine 32 and 36
have been substituted with alanine residues and therefore cannot be targeted to
proteasomal degradation], p50 and p105) overexpression on LC3I processing were also
assessed in HEK 293T cells treated or not with 25µM ceramide.
Figure 5D
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Figure 6A: Upper and middle panels: Silencing of p65 decreases LC3 processing. U2OS and Hela cells
were transfected with specific p65 siRNA and with a scramble control RNA for 72h and subsequently
treated for 12h with 25µM ceramide or 10µM tamoxifen. Effect of p65 knock down on LC3 processing
(e.g. on autophagy) was evaluated. Cell lysates were subjected to SDS-PAGE and subsequently analyzed
by western blot using our αLC3 antibody. Autophagy induction is indicated by the increase of LC3II
band observed after tratment with both drugs. Quantification of LC3I and LC3II bands was performed
using Image J program and values reported indicating LC3II/LC3I ratio are representative of the
autophagic process activation. Lower panel: LC3I processing in HEK 293T overexpressing the indicated
constructs was monitored.
              
Figure 6A
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Of note, when overexpression of p65 inhibitor proteins was performed we couldn’t see
any increase of LC3I processing following ceramide treatment, while the same
processing was not blocked following p65 overexpression. Unfortunately, HEK293T
cell line LC3II levels seemed to be significantly higher with respect to LC3II levels
observed in U2OS and Hela cell lines, rendering LC3I processing more difficult to
detect.
Next, the effect of p65 depletion on autophagosome formation was monitored by means
of immunofluorescence experiments using GFP-LC3 as a read-out. U2OS cells
transfected either with specific p65 siRNA or with a scrambled control RNA for 72
hours; later small amounts of human GFP LC3 (about 100ng) were overexpressed in the
same cells, and after 6 hours the cells were treated with tamoxifen for 12 hours.
In the absence of an autophagic stimulus, GFP LC3 staining appears diffused
throughout the cytoplasm, while following autophagic induction, autophagosome
formation is evidenced by a punctuate perinuclear staining. As shown in Figure 6B, p65
silencing significantly abolished autophagosome formation, this effect being more
prominent in tamoxifen treated cells.
                             
Figure 6B: U2OS cells were transfected with specific p65 siRNA and with a scramble control RNA for
72h; subsequent overexpression of 100ng of human GFP LC3 for 6h was performed. Finally cells were
either treated or not with 10µM tamoxifen for 12h. Immunofluorescence was than performed and some
representative images are shown in the lower panel. Upper panel: 200 cells were counted in each
experiment, and the number of cell presenting a punctuate GFP LC3 staining are reported. Data represent
the means of at least three independent experiments.
Figure 6B
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Beclin 1 steady state levels and autophagy regulation  in U2OS derivative cells lines
inducible for p65 or IkBα SR expression
The results reported in the previous section argue for an involvement of p65 in
autophagy induction suggesting that this induction might result from the upstream p65-
mediated enhancement of beclin 1 transcription. In spite of evidences demonstrating
p65-mediated upregulation of beclin 1 transcription, we were not able to see any
significant change of beclin1 protein steady state levels neither with the use of a specific
p65 siRNA, nor by overexpression. Several can be the reasons beyond these discordant
data. One explanation could rely in the low transfection efficiencies that can be reached
when performing transfection of either siRNAs or cDNAs with the conventional
protocols. In fact, using conventional transfection strategies usually the transfection
efficiencies obtained range from 20 up to 50%; thus, the final effect of transfection
could not be strong enough when considering specific processes. An other possibility
that arises when working with transcription factors, is that transcription and translation
of other target genes, beyond the one of interest, might interfere by temporal and spatial
means in some processes (e.g. in translation or in the activation of proteolytic systems
etc), rendering the detection of the final effect more difficult to see. Furthermore, it is
necessary to bear in mind that p65 signalling occurs through tightly regulated waves of
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activation; consequently it is fundamental to work at appropriate times after p65
activation.
In order to circumvent these problems, we decided to produce U2OS cell lines inducible
for both p65 and IkBSR. Indeed, in this way, we could assure a 100% p65 and IkBSR
expression efficiency and, more importantly, we could better regulate the timing of p65
or IkBSR induction/expression.
U2OS ponasterone A inducible cell lines for either p65 or IkBSR (Super Repressor)
were obtained as described in the experimental procedures section.
Inducibility of two clones for each inducible cell line was tested. As shown in figure 7A
                 
Figure 7A: generation of U2OS cell lines inducible for either p65 or IkBSR inducible cell lines were
obtained as described in the ‘experimental procedures’ section. Two clones for each kind of inducible
U2OS cells were tested. Treatment with 5µM ponasteron A for 16h significantly increased the expression
of both p65 and IkB of the selected clones.
all the clones selected showed proper induction of p65 or IkBSR after ponasterone A
treatment.
                               
Figure 7A
Figure 7B
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Figure 7B: p65 upregulates beclin 1 steady state levels and induces autophagy. Upper panel: clones
1and 2 inducible for p65 were treated with 5µM ponasterone A  for 6 hours. Cell lysates were subjected
to western blot analysis for monitoring beclin1 levels and LC3I processing. Lower panel: western blot
analysis of clones 1 and 18 inducible for IkBSR was preformed; again, beclin1 levels and LC3I
processing were monitored. (NI: not induced; I: induced). Quantification of the bands was performed
using Image J tool.
Therefore, we went on monitoring beclin 1 protein levels and LC3I processing in all the
clones selected after induction with ponasterone A. Figure 7B shows that p65 induction
significantly enhanced beclin 1 levels; on the other hand, LC3I processing efficiently
occurs in Cl.1p65, but not in Cl.2p65. One likely explanation for this contradictory
behaviour might be provided when considering that p65 induction triggers the activation
of several downstream effectors, mainly through its ability to transactivate a plethora of
target genes. Among them, IkBα  undergoes to p65-mediated transactivation after
ponasterone A treatment (see Figure 7D lower panel) and this event can both halt or
limit p65 signalling.
Analysis of beclin1 levels and LC3I processing in Cl1IkB and Cl.18IkB revealed a
prominent downregulation of beclin1 steady state levels and a net decrease of LC3I
processing.
Several experiments have been performed using these clones in order to verify p65 or
IkBSR-mediated effects in autophagy induction. A common observation was that the
aforementioned effects were more reproducible when using IkBSR clones. Explanation
for these observations might again be the ones mentioned above: activation of p65 leads
to downstream activation of several genes, the effect of which is hardly predictable.
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Thus, IkBSR might represent a better tool for understanding p65-mediated effect in our
experimental settings.
Finally, immunofluorescence assays were performed and each p65 or IkBSR clone was
tested for its ability to induce autophagosome formation. All the clones were transfected
with low amounts of human GFPLC3 for 6h and then induced with ponasterone A for
12 hours. Figure 7C shows representative images. Similarly to what was emerged by
previous western blot analysis of the clones, in this settings p65 expression induction
increases the number of GFPLC3 positive autophagosomes. Strikingly, in these settings,
IkBSR was almost completely unable to induce autophagosome formation.
Furthermore, endogenous LC3 staining and autophagosome formation was monitored
by fluorescence microscopy and the ability of p65 to induce autophagosome formation
was confirmed (Figure 7D).
Altogether, the data obtained with these derivative U2OS cell lines, stronlgy suggest
that p65, in these settings, is a positive regulator of the autophagic process. Nonetheless,
p65-mediated regulation of autophagy is likely to be finely tuned, since p65 induction
caused waves of activation or inactivation of its signalling. For this reason, the use of a
derivative U2OS cell line expressing IkBSR that overcomes p65 tuning and halts is
signalling, better elucidated p65 role in the autophagic process.
Thus, the results presented led us to hypothize that p65-mediated autophagy induction
should occur via p65 upstream ability to directly regulate beclin 1 expression at a
transcriptional level.
Furthermore, since we demonstrated that IkBSR almost completely abolishes
autopahgosome formation, it is likely that a canonical NF-kB is involved in the
regulation of autophagy.
                                
Figure 7C
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Figure 7C: Lower panels: U2OS derivative Cl1p65, Cl2p65, Cl1IkBSR and Cl8IkBSR cells were initally
transfected with low amounts (100ng) of GFPh LC3 for 6h and then treated or not with ponasterone A for
12h; immunofluorescence was performed and some representative images are shown in the upper panel.
Upper panel: 200 cells were counted in each experiment, and the number of cell presenting a punctuate
GFP LC3 staining are reported. Data represent the means of at least three independent experiments.
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Figure 7D: p65 Upper panels: U2OS derivative Cl1p65 and Cl1IkBSR cells were treated or not with
ponasterone A for 12h; afterwards the cells were fixed and analyzed by fluorescence microscopy;
endogenous LC3 staining  was monitored using anti-LC3 anibody. A punctuate staining indicates
Figure 7D
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autophagosome formation. Representative fields are shown. Lower panel: contemporaneously, the same
clones were treated in the same way and subjected to western blot analysis.
                               
Involvement of p65 mediated autophagy during K562 chronic myeloid leukemia
differentiation towards megakaryocytic phenotype in response to PMA
In order to address the physiological significance of p65 mediated autophagy our
investigations were focused on human K562 chronic myeloid leukemia cell line.
K562 cells have been frequently used as a model system for studying early steps in
megakaryocytic and erythroid differentiation. In particular these cells can be induced by
PMA to differentiate into cells with megakaryocytic characteristics, including cell
growth arrest, changes in cell morphology and adhesive properties, and expression of
markers associated with the megakaryocytes (Alitalo, 1990).
Previous studies demonstrated that PMA-induced differentiation of K562 cells was
significantly downregulated by NF-kB inhibitors, whereas NF-kB subunit transfected
cells were shown to be more sensitive to PMA-induced differentiation into
megakaryocyte phenotypes than parental cells (Kang et al., 1996; Kang et al., 1998).
Furthermore, M.I Colombo (Colombo and Fader, 2006) recently reported indicate that
K562 GFP-LC3 expressing cells present a high basal level of GFP-LC3 bodies with
respect to CHO cells suggesting a role for the autophagic pathway in the differentiation
process of this cell type.
In light of these observations, we used this cellular system to explore whether NF-kB
inhibition could prevent autophagy induction.
To this aim HA- tagged IkBαSR was subcloned into an adeno-associated virus (AAV)
expression vector and its  expression was tested in Hela cells.
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As shown in Figure 8A, 2 days of infection with AAV-HA-IkBαSR were sufficient to
induce proper HA-IkBα  expression and to downregulate NF-kB-mediated
transactivation of IkBα and COX-2 target genes when compared with AAV-MCS
control infection in Hela cells.
Moreover AAV-HA-IkBα infection induced a clear downregulation of beclin 1 steady
state levels and an impaired LC3I processing, confirming the previous results obtained
by specific p65 knockdown on LC3I processing in the same cell line.
       
Figure 8A: HeLa cells were subjected to AAV-HA-IkBα  and AAV-MCS infection for two days.
Western blot analysis of COX-2 (left panel), beclin 1, actin, IkBα and LC3 (right panel) protein levels
was performed. Quantification of beclin 1, actin and LC3I and LC3II was performed using Image J
program.
Next we went on analyzing the effect of NF-kB inhibition in K562 cells. 6 days after
infection with AAV-HA-IkBαSR, HA-IkBαSR expression was still detectable as well
as its effect on downregulation of COX-2 NF-kB target gene (Figure 8B).
As expected PMA-mediated NF-kB induction resulted in a clear increase of COX-2 in
AAV-MCS infected control cells, whereas AAV-HA-IkBαSR infection perfectly
rescued the effect of PMA treatment.
Interestingly, PMA treatment resulted in the induction of autopahgic activity in K562
cell line, as demonstrated by the clear increase of LC3I to LC3II processing observed in
Figure 8A
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AAV-MCS infected cells following PMA treatement. Of note, in these settings, HA-
IkBα clearly rescued PMA induced autophagy. Furthermore and coherently with the
aforementioned effect on LC3I processing, HA-IkB expression downregulated beclin 1
protein steady state levels both in not treated and in PMA-treated cells. These results
confirm that p65 is involved in autophagy induction also in K562 cellular system,
possibly suggesting that p65-mediated autophagy induction might be required for K562
cells to undergo megakaryocyte differentiation.
   
Figure 8B: K562 cells were infected for 6 days with AAV-HA-IkBαSR and AAV-MCS as a control, and
treated or not with PMA (10ng/ml). Western blot analysis of cell lysates and steady state levels of COX-2
(left panel), beclin-1, LC3, IkBα and actin (right panel) was performed.
Preliminary evidences of p65 binding to beclin 1 promoter using chromatin
immunoprecipitation (ChIP) assay
In light of the results presented in the paragraphs “p65 enhances transcritional activity
of beclin 1 promoter” and “ Isolation of p65/RelA consensus on ChET4 beclin 1
promoter”, it was reasonable to hypothesize a p65 binding to beclin 1 promoter in the
p65/RelA consensus region, specifically to the putative kB site identified with the
previously reported in silico analysis.
In order to verify this hypothesis, preliminary chromatin immunoprecipitation (ChIP)
assays of endogenous p65 were performed in Hela cells expressing or not HA-tagged
IkBαSR. In order to reach 100% HA-IkBαSR expression, proper HA-tagged IkBαSR
expression was reached after 2 days of infection with AAV-HA-IkBαSR.
Figure 8B
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Preliminary ChIP of endogenous p65 assays were thus performed in Hela cells infected
with AAV-HA-IkBα or AAV-MCS as a control. In this settings we could observe a
decreased ability of p65 to bind the identified putative kB site in the promoter of
endogenous beclin 1: the ability of p65 to bind beclin 1 promoter in Hela cells
expressing HA-tagged -IkBαSR was in fact almost abolished, with respect to Hela cells
infected AAV-MCS (Figure 9).
          
                                 
Figure 9: ChIP experiment was performed in Hela cell line infected for 2 days with AAV-MCS or AAV-
IkBαSR. Black bars: IP with αp65 specific antibody; white bars: IP performed using an unrelated
antibody. In the upper panel ChIP results relative to Beclin 1 specific bindind and to DHFR aspecific
binding are shown. Lower panel represents the ratio of the folds of p65 specific binding to beclin 1
promoter normalized with DHFR.
Figure 9
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DISCUSSION
NF-kB family of transcription factors can be found in all cell types and gives rise to a
wide and often contradictory spectra of biological responses, depending on the cellular
context and on the inducing stimulus. A further level of complexity is given by NF-kB
activation pathway modalities, which show significant differences concerning the
modes and the kinetics if IkB degradation, the requirement of different IKK, adaptor
proteins and NF-kB dimers. All of these aspects account for NF-kB ability to generate
waves of activation and inactivation in response to a given stimulus, leading to finely
tuned persistence of its signaling and transcriptional response (Tiana et al., 2007).
Recent work performed in our lab focused on calpain involvement in the modulation of
alternative pathways of cell death has shown that calpain is involved in NF-kB
activation and in its relative prosurvival function in response to ceramide (Demarchi et
al., 2005). In this work we demonstrated that p105 and p50 are calpain targets and that
calpain expression knock down resulted in the stabilization of endogenous p105 and
p50. Ceramide treatment of cells deficient for calpain activity impaired p105 processing
and NF-kB signaling and triggers apoptosis. Altogether these data suggest that ceramide
engages an NF-kB-dependent survival pathway that counteracts ceramide-induced cell
death and that calpain activity is required for NF-kB prosurvival function in response to
ceramide treatment. Furthermore, previous works demonstrated that regulation of NF-
kB transcriptional activity partially relies on calpains through degradation of IkBα
(Shumway et al.1999; Schoonbroodt et al., 2000), suggesting that calpains act in
parallel to the proteasome in regulating NF-kB. Several works demonstrated that
ceramide, besides triggering apoptosis, also induces alternative cell death pathways
among which necrosis and autophagy. The involvement of ceramide in autophagy
induction was further strenghtened by Scarlatti and Lavieu, who investigated the
mechanisms leading to autophagy induction after ceramide treatment (Lavieu G. et al.,
2006; Scarlatti F. et al., 2004).
More recently we investigated the role of calpain in the modulation of cell death,
addressing its role in autophagy. We demonstrated that calpain depletion impairs the
formation of bona fide autophagosomes both in human and mouse cell lines following
amino acid or serum starvation and treatment with ceramide, rapamycin and etoposide.
(Demarchi F. et al., 2006)  In the same work we also highlighted the importance of
calpain in inducing cytoprotective autophagy: knock down of both calpain and Atg5
90
increased apoptosis following aminoacid starvation. In these experimental settings, the
effect of calpain depletion resulted to be more severe than Atg5 depletion, indicating
that additional and probably upstream prosurvival mechanisms, such as NF-kB
prosurvival activation, are lost in the absence of calpain.
Altogether these data strongly argued for an involvement of NF-kB and possibly other
transcription factors in the autophagic induction and prompted us to further explore
their involvement in this process.
In order to identify whether a common transcriptional regulation mechanism for the
autophagic genes might exist, we screened the promoter region of a list of autophagic
genes conserved both in mouse and human genome using CONFAC tool. Even if not
any common transcription factor was shared among the selected promoters, NF-kB
consensus binding sites were found both on mouse and human beclin 1 promoter.
Beclin 1 gene involvement in the autophagic process has been previously well
documented and it has been defined a tumor suppressor gene since it is frequently
monoallelically deleted in a high percentage of human breast, prostate and ovarian
cancers (Aita et al., 1999). Enforced expression of beclin 1 gene has been demonstrated
to induce autophagy in different contexts, but the final outcome of this autophagic
process seems to be cell type specific and stimulus dependent. Indeed, autophagy has
been proposed to represent on one hand a pathway of cellular demise (PCD II),
especially in cells with impaired ability to undergo apoptosis and, on the other hand, to
function as a prosurvival mechanism allowing survival during starvation and in
response to stressing agents by assuring proper removal of damaged organelles or
unfolded proteins. Independently of the stimulus used, beclin 1 represents an absolute
requirement for autophagy to be induced.
Interestingly many stimuli known to induce autophagy have also been reported to
activate NF-kB (e.g. ROS (Bubici et al., 2006), ceramide (Demarchi et al., 2005),
TNFα, TRAIL (Perkins, 2007), but also viral (Hiscott et al., 2006) and bacterial
infections (Hayden et al., 2006).
We then wished to better analyze beclin 1 promoter and its regulation by p65
transcription factor. To this aim a region corresponding to beclin 1 promoter localized
immediately upstream to beclin 1 ATG-sequence, and previously isolated in Dr.
Farnham’s lab was cloned in a luciferase reporter vector and the ability of different
transcription factors to transactivate luciferase gene was analyzed. We found that p65
alone and together with p50 strongly upregulates beclin 1 promoter activity. To further
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characterize beclin 1 promoter and given that different kB sites with different scores
were predicted to be present in beclin 1 promoter by the bioinformatic tools used,
isolation of the most 3’ region of the promoter encompassing the kB site with the
highest score, was performed and its regulation by p65 was investigated. We found that
this beclin 1 promoter region is highly responsive to p65 transcription factor in U2OS
and 293T cell lines, and shows a clear increase of the reporter activity that is further
enhanced by p65/p50 heterodimer (Figures 2B, 2C, 3B and 3C).
In order to validate beclin 1 promoter responsiveness to autophagic stimuli, its
transactivation potential was evalueted following ceramide or tamoxifen treatment, two
previously characterized autophagic stimuli. Intriguingly, we found that different
susceptibility arose following treatment with these stimuli and was dependent on the
promoter region considered. In fact, when considering a beclin 1 promoter region
encompassing ∼1100 bp upstream of ATG, the activity following both ceramide and
tamoxifen treatment was almost identical to the one observed in not treated cells (Figure
2C). In contrast, when a restricted 5’ region encompassing the most probable kB site
was considered (p65 consensus region), a significant transactivation of the luciferase
gene was observed following ceramide and tamoxifen treatment (Figure 3D).
These data argue for a complex regulation of beclin 1 promoter, in which several
transcription factors could regulate beclin 1 transcription depending on their abundance
in different cellular contexts, or on their availability in specific phases of cell cycle. For
example, we observed a net decrease of the transcriptional activity following E2F
binding to beclin 1 promoter when perfoming luciferase reporter assays (Figures 2B,
2C, 3B and 3C).
 Of note, recent works demonstrate the importance of beclin 1 and of autophagy in
preventing genomic instability following hypoxic stimuli in cells in which the apoptotic
pathway was impaired due to Bcl-2 overexpression, suggesting that several cell cycle
regulated transcription factors are likely to be involved in beclin 1 and thus in
autophagy regulation (Karantza-Wadsworth et al., 2007; Mathew et al., 2007).
More importantly beclin 1 promoter transcriptional activity following depletion of
endogenous p65 was significantly downregulated independently of the promoter region
used and also in not treated cells (Figures 2D and 3D). These pieces of evidence suggest
that p65 regulation of beclin 1 transcription could be constitutive and might contribute
to cellular homeostasis. In fact, besides being activated following different stress
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signals, autophagy is constitutively required as a step of ‘quality control’ for organelles
and proteins, in order to maintain cellular homeostasis (Massey et al., 2006).
Data obtained from semi-quantitative RT-PCR in 293T cells (Figure 4A) and from
qPCR experiments further enforce the aforementioned hypothesis: we demonstrated that
in not treated U2OS cells, p65 depletion is sufficient to decrease beclin 1 mRNA
transcription and the same data were obtained using HeLa cell line (Figure 4D and data
not shown).
Despite the clear effect observed on beclin 1 mRNA levels following p65 depletion, in
the same conditions we were unable to see any change in beclin 1 protein steady state
levels. This problem was circumvented only by the production of a U2OS derivative
cell line inducible for p65 expression. Induction of p65 led to an increase of beclin 1
protein levels (Figure 7B). Intriguingly we observed that beclin 1 protein upregulation
was dependent on the time of p65 induction, suggesting that a kinetic of beclin 1 protein
regulation exists. In fact, we confirmed that p65 induction triggers IkBα trascription and
upregulation (data not shown); this event could engage a negative feedback mechanism
that might halt or limit beclin 1 transactivation thereby influencing the timing of beclin
1 expression. One of the most important characteristics of p65 activation is the ability to
generate waves of transcription that are tightly regulated depending on the persistence
of the p65 activating stimulus. When considering the autophagic process this modality
of p65 activation could be fundamental, since inappropriate induction of autophagy
could be detrimental for cell fate and lead to cellular demise.
Another explanation for the observed results relies in Beclin 1 postranslational
modifications that might tightly regulate its stability and turnover. Preliminary in vitro
proteolysis assays performed in our lab have demonstrated that Beclin 1 protein is a
calpain substrate and it is more susceptible to degradation than p53. Interestingly,
following ceramide treatment, both calpain and NF-kB are activated, suggesting that
complex beclin 1 postranslational modifications might occur.
Of note, when an inducible IkBSR derivative U2OS cell line was used, clear
downregulation of beclin 1 protein was observed (Figure 7B). In this experimental
settings, IkBSR induction downregulated Beclin 1 protein levels independently of the
duration of IkBSR induction.
These results prompted us to better characterize the role of p65 in autophagy induction.
LC3 processing and its conjugation with PE represents a reliable and widely used
marker of autophagy induction. Autophagy induction can be examined either by
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immunofluorescence assays to follow the appearance of punctuate fluorescent LC3-
containing structures, or by western blot analysis to detect the appearance of the
phosphatidylethanolammine-conjugeted form of LC3 (LC3II), which is found
associated to the autophagosomal membranes. Alternatively, a GFP-LC3 expression
plasmid can be transfected in the cells of interest, and the formation of punctuate
fluorescent autophagosomal structures can be analyzed by microscopy.
In order to monitor autophagy induction we produced an antibody that showed good
immunoreactivity towards both processed and unprocessed human, murine and rat LC3
protein. We used this reagent for further dissecting p65 role in autopahgy induction.
We observed impaired formation of LC3II form in both U2OS and HeLa cell lines
following p65 depletion, suggesting that a blockage in autophagosome formation occurs
and that p65 is required for autophagy induction (Figure 6A). This blockage already
occurs at basal level in not treated cells and is maintained after ceramide or tamoxifen
treatment, implying a p65 requirement both in cellular homeostasis control and for the
proficient induction of autophagy that is observed following ceramide and tamoxifen
treatment (Figure 6A). The evidence of an impairment in autophagosome formation was
enforced by immunofluorescence assays in which diffuse GFP-LC3 staining was
observed following p65 depletion, thereby suggesting that autophagosome formation is
halted. A more striking impairement in auophagosome formation was observed using
U2OS derivative cell lines inducible for p65 or IkBSR expression. In these experimental
settings, while GFP-LC3 punctuate staining clearly appeared in p65 inducible cell line,
it does not appear in IkBαSR cell line, where no GFP-LC3 structures are formed
(Figure 7C).
Similar results were obtained in 293T cell line where LC3I processing has been shown
to be impaired following transient overexpression of NF-kB inhibitors, such as IkBαSR
or p105 (Figure 6A). In the same cell line we further observed that a blockage in
autophagy induction again occurs following p50 overexpression (Figure 6A). Of note,
p50 can, in some circumstances, act as a p65 inhibitor at the transcriptional level, since
it is able to bind the same kB elements but it is not compentent for subsequent gene
transactivation. This competition mechanism was already evident in the luciferase
assays presented in this work, in which no significant activation of beclin 1 promoter
has been observed following p50 overexpression (Figures 2B, 2C, 3B and 3C). These
data further suggest that p65 is likely to be required at a transcriptional level, since it
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regulates beclin 1 transcription as demonstrated by the semi-quantitative RT real time
PCR and by qPCR experiments performed in this work.
Another interesting result emerged from semi-quantitative RT-PCR analysis of beclin1
mRNA performed in U2OS cell line (Figure 4C): the data obtained in these experiments
strongly suggest the existence of alternative spliced forms of beclin1 gene. Some
important evidences arose from these analysis and we confirmed that beclin 1 5’UTR is
poorly characterized. We reached this conclusion using two different primers: one of
them (A5’) matched the most 5’ region of 5’UTR and together with A3’ primer was not
able to amplify any 5’ region as shown in figure 4C. Another primer was then designed
and matched a more internal region of beclin 1 5’UTR, but similarly to A5’, it was not
able to amplify the region expected when considering Ensemble beclin 1 genomic
organization (ENSG00000126581) (data not shown). Several annotated cDNA
sequences in EBI and ENSEMBL databases further confirmed this observation.
Concerning other alternative spliced forms of beclin 1, we showed that the use of a set
of primers expected to amplify a cDNA fragment corresponding to a region spanning
from exon 4 to exon 8 led to the amplification of both this expected region of 557 bp
and of a lower molecular weight fragment around 300bp. A similar result was obtained
when amplification was performed with another set of primers expected to amplify a
cDNA fragment spannig form exon 8 to exon 12. In this case two other cDNA
fragments with lower molecular weights around 280 and 150 bp respectively were
amplified. These pieces of evidences suggest that a further level of beclin 1
transcriptional regulation might exist that might confer further complexity to the
regulation of the autophagic process and to the ability of specific transcription factors to
transactivate different beclin 1 splice variants in a cell type and stimulus specific
manner.
Beclin 1 has been demonstrated to contain different domains that enable its interaction
with some regulatory proteins. A Bcl-2 binding domain (aa 86-158 corresponding to
exons 5 and 6) has been characterized; recently resolution of the Bcl-XL beclin 1
peptide structure unveiled the existence of a BH3 domain inside Bcl-2 binding region
(aa107-135). Interestingly, the coding sequence for Bcl-2 binding region of beclin 1 has
been found to be deleted in some human infant brain cDNA clones of the Merck EST
database, suggesting that beclin 1 alternative transcript lacking this region might exists
(Liang et al., 1998). Moreover norther blot experiments also evidenced that besides the
mRNA codifying all 12 beclin 1 exons of 1.7kbp, another transcript of 1.4kbp also
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exists in severel human and mouse tissues (Liang et al., 1998). In line with these
previous reported observations, our semi-quantitative analysis of beclin 1 region
spanning form exon 4 to exon 8 further confirmed the existence of an alternative
amplified cDNA in this region. Of note, Beclin 1 CCD also maps to this region and is
required for Beclin 1 tethering of UVRAG (Liang et al., 2006).
Similarly, amplifications performed with primers designed on exon 8 an exon 12
showed that other cDNAs, besides the expected one of 562bp, are likely to exist.
Noteworthy, this region comprises the so called ECD domain, which is needed for
beclin 1 interaction with Vps34. These evidences, once proved, should be carefully
taken in consideration when characterizing beclin 1 functions in autophagy, but also in
other cellular processes such as apoptosis. Indeed, additional work is required in order
to unveil and confirm the existence of beclin 1 alternative spliced forms.
Concerning p65, we demonstrated that its ability to positively regulate autophagy, in the
cellular systems considered, is probably the result of beclin 1 transcriptional regulation.
Interestingly, both Bcl2 and Bcl-XL p65 transcriptional targets have been demonstrated
to block the autophagic process in some experimental settings. These data seem to be in
contrast with our findings on a positive p65-mediated regulation of autophagy.
Nonetheless other evidences suggest that in many cellular contexts Bcl-2
overexpression is unable to block autophagy (Shimizu et al., 2004; Mathew et al.,
2007). Moreover, the recent identification of beclin1 BH3 domain, that is both
necessary and sufficient for Bcl-XL binding, implies that beclin 1 may be also able to
regulate Bcl-2 in some circumstances, rather than, or in addition to the recently reported
ability of Bcl-2 to regulate Beclin 1 (Pattingre et al., 2005). Intriguingly, with respect to
Bcl-2 family, BH3 domain could mediate novel and unknown beclin 1 functions,
serving as an adaptor for loading of mitochondria into autophagosomes (Kundu and
Thompson, 2005; Edinger and Thompson, 2003). It is noteworthy that different Bcl-2
pools have been suggested to regulate autophagy: considering the aforementioned
suggestions, one could speculate that a mitochondrial Bcl-2 pool might positively
regulate rather than inhibit autophagy. On the other hand, ER targeted Bcl-2 pools that
have been shown to actually inhibit autophagy (Pattingre et al., 2005; Kroemer et al.,
2007), might serve to halt, limit or regulate the proper mambrane sorting that occur at
the early steps of autophagosome formation.
A serie of cell lines expressing mutant beclin 1 deficient in binding Bcl-2, all display
increased levels of type II cell death that can be suppressed by Atg5 specific RNA
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interference (Pattingre et al., 2005). In similar settings, p65-mediated Bcl-2 proper
expression could counteract an autophagic activation that could be detrimental for the
cell, switching on an autophagic prosurvival program through its ability to finely tune
the expression of genes that present, at least at a first glance, quite opposite functions,
such as beclin 1 and Bcl-2.
In contrast to our findings, recent work performed by Djavaheri-Mergny et al., reported
that NF-kB activation represses autophagy induced by TNFα (Djavaheri-Mergny et al.,
2006). This discrepancy could be explained when considering that autophagy is context
and stimulus dependent. In our experimental conditions, in fact, we used different
autophagic stimuli to induce autophagy, such as ceramide and tamoxifen. Our choice
was dictated by our previously published results: as reported above, we clearly
demonstrated that ceramide induces NF-kB activation (Demarchi et al., 2005) and that
ceramide induced autophagy requires calpain (Demarchi et al., 2006). The different
stimulus used might then account for the discrepancy of our data. Indeed, in accordance
with this observation the same authors reported that autophagy can be induced in the
same manner in either NF-kB-competent or in NF-kB incompetent cell lines following
nutrient starvation, further confirming that different p65 regulation of autophagy may be
required depending on the stimulus employed.
Since it has been very well documented that NF-kB activation triggers waves of
responses in order to finely regulate expression of its target genes, we used inducible
cellular systems in which NF-kB activation or repression can be stimulated in a
controlled manner. Thus, the use of these different cellular systems might at least
partially explain the alternative NF-kB role observed in this work. Interestingly, in line
with our RT-real time beclin mRNA analysis, Djavaheri-Mergny et al. demonstrated
that inhibition of p65 in a cell system stably expressing MAD1 (the murine IkB
ortholog) does not lead to increased beclin 1 transcription both in not treated conditions
and following TNFα treatment. Nonetheless, in the same experimental settings they
observed an increase of Beclin 1 protein steady state levels, suggesting that
postranslational regulation of Beclin 1 protein is likely to occur and might be
responsible for beclin 1 upregulation and for autophagy induction (Djavaheri-Mergny et
al., 2006).
Djavaheri-Mergny et al., showed that p65 depletion in MCF-7 cells is sufficient for
autophagy induction. Notably, we observed that p65 overexpression could not activate
beclin 1 promoter in some luciferase assays performed in the same cell line (Figure 1
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Discussion). One explanation for this behaviour is that p65 response is cell type
dependent. In fact it has been previously demonstrated that in this ER positive and
tamoxifen senstive breast cancer cell line p50, rather than p65, is likely to bind DNA
(Zhou et al., 2007; Zhou et al., 2005). Moreover, the same reports also demonstrate that
not any change in the activity of NF-kB driven promoter can be observed following
several SERMs (selective estrogen receptor modulators among which tamoxifen)
treatment, even if they have been demonstrated to activate p65 in other ER positive
breast cancer cell lines (Biswas et al., 2005). We also observed similar results following
tamoxifen, ceramide and TNFα treatment (data not shown). Interestingly, it was
suggested that NF-kB signalling in these cell lines could be largely attributed to p50
DNA-binding and coimmunoprecipitation experiments further demonstrated that, since
p50 lacks a transactivation domain, it requires Bcl-3 co-activator binding for becoming
transcriptionally competent (Zhou et al, 2007).
                               
p65 doesn’t enhance transcriptional activity of beclin 1 promoter ChET4 in MCF7 breast cancer
cell line. MCF7 cells were cotransfected with pGL3ChET4 and E2F, p65, p50, p65 and p50 or a control
empty vector. Luciferase assays were performed 24h after transfection. Data represent the means of at
least four independent experiments and error bars represent standard deviations;
Therefore, it is likely that other pathways besides the canonical, requiring IkB
degradation and probably IKK independent, might be involved in NF-kB signalling in
MCF7 cell line.
Work performed by Djavaheri-Mergny et al., also demonstrates that ROS are involved
in TNFα induced autophagy in cells lacking NF-kB activity and that antioxidant agents
completely abolished autophagosome formation. Noteworthy, a recent report shows that
following nutrient starvation a first wave of ROS production is required for
autophagosome formation and that it is Beclin 1/Vps34-dependent. The same work also
demonstrates that a persistence of ROS signaling at later stages is responsible for
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autophagy impairment, since an oxidizing environment is able to cause Atg4-dependent
LC3 delipidation inhibition and halts autophagy (Scherz-Shouval et al., 2007). These
observations, strongly argue for a step-dependent role of ROS, underlining that a ROS
buffering wave is required for autophagy to occur that follows a first wave of ROS
production. Such a system seems to be more coherent with a tightly regulated mode of
NF-kB activation, indeed several NF-kB target genes such as MnSOD, FHC etc.,
efficiently buffer ROS production. Interestingly, TNFα has been demonstrated to
stimulate ROS production and to trigger strong NF-kB activation. Notably TNFα an
TRAIL have been reported to stimulate autophagy in T-lymphobalstic (Jia et al., 1997;
Jia et al., 2006; Mills et al., 2004) cells and in a model of lumen formation in mammary
acini, suggesting that NF-kB activation might be differentially required for autophagy
induction in different cellular contexts.
Interestingly, a work performed by Cuervo et al., demonstrated that serum removal
caused a significant decrease of IkBα, while following NH4Cl treatment (in order to
inhibit lysosomal degradation) this IkBα levels remained unchanged. These evidences
strongly argued that IkBα is degraded through a lysosomal route. Notably, under the
same conditions, no changes were detected in the NF-kB degradation rates (Cuervo et
al., 1998). When the same authors went on analyzing the relative kinetics of IkBα
degradation in cells cultured in the presence and in the absence of serum, they observed
that after a first fast wave of IkB degradation occurring within minutes and that could
not be inhibited by NH4Cl in both the treatment conditions, a portion of IkBα was
subsequently slowly degraded in cells supplemented with serum. The same portion of
IkBα was also detected in cells deprived of serum, even if the degradation occurred in a
faster way. Strikingly, following 2 days of starvation, a significant decrease in IkBα
cytosolic level was observed and was paralleled by a concomitant significant increase in
NF-kB (p50/p65) DNA binding activity. Another interesting evidence coming from this
work concerned the modalities of NF-kB activation, which was demonstrated to occur
in a cell type specific manner and to be subjected to rises and falls, further undrlying
that NF-kB signalling modalities occur in a time dependent manner. In these
experimental settings the use of PDTC antioxidant inhibits NF-kB signalling and IkBα
degradattion independently of the presence or absence of serum. Hydrogen peroxide
incubation under conditions of serum deprivation were shown to markedly increase
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IkBα degradation, suggesting a partecipation of ROS in the targeting of IkBα to
lysosomes in response to serum withdrawal (Cuervo et al., 1998).
Altogether, the evidences reported suggest that further investigations about NF-kB
signalling activation and involvement in autophagy are required, and need to be
carefully examined. In our experimental settings we demonstrated that: 1) NF-kB
positively regulates beclin 1 at the transcriptional level; 2) NF-kB is required for
constitutive autophagy to occur; 3) NF-kB is required for ceramide and tamoxifen
autophagy induction; 4) NF-kB regulation of beclin 1 protein levels is likely to occur in
a time dependent manner; 5) we suggest that NF-kB might regulate alternative beclin 1
transcripts. Moreover, our evidences indicate that NF-kB might trigger a costitutive
autophagic prosurvival function, rather than a type II PCD program.
Other work is in progress to better characterize p65 binding on beclin 1 promoter kB
site by ChIp experiments and EMSA assays. Recent data suggest that p65 binding to
beclin1 promoter might require formation of a complex since luciferase reporter assays
demonstrate a 2 fold reporter activation following p65/p50/p300 cotransfection with
respect to the p65/p50 heterodimer transfected alone (data not shown). Another
interesting point, that needs to be further explored, concerns beclin 1 splice variants
identification and functional characterization. Recent evidences about beclin 1 structural
oraganization, in fact, point for a beclin 1 involvement in processes other than
autophagy (Maiuri et al., 2007).
Understanding these beclin 1 features and p65 regulation of the autophagic process
needs to be investigated also in different cellular systems and might be instrumental for
the future design of more efficient therapeutical strategies against specific malignancies.
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EXPERIMENTAL PROCEDURES
Cell lines and treatments
U2OS, 293T and Hela cell lines were routinely cultured at 37°C in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS),
penicillin (100 U/ml) and streptomycin (100 µg/ml). K562 cells were grown in
suspension in RPMI medium supplemented with 10% (v/v) FBS, penicillin (100 U/ml)
and streptomycin (100 µg/ml).
C2Ceramide tamoxifen and PMA were purchased from Sigma and were used at the
indicated doses for the indicated times.
The pVgRxR and pIND plasmids (ratio 1: 9) were co-transfected into U2OS cells by the
calcium phosphate method.
U2OS derivative cell lines were obtained by cotransfection of pVgRXR and pIND p65
or pIND IkBαSR in the ratio 1:9 using calcium phosphate method. Selection was
performed with Zeocin (0.5 mg/ml, Invitrogen) and G418 (0.5 mg/ml, Sigma). The
positive inducible clones were identified by Western blot analysis. To induce p65 or
IkBαSR expression, Ponasterone A, a synthetic analog of ecdysone (Invitrogen), was
added to the culture medium at a final concentration of 5 µM for 24 h.
Transfection and vectors
DNA : Subconfluent cells were transfected using Calcium Phosphate method,
Lipopectamine 2000 Reagent (Invitrogen) or FuGENE 6 (Roche Diagnostics) according
to the manufacturer’s instructions. Unless stated otherwise, cells were analyzed 24 h
after transfection.
pIND and pVgRXR were from Invitrogen. pGL3 vector was from Promega. pIND p65,
pIND IKB SR, pGL3 ChET4, pGL3 p65 consensus, pcDNA3HAhp65 and
pCMVtagFLAGp65 were generated by subcloning the relative PCR products into the
vectors of interest. pRSVhRelA/p65 and pRSVNF-kB1/p50 were kindly provided by
Professor N.Perkins; and pCMV4HA-IkBαSR was kindly provided by Professor Shao-
Cong Sun; pcDNA3FLAG p105 was kindly provided by Professor C.Scheidereit;
pEGFPhLC3 and pEGFP rat LC3 were  a kind gift of Professor I.Tanida and
T.Yoshimori respectively; pCMVHAE2F1 was kindly given by Dr. Del Sal G.
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pAAV-MCS was from Stratagene Corporation; pAAV-HAIkBαSR was generated by
HA-IkBαSR subcloning from pCMV4HA-IkBαSR into pAAV-MCS vector.
Replication-deficient Adeno-associated viruses were obtained according to Stratagene
Instruction Manual guidelines.
siRNA: Cells in mid-log growth phase were transfected with siRNA’s (MWG) using
Oligofectamine Reagent (Invitrogen) as recommended by the manufacturer. Cells
transfected with siRNA were analyzed after 48 or 72 h. The control siRNA used was
AACCUUUUUUUUUGGGGAAAA (siCONT/SiCtrl). The mRNA targeted sequences
for beclin1 twelfth exon and p65 were the following: Beclin 1 (NCBI Ac No.
AF077301) (GAUUGAAGACACAGGAGGCTT) (Boya et al. 2005); RelA/p65 (NCBI
Ac No. M62399) (GCCCUAUCCCUUUACGUCATT).
Western Blot Analysis
Western blot analysis was performed according to the standard procedures using the
following primary antibodies: affinity purified anti-ratLC3 polyclonal antibody, anti-
Beclin 1 polyclonal antibody (Santa Cruz Biotechnology), anti-actin polyclonal
antibody (Sigma), anti HA monoclonal antibody (Sigma), anti-p50 monoclonal antibody
(Santa Cruz Biotechnology), anti-FLAG monoclonal antibody (Sigma), anti-IkBα (Cell
Signaling Technology).
Immunofluorescence analysis
Cells were plated on glass coverslips in 3 cm culture dishes. After washing with PBS,
cells were fixed in 3% paraformaldehyde in PBS, treated with 1% glycine in PBS, and
permeabilized in 0.01% saponin in PBS. The staining was performed using specific
antibodies incubated in 5% bovine serum albumin in PBS/0,01%saponin at 37°C
followed by fluorescein isothiocyanate-conjugated secondary antibodies (Sigma).
Semi-quantitative RT-PCR of Beclin 1
RNA from 2x106 cells was extracted using using TRIzol Reagent (Invitrogen). Then it
was incubated with RQ1 Rnase free DNase (Promega) for 30 min at 37 °C. First strand
cDNA synthesis was performed with 4 µg of RNA by using the SuperScript First Strand
Synthesis SystemTM (Invitrogen). The following primers were used to amplify
GAPDH cDNA (5"-cggagtcaacggatttggtcgtat-3"/5"-agccttctccatggtggtgaagac-3") while
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for beclin 1 cDNA amplification the following set of primers have been used: A5’/A3
(5’-gggaagtcgctgaagacaga-3’/5’-gatccacatctgtctggccc-3’); B5’/B3’ (5’-
ccaggatggtgtctctcgca-3’/5’-ctgcgtctgggcataacgca-3’) and C5’/C3’ (5’-
cccagacgcagctggataag-3’/5’-ggacacccaagcaagacccc-3’). The thermal cycle conditions
were 1 cycle for 2 min at 94 °C, followed by 27 cycles of 1 min at 94 °C, 1 min at 63
°C, and 1 min at 72 °C and terminated by 1 cycle for 5 min at 72 °C. Under these
conditions PCR products were amplified in the linear range. GAPDH primers were
added to the amplification mixture after the beginning of the seventh cycle, during the
denaturation phase. Aliquots of each PCR were subjected to electrophoresis at 100 mV
on a 2% agarose gel in the presence of 0.5 µg/ml ethidium bromide. The products of the
amplification were revealed under UV light and photographed on Kodak paper.
qPCR
Quantitative Real Time PCR was performed  as follows: briefly, RNA 3 dishes U2OS
cells (previously silenced for  48 or 72h) was extracted using using TRIzol Reagent
(Invitrogen). Subsequently it was incubated with RQ1 Rnase free DNase (Promega) for
30 min at 37 °C in a thermocycler. RQ1 DNase Stop Solution was added to terminate
the reaction. First strand cDNA synthesis was performed with 0,5 µg of RNA using
oligo dT by and the SuperScript II Rnase H Reverse Transcriptase (Gibco BRL),
according to manufacturer instructions. Of note, the same reaction was performed on the
same samples in the absence of SuperScript II Rnase H Reverse Transcriptase in order
to check genomic DNA background during amplification (it always resulted
undertermined, indicating no genomic DNA contamination). 50ng of each sample was
used for mRNA quantitation. The Beclin 1 gene expression was detected by real time
qPCR assay. Quantification of beclin 1 mRNA was achieved by means of the ABI-
PRISM 7000 Sequence Detection System (PE Applied Byosystems) using TaqMan
Universal Master Mix (Applied Byosystems). RT-PCR was based upon Taqman
fluorogenic detection system Taqman (Applied Byosystems), using a fluorogenic
oligonucleotide probe designed to hybridize the specific target sequence. The Taqman
probes were labeled at 5’ end with the fluorescence reporter dye FAM for beclin1 or
VIC for GAPDH control, and at the 3’ end with the quencher dye TAMRA. The
sequences for gene-specific forward and reverse primers and the probes were designed
using Primer Express 1.0 software (PE Applied Biosystems). The following sequences
of primers and probe were used for RT-PCR of Beclin 1 mRNA: beclin-1 primers on
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12° exons : 5’-gtcctccccgtatcataccattc-3’/5’-acgatggtaaagggagggaagt-3’; Taqman FAM
probe: 5’-cagtggcggctcc-3’; pre-developed Human GAPDH probe was purchased by
Applied Biosystem . RT-PCRs were performed in a MicroAmp optical 96-well plate. 25
microliters of reaction mixture were used, containing 50 ng of total RNA, 1x Taq-Man
Master Mix buffer, 0.9 µM forward and reverse primers, 0.2 µM TaqMan probe.
Amplification settings were performed as previously described (Kaeser et al. 2002),
Triplicate RT-PCR reactions were prepared for each sample. The point at which the
PCR product is first detected above a fixed threshold, termed cycle threshold (Ct) was
determined for each sample, and the average Ct of triplicate samples was calculated for
both Beclin1 and GAPDH. ΔΔCt method was used in order to calculate folds of increase
ore decrease relative to the control sample. A one-tailed Student’s t-test was used to
assess the statistical significance of the observed mRNA differences in qPCR
experiments as previously reported (Benetti et al., 2007). Microsoft excel was used for
statistical calculations. Diferences were considered significant at P<0,05.
Production of anti-LC3 antibody
Briefly, a polyclonal anti-LC3 antibody against full lenght recombinant rat LC3 protein
was produced in  rabbit as follows: pETM30 rat LC3 and pETM11ratLC3 constructs
were obtained by subcloning rat LC3 PCR product. BL21 DE3 bacteria strain was
transformed with these constructs and the relative proteins (e.g. 6His GST rat LC3 and
6His rat LC3 respectively) were purified using NiNTA agarose resin. Proteins were
eluted from the resin by means of a step imidazole gradient (Imidazole 100-250mM);
1mg of pure 6His GST rat LC3 protein was used for rabbit immunization and 4.5mg
6His rat LC3 were covalently coupled to Affi-Prep 10 matrix (BioRad) following
manufacturer instructions. 6His rat LC3 coupled to Affi Prep 10 matrix was used for
subsequent rabbit sera purification.
In silico analysis
In silico analisys of the autophagic genes and NF-kB target genes datasets was
performed using CONFAC (Karanam and Moreno, 2004). The length of sequence
analyzed upstream of the TSS was 500bp. Transfac parameters were set as follows:
Matrix Similarity and Core Similarity at 0,85 and at 0,95 respectively. The Vertebrate
matrix was used and Repeatmasker was applied.
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ConSite (Sandelin et al., 2004) was used to analyze ChET4 sequence using a TF score
cutoff of 85% and 95%. “95%” TF score cutoff analysis confirmed the presence and the
position of the kB site identified using CONFAC; “85%” TF score cutoff was used in
order to verify the exact position of kB elements other than the one identified with
CONFAC.
Chromatin Immunoprecipitation (ChIP)
Cells were crosslinked with 1% final formaldehyde using Fixing solution (11%
formaldehyde, NaCl 100mM, EDTA 1mM, EGTA pH8 0,5mM, TrisHCl pH8.0 50mM)
for 10 min, neutralized with 125 mM glycine in PBS, collected and washed in PBS.
Nuclei were prepared by hypotonic lysis (EDTA 10mM, EGTA 0,5mM TrisHCl pH8.0
10mM, 0.25% Triton X-100), washed in B2 solution (EDTA 1mM, EGTA 0,5mM,
NaCl 200mM, TrisHCl pH8.0 10mM) centrifugated, and resuspended in RIPA-50
buffer (20 mM Tris HCl, pH 7.5, 50 mM NaCl, phophatase inhibitors, NaF 10mM and
Na3VO4 1mM, DFP 2mM and Proteinase Inhibitor Cocktail (Sigma)). Chromatin was
sonicated with Bioruptor (Diagenode) to 500-1000 bp average fragment size and cleared
by centrifugation. Detergents were added to the sonicated samples: NP-40 0,5% DOC
0,5% and SDS 0,1% final concentrations. IP was performed overnight at 4°C with
either: rabbit anti-p65 sc-109 and goat anti-p65 sc-372 (both Santa Cruz
Biotechnology); a negative control was performed in the presence of isotype-specific
unrelated Ab. Real-time PCR was performed on an ABI PRISM 7000 cycler, using
TaqMan Universal PCR Master Mix (Applied Biosystems) as described before. Folds of
promoter occupancy were calculated using ABI-PRISM 7700 software method. Primer
sequences: ChET4 primers 5’-gtcctccccgtatcataccattc-3’/5’-acgatggtaaagggagggaagt-3’;
Taqman FAM probe: 5’-aacggcgcaggttg-3’; DHFR primers: 5’-tcgcctgcacaaatagggac-
3’/5’-agaacgcgcggtcaagttt-3’; Taqman FAM probe: 5’-gggcggccacaatttcgcg-3’.
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!-Catenin is a multifunctional protein serving both
as a structural element in cell adhesion and as a sig-
naling component in the Wnt pathway, regulating em-
bryogenesis and tumorigenesis. The signaling fraction
of !-catenin is tightly controlled by the adenomatous
polyposis coli-axin-glycogen synthase kinase 3! com-
plex, which targets it for proteasomal degradation. It
has been recently shown that Ca2" release from inter-
nal stores results in nuclear export and calpain-medi-
ated degradation of !-catenin in the cytoplasm. Here
we have highlighted the critical relevance of constitu-
tive calpain pathway in the control of !-catenin levels
and functions, showing that small interference RNA
knock down of endogenous calpain per se (i.e. in the
absence of external stimuli) induces an increase in the
free transcriptional competent pool of endogenous
!-catenin. We further characterized the role of the
known calpain inhibitors, Gas2 and Calpastatin, dem-
onstrating that they can also control levels, function,
and localization of !-catenin through endogenous cal-
pain regulation. Finally we present Gas2 dominant
negative (Gas2DN) as a new tool for regulating calpain
activity, providing evidence that it counteracts the
described effects of both Gas2 and Calpastatin on
!-catenin and that it works via calpain independently
of the classical glycogen synthase kinase 3! and pro-
teasome pathway. Moreover, we provide in vitro bio-
chemical evidence showing that Gas2DN can increase
the activity of calpain and that in vivo it can induce
degradation of stabilized/mutated !-catenin. In fact, in
a context where the classical proteasome pathway is
impaired, as in colon cancer cells, Gas2DN biological
effects accounted for a significant reduction in prolif-
eration and anchorage-independent growth of colon
cancer.
!-Catenin plays a dual role both as a major structural ele-
ment of cell-cell adherent junctions and as a pivotal signaling
molecule in the Wnt pathway, transmitting transcriptional
cues into the nucleus (1–3). In the absence of Wnt signaling, the
cytoplasmic levels of !-catenin are kept low through interaction
with a protein complex that can phosphorylate !-catenin and
target it to ubiquitin-mediated proteasomal degradation (4).
Activation of Wnt signaling leads to inactivation of glycogen
synthase kinase 3! (GSK3!),1 a kinase responsible for phos-
phorylation of !-catenin, resulting in accumulation of cytoplas-
mic !-catenin (5). Enhanced cytoplasmic levels of !-catenin
allow its translocation to the nucleus where it cooperates with
a member of the T cell factor (TCF)/lymphocyte-enhancer bind-
ing factor (LEF) family of transcription factors to activate ex-
pression of target genes (6). The three regulatory genes in this
pathway most frequently mutated in human cancers are APC,
!-catenin, and axin. Their mutations result in the accumula-
tion of nonphosphorylated !-catenin, thereby constitutively ac-
tivating gene transcription and promoting carcinogenesis (7).
Wnt signaling operates via cell surface receptors to stimulate
also the activation of Gq pathway and the subsequent increase
in intracellular calcium (8). Li and Iyengar (9) highlighted the
consequences of activation of Gq signaling pathway showing
that calcium release from internal stores results in "-calpain-
dependent degradation of !-catenin.
Calpains are a large family of calcium-dependent intracellu-
lar proteases whose precise and limited cleavage of specific
proteins, in concert with their endogenous inhibitor Calpasta-
tin, is thought to play an integral regulatory aspect in various
signaling pathways from cytoskeletal remodeling to cell cycle
regulation and apoptosis (reviewed in Ref. 10). In addition to
Calpastatin, we have recently characterized Gas2 as an impor-
tant calpain inhibitor (11).
Gas2 is a component of the microfilament system and colo-
calizes with actin fibers (12); it binds the calmodulin-like region
of m-calpain (domain III and IV of large subunit) with its
amino-terminal domain and with its carboxyl-terminal region
exerts an inhibitory function (11). The isolated amino-terminal
region has been demonstrated to act as a dominant negative
form of Gas2 (Gas2DN), being able to bind, but not to inhibit,
calpain activity and to rescue in vivo the effects of Gas2 on
calpain function.
Here we underline the contribution of the calpain system to
!-catenin degradation, showing that m-calpain, as regulated by
the endogenous inhibitors Calpastatin and Gas2, can modulate
!-catenin levels and activity in the absence of external stimuli.
More importantly, we focused our attention on the properties of
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Gas2DN, which can abrogate both Gas2 and Calpastatin ef-
fects, providing biochemical evidence that it can stimulate cal-
pain activity. The Gas2DN-mediated calpain activation was
utilized in colon cancer cells, where !-catenin degradation via
proteasome is impaired. We show that in this cellular context,
the calpain system controls deregulated !-catenin and that the
biological effects of Gas2DN account for a significant reduction
in the proliferation and anchorage-independent growth of colon
cancer cells, therefore representing a potentially critical way to
control deregulated !-catenin.
MATERIALS AND METHODS
Cell Lines, Transfections, and Reporter Assay—Cells were cultured
in Dulbecco’s modified Eagle’s medium (Sigma) with 10% fetal bovine
serum, penicillin, and streptomycin at 37 °C and 5% CO2. Transfections
were performed using FuGENE 6 (Roche Applied Science) or Lipo-
fectamine 2000 (Invitrogen) according to the manufacturer’s recommen-
dation. Luciferase assays were performed with the dual luciferase kit
(DLR) from Promega.
U2OS are human osteosarcoma cells; HCT-116 are human colon
carcinoma cells harboring !-catenin mutation on exon 3 of !-catenin
with three base deletions at codon 45. LS-174 are human colon carci-
noma cells harboring !-catenin mutation, whereas HT-29 are human
colon carcinoma cells harboring APC deletion. MEF GSK3!!/! are
murine embryo fibroblasts null for GSK3!, provided by Dr. J. Woodgett
(Ontario Cancer Institute); H1299 are lung carcinoma cells. The TS-20
cell line is a temperature-sensitive mutant derived from the mouse cell
line BALB/c 3T3 obtained from Dr. Gianni Del Sal (Laboratorio Nazio-
nale del Consorzio Interuniversitario per le Biotecnologie, Trieste,
Italy).
Plasmids—pEGFPC1-Gas2DN (12), pCMVHA-tagged !-catenin
cloned from pMT2-VSV-tagged !-catenin (13), pGDSV7S Gas2wt (12),
and the Calpastatin plasmid (PM194) have been described previously
(14). TOP Luc plasmid was provided by H. Clever. His6-tagged Gas2wt,
His6-tagged Gas2DN, and His6-tagged Calpastatin were generated as
described below under “Calpain Activity Assay.”
Western Blot and Antibodies—Western blot analysis was performed
according to standard procedures using the following primary antibod-
ies: anti-!-catenin (C19220; Transduction Laboratories), anti-Gas2 an-
tibody (12), anti-Calpastatin (monoclonal antibody-C-270), anti-HA
(Roche Applied Science), and anti-m-calpain polyclonal antibody
(C0728) and anti-actin polyclonal antibody (A2066) from Sigma. Anti-
GFP (Invitrogen):polyclonal GFP antiserum (Invitrogen).
Stable Cell Lines—To obtain GFP-Gas2DN/HCT116 and GFP/HCT-
116 cells, selection was performed for 2 weeks in the presence of 1
mg/ml G418. G418-resistant colonies were clonally expanded, and ex-
pression of Gas2DN and GFP was analyzed by Western blot.
Calpain Cleavage Assay in Vitro and in Vivo—In vitro cleavage assay
was performed as previously described (11). The in vivo protein assays
were performed on HCT-116. Cell lysates were prepared freshly at 4 °C
in ice-cold Nonidet P-40 buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
0.4% Nonidet P-40, 1 mM dithiothreitol, 2 mM phenylmethylsulfonyl
fluoride, 1 mM EGTA) and rotated for 30 min at 4 °C. Cell debris was
pelleted by centrifugation (15 min, 13,000 RPM, 4 °C), and the super-
natant was used in !-catenin cleavage assay. 2 mM CaCl2 was added for
endogenous m-calpain activation, and different aliquots of the samples
were collected at the indicated time points. 8 mM EGTA was added to
one of the samples to completely inhibit calcium-dependent calpain
reaction.
Inhibition of m-calpain Expression by RNAi—Small interfering RNA
duplexes, si-m-calpain, were purchased from Dharmacon: siCONT 5"-
AACCUUUUUUUUUGGGGAAAA-3", si-m-calpain 5"-GUACCU-
CAACCAGGACUAC-3", and siGENOME SMARTpool Upgrade MU-
009979–00-0020 human CAPNS1 for calpain small subunit. Cells were
transfected using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s suggestions.
Immunofluorescence and BrdUrd Incorporation Assay—After trans-
fection with the various plasmids, cells were fixed with paraformalde-
hyde (3% in phosphate-buffered saline) and then processed for immu-
nofluorescence with 12CA5 anti-HA antibody (Roche Applied Science).
For BrdUrd incorporation assay, 24 h after transfection cells were
pulsed with 50 "M BrdUrd for 4 h and fixed with paraformaldehyde. To
reveal incorporated BrdUrd, coverslips were treated with 50 mM NaOH
for 30 s and immediately washed with phosphate-buffered saline.
BrdUrd was revealed by anti-BrdUrd monoclonal antibody (GH Health-
care) followed by incubation with rhodamine isothiocyanate (RITC)-
conjugated anti-mouse IgG2a antibody (Southern Biotechnology). Nu-
clei were counterstained with Hoechst 33342.
Soft Agar Assay—For each cell pool, 30,000 cells were suspended in
2 ml of Dulbecco’s modified Eagle’s medium # 10% fetal bovine serum
and warmed to 37 °C. 200 "l of prewarmed (52 °C) 5% agarose/phos-
phate-buffered saline solution was mixed with the cell suspension and
then layered into 60-mm dishes that were previously coated with 2 ml
of 1% agarose in Dulbecco’s modified Eagle’s medium. The agar was
allowed to solidify at room temperature for 20 min before the addition
of 2 ml of growth medium to each well. After 14 days, the colonies were
counted.
Subfractionation Experiments—Subfractionation experiments were
performed as indicated by the manufacturer (ProteoExtract subcellular
proteome extraction kit 539790; Calbiochem).
Calpain Activity Assay—Recombinant His6-tagged Gas2
(pQE11Gas2wt), His6-tagged Gas2DN (pETM11Gas2DN), and His6-
tagged Calpastatin (pETM11Calpastatin) were used to evaluate calpain
activity in biochemical studies. To generate His6-tagged Gas2wt pro-
tein, full-length Gas2wt was subcloned from pGDSV7SGas2wt (12) into
pQE11 vector using BamHI and HindIII sites. For the construction of
His6-tagged Gas2DN and Calpastatin fusion proteins, specific oligonu-
cleotides upstream and downstream containing, respectively, NcoI and
BamHI or NcoI and XhoI sites were used to generate polymerase chain
reaction fragments of Gas2DN or Calpastatin that were cloned in
pETM11 vector. One unit of calpain activity was defined as the amount
of the enzyme causing the production of 1 "mol acid-soluble NH2 re-
vealed with fluorescamine and using acid-denatured globin as substrate
(15). Rat skeletal muscle m-calpain activity was monitored after incu-
bating for 3 min with His6-tagged recombinant proteins Gas2, Gas2DN,
and Calpastatin in a calpain assay buffer containing 50 mM sodium
borate buffer, pH 7.5, 50 "M CaCl2, and rat skeletal muscle m-calpain.
Activity was measured 10 min after the addition of 1 mM calcium and 2
mg/ml denatured globin as previously described (15). Gas2 and Cal-
pastatin, known calpain inhibitors, were used as control of calpain
activity in the same assay.
RESULTS
Constitutive Activity of Calpain in Vivo Regulates !-Cate-
nin—To address the role of constitutive activity of calpain
toward !-catenin, we designed small interference RNA (siRNA)
to selectively knock down calpain levels. Because the two ubiq-
uitous calpain isoforms, m- and "-calpain, are functional only
when associated with the common regulatory small subunit, we
decided to design siRNA to selectively knock down the small
regulatory subunit to block both calpain isoforms and a siRNA
to specifically knock down m-calpain to address the relevance
of this isoform in this context. The ability of the specific siRNAs
(siSmall or si m-calpain) to down-regulate calpain protein lev-
els was tested in U2OS cells, where expression of endogenous
small subunit of calpain or of endogenous m-calpain was, re-
spectively, almost completely abolished already at 24 h after
specific silencing transfection (Fig. 1A). A scrambled siRNA
(siControl) was used as control. To evaluate the effects of cal-
pain siRNAs toward the activity of !-catenin, U2OS cells were
transfected as indicated in Fig. 1B. The TOPflash construct is
a !-catenin-sensitive promoter widely used as an indicator for
binding of !-catenin to hTCF-4. The resulting complex is re-
sponsible for activating transcription of the TOPflash reporter
(16). Data were normalized by cotransfection with a pCMV-
Renilla luciferase vector, which controls for the variability in
transfection efficiency. Luciferase assays were performed 48 h
after transfection, and Western blot analyses were carried out
using the same lysates to monitor steady-state levels of endog-
enous or overexpressed !-catenin. As shown in Fig. 1B, down-
regulation of calpain levels as induced either by siSmall or si
m-calpain resulted in the stabilization and activation of both
endogenous and overexpressed !-catenin. These results
strengthen the argument for a role of the m-calpain isoform for
the observed effects. As a negative control for the transcrip-
tional competence of !-catenin, we used FOPflash reporter,
which contains mutant Tcf-4 binding site, and this was not
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affected by !-catenin and siControl or siSmall/si m-calpain
(Fig. 1B).
These observations suggest that, by regulating calpain and
particularly the m-calpain isoform, the free cytoplasmic levels
of !-catenin could be altered, inducing its translocation into the
nucleus where it can function as a transcription factor. To
confirm our hypothesis, we transfected U2OS cells with siCon-
trol and si m-calpain. 36 h after siRNA transfection, cell frac-
tionation was performed and cytoplasmic (C), membrane (M),
and nuclear (N) fractions were separately analyzed. Western
blot analysis indicated that the increased levels of !-catenin
after m-calpain down-regulation are significantly accumulated
FIG. 1. Constitutive activity of calpain toward !-catenin. A, U2OS cells were transfected with siControl and siSmall (left panel) or siControl
and si m-calpain (right panel). 24 and 48 h later, lysates were analyzed by Western blot using anti-small subunit of calpain (upper panel) and
anti-actin (lower panel) antibodies in the first case and anti-m-calpain (upper panel) and anti-actin (lower panel) in the second case. B, U2OS cells
were transfected as indicated. 24 h later, Western blot analysis was performed using anti-HA antibody (left panels) and an anti-!-catenin (right
panels). Loading control was tested using anti-actin antibody (lower panels). Luc activity was determined in the same lysates by calculations of
Top-Luc and Fop-Luc (as negative control). The data represent means $ S.D. from three independent experiments. C, U2OS cells were transfected
with siControl and si-m-calpain. 36 h later cell fractionation was performed and cytoplasmic (C), membrane (M), and nuclear (N) fractions were
analyzed. Western blot was performed using anti-!-catenin antibody or anti-c-Fos and anti-actin to check for fractionation efficiency. D, the same
experiments as in panel C were performed in H1299 cells. E, confocal microscope image of U2OS cells transfected with HA-tagged !-catenin
together with siControl (a) or si-m-calpain (b) and indicating change of !-catenin localization. Panels show two different corresponding fields of cells
stained for !-catenin (red).
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in the nucleus (Fig. 1C). The same results were obtained in the
H1299 cell line (Fig. 1D) and by using siSmall (data not shown).
Cellular localization of overexpressed !-catenin after si m-
Calpain treatment was also tested by immunocytochemistry,
and a supportive change in the nuclear localization was ob-
served by knocking down calpain expression (Fig. 1E). Alto-
gether, these results demonstrate that the calpain proteolytic
system can alter the transcriptionally active fraction of !-cate-
nin, thus representing a potential mechanism to regulate
!-catenin in parallel to the proteasome.
Gas2 and Calpastatin, the Two Endogenous Inhibitors of
Calpain, Regulate the Levels and Function of !-Catenin—To
better characterize the constitutive m-calpain function toward
!-catenin, we decided to analyze the effects of both its endog-
enous inhibitors, Gas2 (11) and Calpastatin (10). As a first
approach, we tested whether overexpression of Gas2 and Cal-
pastatin might enhance the steady-state levels of !-catenin in
vivo. Cotransfection of HA-tagged !-catenin with Gas2 (Fig.
2A, left panel) and Calpastatin (right panel) caused a substan-
tial accumulation of !-catenin, indicating that calpain regula-
tion by its inhibitors could function as a constitutive system to
regulate !-catenin.
As a next step we evaluated the transcriptional competence
of stabilized !-catenin by determining the effect of Gas2 and
Calpastatin overexpression on the ability of !-catenin to stim-
ulate transcription from TCF-responsive elements. The rela-
tive luciferase activity (normalized by cotransfection with
pCMV-Renilla luciferase) was significantly stimulated by over-
expression of Gas2. A similar response was obtained with
transfection of Calpastatin (Fig. 2B), suggesting that both Gas2
and Calpastatin overexpression can render !-catenin tran-
scriptionally competent. As a control, we looked for the ability
of Gas2 and Calpastatin to cause !-catenin translocation into
the nucleus (Fig. 2C) where it can function as a transcription
FIG. 1—continued
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factor. We therefore transfected !-catenin into U2OS together
with GFP-tagged Gas2, GFP-tagged Calpastatin, and GFP pro-
tein alone as negative control. 24 h after transfection, immu-
nofluorescence analyses were performed to visualize !-catenin
localization. As can be seen in Fig. 2C, the presence of both
GFP-tagged Gas2 and GFP-tagged Calpastatin was able to
relocalize the cytoplasmic !-catenin into the nucleus. Finally,
to confirm that endogenous calpain is critical for the effect of
Gas2 and Calpastatin on !-catenin stability, HA-tagged !-cate-
nin levels were monitored after transfection in U2OS cells
together with Gas2 or Calpastatin and SiControl or siSmall.
Calpain silencing abrogated both Gas2 and Calpastatin effects
on !-catenin stabilization, thus indicating the critical role for
calpain in the Gas2 and Calpastatin regulation of !-catenin
levels (Fig. 2D). Altogether, these data suggest that Gas2 and
Calpastatin, as endogenous calpain inhibitors, play important
roles in controlling !-catenin levels, localization, and transcrip-
tional activity.
FIG. 2. Gas2 and Calpastatin regulate levels and function of !-catenin. A, U2OS cells were transiently transfected as indicated. Western
blot analysis was performed using anti-HA (upper panel), anti-Gas2 or anti-Calpastatin (middle panel), and anti-actin (lower panel) antibodies. B,
U2OS cells were cotransfected with indicated plasmids. Luc activity was evaluated 48 h later. Data represent means $ S.D. from three
independent experiments. C, confocal microscope images of U2OS cells transfected with HA-tagged !-catenin together with GFP (1), GFP-
Calpastatin (2), and GFP-Gas2 (3). Panels show corresponding fields of cells stained for !-catenin (red) and expressing GFP-tagged proteins (green).
D, U2OS cells were transfected with HA-!-catenin together with a combination of vectors and siRNA oligos as indicated. Cells were harvested 48 h
after transfection and analyzed by Western blot analysis using the indicated antibodies. The nonspecific band with arrows was considered as a
loading control.
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Gas2DN Blocks Both Calpastatin and Gas2 Regulatory Arms
on Calpain Activity—We have previously characterized
Gas2DN as a dominant negative form of Gas2, demonstrating
that it can still bind m-calpain without showing any inhibitory
function (11). We therefore decided to analyze the effects of
Gas2DN on the levels and activity of transfected !-catenin.
Gas2DN was transfected into U2OS cells together with
!-catenin alone or !-catenin and Gas2. As can be seen in Fig.
3A, its overexpression reduced the levels of !-catenin and of the
Gas2-dependent !-catenin stabilization.
As a next step we evaluated the transcriptional competence
of endogenous !-catenin by determining the effects of Gas2DN
overexpression on the ability of !-catenin to stimulate tran-
scription from TCF-responsive elements. We observed that
Gas2DN significantly decreased !-catenin transcriptional ac-
tivity in a dose-dependent manner (Fig. 3B). Altogether, the
FIG. 3. Gas2DN can counteract both Gas2 and Calpastatin effects. A, U2OS cells were transfected as indicated. Protein levels were
monitored by using anti-HA (upper panel), anti-Gas2 (middle panel), and anti-actin (lower panel) as loading control antibodies. B, U2OS cells were
transfected with Top-Luc reporter together with increasing amounts of Gas2DN. Luc activity was evaluated 48 h later. Data represent means $
S.D. from at least three independent experiments. C, U2OS cells were transiently transfected with the combination of plasmids as indicated.
Luciferase and Western blot analysis were performed with the same lysates. D, IVT !-catenin was incubated with m-calpain (lanes 1-3), m-calpain
and IVT Calpastatin (lanes 4-6), or m-calpain, IVT Calpastatin, and IVT Gas2DN (lanes 7-9). Samples were collected at the indicated time points,
analyzed by SDS-PAGE, and evaluated by autoradiography. Arrows indicate full-length proteins. Being itself a calpain substrate, the Calpastatin
band is also degraded during the time although it is fully functional as a calpain inhibitor after its cleavage (40, 41). E, biochemical assay to test
the effect of recombinant Gas2, Calpastatin, and Gas2DN on m-calpain activity. Assay was performed as described under “Materials and Methods.”
F, biochemical effect of Gas2DN on Gas2 and Calpastatin ability to inhibit calpain activity. Assay was performed as described under “Materials
and Methods.”
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data indicating the relevance of m-calpain pathway in !-cate-
nin regulation, together with the evidence that Gas2DN is able
to down-regulate !-catenin levels and function (Fig. 3, A and
B), prompted us to investigate whether Gas2DN interference
with m-calpain activity could counteract not only Gas2 but also
Calpastatin function, thus serving as a general reagent to
control calpain pathway. As shown in Fig. 3C, in U2OS cells
HA-!-catenin transcriptional activity as stimulated by Gas2 or
Calpastatin coexpression was repressed in both cases by
Gas2DN, and as expected HA-!-catenin levels, due to the pres-
ence of Gas2 or Calpastatin, were clearly reduced when
Gas2DN was cotransfected. We therefore conclude that
Gas2DN can also rescue Calpastatin effects on !-catenin sta-
bilization. We decided to perform an in vitro assay to analyze
whether the ability of Calpastatin to protect calpain-dependent
!-catenin degradation could be abrogated by Gas2DN. As
FIG. 4. Gas2DN induces !-catenin degradation independently of GSK3!, and calpain regulates !-catenin functions independently
of the proteasome. A, U2OS cells were transfected with indicated plasmids and then treated with an aqueous vehicle or LiCl 30 mM for 18 h as
indicated. Cells lysates were analyzed by Western blot using anti-HA (upper panel), anti-Gas2 (middle panel), and anti-actin (lower panel)
antibodies. B, U2OS cells were transfected with the indicated plasmids and then treated with an aqueous vehicle or LiCl 30 mM as indicated. Luc
activity was evaluated 48 h later. Data represent mean$ S.D. from three independent experiments. C, U2OS cells were transfected with siControl
or si m-calpain and treated or not with lactacystin for the indicated times. Lysates of the cells were then analyzed using anti-!-catenin antibody
and anti-actin as a loading control. D, U2OS cells were transfected with the indicated plasmids and treated with lactacystin for 16 h. Lysates of
the cells were then analyzed as in panel C. E, GSK3!!/! mouse embryo fibroblasts were transfected as indicated. Protein levels were monitored
by using anti-HA (upper panel), anti-Gas2 (middle panel), and anti-actin as loading control (lower panel) antibodies. F, TS20 cells were transfected
as indicated. Cells were then grown at non-permissive temperature for 12 h. Cell lysates were subsequently analyzed by Western blot, and the
endogenous levels of !-catenin, p53, and actin as loading control are indicated.
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shown in Fig. 3D, whereas Calpastatin can efficiently block
!-catenin degradation (compare lanes 4-6 with lanes 1-3),
Gas2DN can effectively recover the inhibitory effect of Cal-
pastatin on m-calpain (lanes 7-9). The same amount of in vitro
translated (IVT) glyceraldehyde-3-phosphate dehydrogenase
failed to show a similar result (data not shown). To provide
final evidence of the calpain activator properties of Gas2DN, its
effect on calpain activity was tested in a biochemical in vitro
assay measuring calpain activity. Rat skeletal muscle m-cal-
pain activity was measured as described under “Materials and
Methods” and was monitored in the presence of both the re-
combinant inhibitors Gas2wt and Calpastatin and in the pres-
ence of Gas2DN. Whereas the function of calpain, as can be
observed in Fig. 3E, was efficiently blocked by its inhibitors
Gas2 and Calpastatin, the presence of recombinant Gas2DN
induced an increase in calpain activity, suggesting a potential
FIG. 5. Gas2DN affects !-catenin activity and growth rate in colon carcinoma cells. A, proteolytic cleavage of endogenous !-catenin by
endogenous m-calpain was followed in GFP/HCT-116 or GFP-Gas2DN/HCT-116 cells. Aliquots of the samples were collected at the indicated time
points in the presence of CaCl2 (2 mM) or EGTA (8 mM). !-Catenin proteolysis in each sample was monitored by Western blot. B, HCT-116, HT-29,
and LS-174 were transfected as indicated. Luciferase activity was measured 48 h after transfections. Graphs are the mean of at least three different
experiments. C, HCT-116 and HT-29 cells were transfected with equal amounts of HA-Gas2DN or a control protein (HA-E4D%60-Pst). 24 h after
transfection cells were pulsed with 50 "M BrdUrd for 4 h and then fixed and stained with anti-BrdUrd and anti-HA antibodies. Results are the
mean of at least four independent experiments and were obtained by scoring more than 500 cells for each transfected construct in every cell line.
Percentage of S-phase inhibition & [(percentage of cells in S-phase in the background ! percentage of cells in S-phase in the transfected
cells)/(percentage of cells in S-phase in the background)] ' 100. D, 3 ' 104 GFP/HCT-116 or GFP-Gas2DN/HCT-116 cells were plated as described
under “Material and Methods.” The colony number obtained with GFP stable expressing cells was set as 100%. Experiments were repeated five
times with consistent and repeatable results.
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activator role for this protein. With the same biochemical ap-
proach we confirmed in vitro the ability of Gas2DN to counter-
act the inhibitory effects of both Gas2 and Calpastatin (Fig.
3F). We therefore conclude that Gas2DN can disengage endog-
enous m-calpain from both its inhibitors, Gas2 and Calpasta-
tin, possibly because both inhibitors share the same binding
region on the calmodulin-like domain of m-calpain, as already
described (11, 17).
Calpain Regulates !-Catenin Functions Independently of
GSK3! Activity and of the Proteasome—After showing Gas2/
Calpastatin/Gas2DN as tools to regulate !-catenin levels and
function via calpain, we investigated whether !-catenin could
be regulated in the absence of GSK3!, a critical component of
the multimolecular complex responsible for targeting !-catenin
to the proteasome (18). As a first approach, the Gas2DN effect
as a general calpain activator was analyzed on stabilized
!-catenin in U2OS cells treated with LiCl, a known inhibitor of
GSK3! activity (19). Under these conditions, Gas2DN overex-
pression was still able to reduce !-catenin levels (Fig. 4A) as
well as to decrease its transcriptional competence (Fig. 4B),
indicating that its effect on !-catenin is a GSK3!-independent
process. However, because !-catenin can also be degraded in a
proteasome-dependent, but GSK3!-independent, mechanism
(20, 21), we investigated whether calpain is truly acting in a
proteasome-independent manner by using lactacystin as a pro-
teasome-specific inhibitor. To set the conditions we followed the
well characterized p53 protein stability as an independent
marker of proteasome inhibition. In U2OS cells we found that
p53 reaches its highest levels 8 h after lactacystin treatment
and maintains such levels for 24 h (data not shown), suggesting
that during this time the proteasome system can be considered
significantly blocked. In the same context, transfections of
U2OS cells with siControl or si m-calpain confirmed that m-
calpain knock down causes the increased levels of !-catenin
even when the proteasome is blocked (Fig. 4C). The same
effects were observed when lactacystin-treated cells were
transfected with Gas2 and Calpastatin (Fig. 4D). Altogether,
these data indicate that calpain acts in a GSK3!- and protea-
some-independent manner to regulate !-catenin levels and
functions. To confirm this hypothesis, we chose two alternative
cell lines, respectively knocked out for GSK3! (mouse embryo
fibroblast GSK3!!/!) and containing a thermolabile ubiq-
uitin-activating enzyme (E1) that is inactivated at 39 °C, thus
preventing ubiquitination (TS20 cells). In GSK3!!/! mouse
embryo fibroblasts, Gas2wt was still able to stabilize !-catenin
(Fig. 4E), and, more importantly, Gas2DN maintained its abil-
ity to reduce !-catenin levels either alone or when cotrans-
fected with Gas2. Finally, as shown in Fig. 4F, transfection of
TS20 cells at the non-permissive temperature (39 °C) with
Gas2 or Calpastatin resulted in the accumulation of endoge-
nous !-catenin, confirming that ubiquitination of !-catenin
does not seem to be required for its regulation by calpain
system. We can therefore conclude that calpain modulates
!-catenin levels and activity independently of both GSK3! and
proteasome function, thus indicating that the calpain pathway
could play an alternative role when canonical proteasome-me-
diated !-catenin degradation is impaired.
Gas2DN Modulates the Activity of !-Catenin in Colon Carci-
noma Cells, Reducing Their Proliferation and Anchorage-inde-
pendent Growth—Colon cancer cells represent an interesting
model to study the relevance of calpain pathway because in this
context canonical proteasome-mediated !-catenin degradation
is strictly impaired. Therefore we decided to test whether
Gas2DN is able to induce endogenous !-catenin degradation in
HCT-116 colon carcinoma cells, which harbor mutations in
!-catenin that prevent proteasome-dependent turnover. We
generated a cell line stably expressing GFP-Gas2DN or GFP
(GFP-Gas2DN/HCT-116 and GFP/HCT-116). Lysates of these
cells were then separately incubated with CaCl2 to activate
m-calpain or EGTA to block its activity. Aliquots were taken at
defined time points (0, 4, and 8 h) to follow the kinetics of
!-catenin degradation. As can be observed in Fig. 5A, lanes 3
and 4, addition of calcium, but not EGTA, to the cell lysates
promoted !-catenin degradation. Notably, GFP-Gas2DN/HCT-
116 cells show degradation of !-catenin starting earlier and
becoming significantly more pronounced compared with GFP/
HCT-116 (Fig. 5A, lanes 3 and 4). In all cases !-catenin cleav-
age was inhibited by EGTA (lanes 1 and 2).
These results indicate that endogenous m-calpain can de-
grade endogenous !-catenin in cells that are defective in regu-
lating its levels through the classical proteasomal pathway.
Even more interesting, it suggests the possibility that Gas2DN
can stimulate such degradation.
We then tested the effect of Gas2DN in various colon carci-
noma cell lines, where proteasome degradation is blocked be-
cause of mutations of !-catenin itself (HCT-116 and LS-174) or
of its regulator APC (HT-29). As shown in Fig. 5B, overexpres-
sion of Gas2DN induced a significant reduction in !-catenin
activity in all tested cells. These results suggest that overex-
pression of Gas2DN can regulate the activity of a form of
!-catenin that is not under the control of proteasome-depend-
ent degradation.
Because accumulated evidence demonstrates that !-catenin
alters cell cycle progression (22), we tested whether the nega-
tive effect of Gas2DN on !-catenin was also manifested in the
proliferation rate of colorectal cancer cells. Transient overex-
pression of Gas2DN in HCT-116 and HT-29 cells showed a
significant inhibition of S-phase entry as assessed by BrdUrd
incorporation assay (Fig. 5C).
Finally, because a characteristic feature of transformed
cells is their ability to grow in an anchorage-independent way
and !-catenin is involved in this process, we compared the
ability of GFP-Gas2DN/HCT-116 or GFP/HCT-116 cells to
form colonies in semisolid medium. Significant reduction in
the ability to form colonies for Gas2DN-expressing cells was
observed with respect to GFP-expressing cells (Fig. 5D). Al-
together, these results demonstrate that Gas2DN modulates
the function of deregulated !-catenin and reduces both pro-
liferation and anchorage-independent growth in a context of
deregulated !-catenin.
DISCUSSION
The intracellular signaling pathway of Wnt is most con-
served during evolution and regulates cellular proliferation,
morphology, motility, cell fate, and organ development. Aber-
rant Wnt signaling pathway is an early event in 90% of colo-
rectal cancers that results in !-catenin accumulation. It can
occur through inefficient phosphorylation of !-catenin by
GSK3! or because of mutations on APC, !-catenin, and/or axin.
As a result of a defective degradation via proteasome, accumu-
lated !-catenin translocates into the nucleus and becomes tran-
scriptionally active, enhancing expression of genes regulating
cell proliferation and survival. Our results indicate a constitu-
tive calpain-dependent mechanism regulating !-catenin stabil-
ity and function and suggest Gas2DN as a reagent to activate
calpain pathway, emerging as an effective way to reverse on-
cogenic !-catenin/LEF/TCF signals that occur when !-catenin
degradation via the proteasome is defective (Fig. 6).
In this study, we have shown the physiological and constit-
utive involvement of calpain in the regulation of signaling !-
catenin, which can translocate into the nucleus where it func-
tions as a transcription factor. The physiological involvement of
calpain in the regulation of !-catenin was demonstrated by
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siRNA-mediated knock down of calpain that resulted in a sig-
nificant increase of both the levels and transcriptional activity
of !-catenin and in its clear translocation into the nucleus (Fig.
1). Control over calpain activity through the overexpression of
Gas2 and Calpastatin was shown to be crucial for !-catenin
regulation (Fig. 2). To better characterize the effects of both
inhibitors, we studied the effects of Gas2DN, which was initi-
ally defined as Gas2wt-dominant negative form, being able to
still bind calpain but not to inhibit its activity. We provided
evidence that Gas2DN can be considered a novel and specific
molecule to modulate calpain activity because it can efficiently
counteract the inhibitory effect of both Gas2 and Calpastatin in
vivo. The recombinant Gas2DN protein can also be used to
stimulate endogenous calpain activity in a biochemical in vitro
assay (Fig. 3). These results suggest that Gas2DN can disen-
gage endogenous calpain from both its inhibitors, Gas2 and
Calpastatin, possibly because Gas2 and Calpastatin share the
binding region on the calmodulin-like domain of calpain. In
fact, we have previously demonstrated that the amino-terminal
region of Gas2 (which comprises Gas2DN) binds subdomains
III and IV of m-calpain and that the Gas2 CT region is required
to exert the inhibitory function (11). The inhibitory domains of
Calpastatin are defined by three highly conserved regions, A,
B, and C. Whereas subdomain B is responsible for inhibition,
regions A and C are responsible for binding calpain in a strictly
Ca2#-dependent manner to subdomains III and IV, where Gas2
also binds (23, 24). Binding of regions A and C of Calpastatin
shifts the conformational equilibrium of calpain toward the
active form, but activation of calpain is not manifested because
its active site is blocked by subdomain B. Regions A and C, on
the other hand, lack this inhibitory potential and have been
suggested as potential activators for m-calpain (24). Similarly,
Gas2DN, lacking the carboxyl domain of Gas2 that is respon-
sible for the calpain inhibitory function, could be involved in
calpain activation.
In all tested cases, regulation of calpain proteolytic activity
through overexpression of Gas2DN was shown to be crucial to
regulate both !-catenin protein levels and its transcriptional
activity in the absence of GSK3! or under conditions where
GSK3! is blocked through the addition of LiCl. The use of LiCl
has been reported to similarly block GSK3# (25), thus exclud-
ing any role for both GSK3 isoforms (Fig. 4).
These results indicate that the calpain pathway works inde-
pendently of the !-catenin phosphorylation state as regulated
by GSK3 activity. Moreover, because it has been demonstrated
that !-catenin can also be degraded in a GSK3!-independent
but proteasome-dependent manner (20, 21), we performed a set
of experiments to exclude any involvement of the proteasome in
the calpain-mediated degradation of !-catenin. We provide ev-
idence that when the proteasome pathway is impaired by using
a specific proteasome inhibitor the alternative calpain-depend-
ent !-catenin degradation is still active. The same conclusions
were obtained using a mutant cell line with a thermolabile E1
ubiquitin-activating enzyme, demonstrating that calpain func-
tion toward !-catenin can occur in the absence of a functional
proteasome pathway. Altogether, these observations suggest
that under physiological conditions the calpain system can
cooperate with the proteasomal pathways to regulate !-catenin
degradation and could therefore represent a mechanism to
recapture non-phosphorylated and accumulated cytoplasmic
!-catenin, targeting it to an alternative degradation when the
most established proteasome pathway becomes altered during
tumorigenesis, such as in a colon carcinoma context. Our find-
ings are in apparent contrast with a prior study on prostate
tumor cells, in which it has been reported that calpain cleav-
age, by removing the NH2-terminal regulatory domain of the
!-catenin protein, leads to the accumulation of a stable 75-kDa
deletion able to increase TCF/LEF-dependent transcription
(26). However, in the context of colon cancer cells we observed
that calpain-dependent cleavage of endogenous !-catenin
causes a complex pattern of smaller degradation products (Fig.
5A and data not shown), suggesting either that this unique
75-kDa proteolytic cleavage product is not formed in colon
cancer or that it is unstable in these cells. The different deg-
radation patterns observed in colon cancer cells and prostate
cells could be due to the different complexes formed by !-cate-
nin in the two cell types, limiting further degradation of the
75-kDa product in the case of prostate cells by calpains, or to
amino acid difference of !-catenin at the cleavage sites. The
molecular basis of this difference represents an interesting
subject for future investigations.
Considering the relevance of !-catenin function in colon can-
cer cells, we showed that colon cancer cells stably expressing
Gas2DN are suppressed both in proliferation and anchorage-
independent growth (Fig. 5). These results underline the rele-
vance of calpain activity toward !-catenin regulation. It is
worth noting the recent evidence obtained with microarray
analysis on colon carcinoma cells associating increased expres-
sion of Calpastatin mRNA (27) with increased metastatic po-
tential. This could represent an interesting system to definitely
link !-catenin and the calpain system, possibly suggesting a
potential mechanism to alternatively regulate !-catenin deg-
radation along with the metastatic phenotype.
In conclusion, we demonstrated that accumulated !-catenin
that cannot be degraded through the proteasome can be tar-
geted to the alternative calpain-dependent degradation, thus
FIG. 6. A working model for the regu-
latory network involving Gas2, Cal-
pastatin, Gas2DN, calpain, and !-cate-
nin. Control over calpain activity by
overexpression of its inhibitors Gas2 and
Calpastatin is crucial to up-regulate !-cate-
nin levels, to relocate !-catenin to the nu-
cleus, and therefore to increase its signaling
properties through a pathway that does not
require the proteasome function. Gas2DN,
disengaging calpain from both its inhibitors,
stimulates endogenous calpain activity ver-
sus !-catenin and therefore can be used to
down-regulate !-catenin signaling potential
in the context of colon cancer, where accu-
mulated !-catenin cannot be degraded
through the classical proteasome pathway.
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blocking its oncogenic activity. In this respect, Gas2DN
emerged as a tool to modulate the protease activity. Interest-
ingly Gas2DN (amino acids 1–171) contains one Calponin ho-
mology domain (CH domain) (amino acids 37–153). This do-
main has been found in a variety of proteins ranging from actin
cross-linking to signaling elements and has been proposed to
function with a quite striking variability (28). In general, pro-
teins containing a single CH domain act as regulatory proteins
(29). It will be interesting to clarify whether and how the single
CH domain could be linked to modulation of calpain activity. In
this view, it can be hypothesized that the CH domain could
function in the recruitment of calpain to a specific subcellular
compartment for localized activation, therefore providing in
such a microenvironment the requested calpain conformational
changes necessary to reduce the calcium requirement for the
activation. Our findings reveal a mode of control over calpain
that is extensively implicated in diverse cellular and develop-
mental contexts and open interesting avenues on the mecha-
nisms regulating its activation, thus complementing the de-
scribed requirement for Ca2# signaling (30–32). Further
biochemical in vitro and in vivo studies on the involvement of
the CH domain contained in Gas2 with respect to calpain
activity could finally provide new tools for therapeutic inter-
vention in the control of the Wnt/!-catenin signaling pathway
and, specifically, for the treatment of colon cancer.
In addition to its function in the conventional Wnt signaling
pathway, !-catenin also binds tightly to the cytoplasmic do-
main of type I cadherins and plays an essential role in struc-
tural organization and function of cadherins by linking cad-
herins through #-catenin to the actin cytoskeleton (33, 34).
Progress in understanding !-catenin signaling, as well as cad-
herin-mediated cell adhesion, generally followed separate lines
of investigation. However, it is clear that there are many con-
nections between these pathways; alteration in cell fate, adhe-
sion, and migration are, for example, characteristics of cancer
in which cells ignore normal regulatory cues from their envi-
ronment. Unchecked Wnt signaling (4) and/or the loss of cell-
cell adhesion (35–37) are involved in cancer induction and
progression. Moreover, recent studies have shown that both
Wnt signaling and cadherin-mediated cell-cell adhesion are
important in the organization and maintenance of stem cells
(38). The critical component of these pathways is !-catenin,
and the key events are the regulation of !-catenin stability and
availability. In this view, calpain could really represent an
important bridge to switch the signaling of nuclear !-catenin
that affects gene expression to a signaling toward the cytoskel-
eton and cell polarity in tissues. In fact, whereas inhibition of
calpain activity through its endogenous inhibitors causes
!-catenin translocation to the nucleus where it becomes tran-
scriptionally competent (Fig. 1), stimulation of calpain activity
induces !-catenin exit from the nucleus (9) (Fig. 3), where it
lacks its transcriptional ability (Fig. 3) and could be strictly
involved in cytoplasmic signaling. Cell migration requires dy-
namic interaction among a cell, its substratum, and the actin
cytoskeleton. It is worth noting that calpain is an attractive
candidate to be a regulator of cell migration and membrane
protrusion through its capacity to regulate focal adhesion dy-
namics and rear retraction (39, 40). In this context it will be
very interesting to connect the regulation of !-catenin by the
calpain system to the described role of calpain activity with
respect to E-cadherin degradation (41, 42) to contribute to the
integration of the complex and still puzzling interplay of cell
motility, cytoskeleton rearrangement, and cell polarity re-
quired during tissue morphogenesis. In this perspective tight
and localized control on calpain activity could represent a crit-
ical link for the different !-catenin actions both during devel-
opment and in a cancer context.
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Introduction
Macroautophagy, which is usually referred to as autophagy, is 
responsible for degradation of the majority of intracellular pro-
teins in mammalian cells, particularly during starvation-induced 
proteolysis. Cytosolic proteins, organelles, and selected regions 
of the nucleus can be cleared by autophagy to ensure cellular 
homeostasis and remove damaged or unwanted products 
(Klionsky, 2005). Cytoplasmic constituents are ! rst enclosed 
by a double-membrane autophagosome; next, the outer mem-
brane of the autophagosome fuses with the lysosome, with the 
consequent destruction of the cargo and the inner membrane of 
the autophagosome by hydrolytic enzymes.
The autophagic pathway has been dissected at the mo-
lecular level in yeast, in which 27 genes, referred to as ATG, 
have been found to be required for autophagosome formation 
(Klionsky and Ohsumi, 1999; Yorimitsu and Klionsky, 2005). 
Two ubiquitin-like conjugation systems are involved in the 
 process: one mediates the covalent attachment of Atg12 to Atg5, 
and the other mediates the conjugation of Atg8 to phosphatidyl-
ethanolamine (Ichimura et al., 2000). The resulting products, 
Atg12–Atg5 and Atg8-phosphatidylethanolamine, are essential 
for proper autophagosome formation. Only a small fraction of 
the Atg12–Atg5 complex localizes at the autophagic isolation 
membrane throughout elongation, and the complex dissociates 
when the phagosome is complete. On the other hand, Atg8 
 remains on the mature autophagosome constituting the recog-
nized consensus marker of this structure. These two conjugation 
systems are highly conserved in mammalian cells. ATG5-
 de! cient stem cells have been instrumental for demonstrating 
that the Atg12–Atg5 complex localizes at autophagosome pre-
cursors and plays an essential role in autophagosome formation 
(Mizushima et al., 2001). The production of ATG5-de! cient 
mice has revealed that autophagy is required for neonatal 
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Ubiquitously expressed micro- and millicalpain, which both require the calpain small 1 (CAPNS1) regulatory subunit for function, play important roles 
in numerous biological and pathological phenomena. 
We have previously shown that the product of GAS2, 
a gene specifi cally induced at growth arrest, is an inhibitor 
of millicalpain and that its overexpression sensitizes cells 
to apoptosis in a p53-dependent manner (Benetti, R., 
G. Del Sal, M. Monte, G. Paroni, C. Brancolini, and 
C. Schneider. 2001. EMBO J. 20:2702–2714). More 
 recently, we have shown that calpain is also involved in 
nuclear factor κB activation and its relative prosurvival 
function in response to ceramide, in which calpain defi -
ciency strengthens the proapoptotic effect of ceramide 
(Demarchi, F., C. Bertoli, P.A. Greer, and C. Schneider. 
2005. Cell Death Differ. 12:512–522). Here, we further 
explore the involvement of calpain in the apoptotic switch 
and fi nd that in calpain-defi cient cells, autophagy is im-
paired with a resulting dramatic increase in apoptotic cell 
death. Immunostaining of the endogenous autophagosome 
marker LC3 and electron microscopy experiments demon-
strate that autophagy is impaired in CAPNS1-defi cient 
cells. Accordingly, the enhancement of lysosomal activity 
and long-lived protein degradation, which normally occur 
upon starvation, is also reduced. In CAPNS1-depleted 
cells, ectopic LC3 accumulates in early endosome-like 
 vesicles that may represent a salvage pathway for protein 
degradation when autophagy is defective.
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 survival before maternal feeding (Kuma et al., 2004). The anal-
ysis of endogenous LC3, which is one of the mammalian homo-
logues of Atg8, and the production of transgenic mice expressing 
a " uorescent autophagosomal LC3 have shown that the regula-
tion of autophagy is organ dependent and that the role of auto-
phagy is not restricted to the starvation response (Mizushima 
et al., 2004).
A pivotal role for autophagy in growth control has emerged 
from studies on Beclin1, the mammalian homologue of ATG6. 
The Beclin1 gene is deleted in several types of breast cancer 
that are unable to activate autophagy (Liang et al., 1999) and 
functions as a haploinsuf! cient tumor suppressor gene (Yue 
et al., 2003). In addition to involvement in growth control, 
 programmed autophagy plays a role in differentiation (Ghidoni 
et al., 1996; Lee et al., 2002) and tissue remodeling (Rusten et al., 
2004). Moreover, autophagy may be arti! cially induced by ra-
diation and treatment with certain drugs, including rapamycin 
(Noda and Ohsumi, 1998), ceramide (Scarlatti et al., 2004), 
 arsenic trioxide (Kanzawa et al., 2003), and tamoxifen (Bursch 
et al., 2000); the ! nal outcome of such induction is still a matter 
of debate (Kroemer and Jaattela, 2005).
The calpain family of cysteine proteases is composed of 
both ubiquitous and tissue-speci! c isoforms that share homol-
ogy in their protease domain and are calcium dependent (Goll 
et al., 2003). The best-characterized ubiquitous calpains are the 
isoforms μ- and m-calpain, which are also known as calpain 1 
and calpain 2, respectively. Both contain an 80-kD catalytic 
subunit and share a common 28-kD regulatory subunit com-
monly known as calpain 4 that is required for proper activity. 
Hereafter, calpain 4 will be referred to as calpain small 1 
(CAPNS1) in accordance with the nomenclature reported at the 
calpain website (http://ag.arizona.edu/calpains). A homologue 
to CAPNS1, CAPNS2, has been described previously (Schad 
et al., 2002). This protein appears to be a functional equivalent 
to CAPNS1 in vitro; however, its in vivo function and tissue 
distribution are still controversial. Interestingly, ubiquitous cal-
pains are associated with the endoplasmic reticulum and Golgi, 
a likely reservoir for autophagosome membranes (Hood et al., 
2004), where the essential autophagy regulatory complex 
PI3K–Beclin also localizes (Kihara et al., 2001).
Calpain is required for normal embryonic development. 
Indeed, the targeted disruption of CAPNS1 is embryonic lethal 
at days 10 and 11 as a result of severe defects in vascular devel-
opment (Arthur et al., 2000). Calpain is a regulator of adhesive 
complex dynamics in adherent cells (Bhatt et al., 2002); it plays 
an important role in osteoclastic bone resorption (Hayashi et al., 
2005) and is required for phagocytosis in human neutrophils 
(Dewitt and Hallett, 2002).
We have become interested in calpain function because of 
our observation that the product of GAS2, a gene speci! cally 
induced at growth arrest, is in fact an inhibitor of millicalpain 
and that its overexpression sensitizes cells to apoptosis in a p53-
dependent manner (Benetti et al., 2001). More recently, we have 
shown that calpain is also involved in NF-κB activation and in 
its relative prosurvival function in response to ceramide, in 
which calpain de! ciency strengthens the proapoptotic effect of 
ceramide (Demarchi et al., 2005). In this study, we further ex-
plore the involvement of calpain in the apoptotic switch and 
! nd that in calpain-de! cient cells, autophagy is impaired with 
a resulting dramatic increase in apoptotic cell death.
Results
The lack of calpain activity is coupled 
to a block in autophagy
We have previously reported that calpain plays a crucial role in 
cell death regulation in response to ceramide. Indeed, we demon-
strated that the lack of calpain activity results in a considerable 
Figure 1. CAPNS1−/− MEFs lacking calpain 
activity are defective in autophagosome for-
mation. (A and B) Wild-type and CAPNS1−/− 
MEFs were stimulated for 3 h with rapamycin 
or ceramide and analyzed by immunofl uores-
cence using an anti-LC3–specifi c antibody and 
PI to stain nuclei (A) or were lysed and used 
for Western blot analysis with the same anti-
body to detect both cytoplasmic LC3I and 
membrane-associated LC3II (B). Actin was 
used as a loading control. (B) The ratio be-
tween the intensities of LC3II and LC3I bands is 
indicated below each lane. Bar, 20 μm.
Figure 2. CAPNS1 depletion is coupled to a block in autophagosome 
 formation in human cells. (A and B) U2OS cells were silenced with control 
siRNA or CAPNS1 siRNA and, 72 h later, were stimulated with ceramide 
for 3 h to trigger macroautophagy, as indicated in the fi gure. Afterward, 
the cells were fi xed and decorated with anti-LC3 and PI (A) or were lysed 
to perform Western analysis against endogenous LC3 (B). Actin was used 
as a loading control; anti-CAPNS1 antibody was used to check silencing 
effi ciency. (B) The ratio between the intensities of LC3II and LC3I bands is 
indicated below each lane. Bar, 20 μm.
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increase in apoptotic cell death (Demarchi et al., 2005). To fur-
ther investigate the involvement of calpain in the modulation of 
alternative types of cell death, in this study, we address the role 
of calpain in autophagy. LC3 is the only available speci! c 
marker to detect autophagosomes in mammalian cells (Kabeya 
et al., 2000).
 To directly tackle the question of whether calpain is re-
quired in autophagy, we analyzed endogenous LC3 in response 
to ceramide and rapamycin by means of immuno" uorescence 
in wild-type and CAPNS1−/− mouse embryonic ! broblasts 
(MEFs). CAPNS1−/− MEFs, which are also known as calpain 
4−/− MEFs, were derived from CAPNS1 (calpain 4) knockout 
mice and were shown to lack calpain activity (Arthur et al., 
2000). Wild-type and CAPNS1−/− MEFs were induced with 
each stimulus for 3 h or were left untreated. Afterward, the 
cells were ! xed and subjected to immuno" uorescence analysis 
with an anti-LC3 antibody. As shown in Fig. 1 A (top), wild-
type MEFs are faintly labeled by anti-LC3 antibody and show 
a clear induction of autophagosome formation after rapa-
mycin or ceramide treatment. On the other hand, CAPNS1−/− 
MEFs show a higher diffuse background that does not sub-
stantially vary after stimulation with rapamycin or ceramide 
(Fig. 1 A, bottom).
In a parallel experiment, rapamycin and ceramide were 
used to stimulate wild-type and CAPNS1−/− MEFs, and the 
 lysates were analyzed by Western blotting to detect both cyto-
plasmic LC3-I and its proteolytic derivative LC3-II that pref-
erentially associates with autophagosomal membranes (Kabeya 
et al., 2004). In agreement with the immuno" uorescence data, 
both rapamycin and ceramide trigger an increase of LC3II with 
respect to LC3I in wild-type cells, whereas the ratio between 
the two LC3 forms is not considerably altered by both stimuli in 
CAPNS1−/− MEFs (Fig. 1 B).
The fate of endogenous LC3 upon autophagy induction 
was also addressed in human U2OS cells. U2OS cells were 
transfected with a scrambled siRNA (siRNA control) or with a 
CAPNS1-speci! c siRNA. 72 h later, autophagy was induced by 
a 3-h incubation with ceramide, and the cells were either ! xed 
and analyzed by immuno" uorescence or lysed and subjected to 
Western blot analysis. As shown in Fig. 2 A, CAPNS1 depletion 
prevents the formation of bona-! de autophagosomes upon in-
duction with ceramide. Accordingly, the increase in the endoge-
nous membrane-bound LC3II after ceramide treatment is clearly 
defective after CAPNS1 silencing (Fig. 2 B).
Calpain-defi cient cells show a defect 
in lysosomal activation and long-lived 
protein degradation
To further assess the requirement of calpain for the autophagic 
process, we followed the increase of lysosomal activity occurring 
Figure 3. Lysosomal induction and long-lived protein degrada-
tion are hampered in CAPNS1-defi cient MEFs. Wild-type and 
CAPNS1 MEFs were incubated with the stimuli indicated, namely 
rapamycin (rapa), etoposide (ET), EBSS (EBS), serum-free medium 
(sf), and ceramide (cera), in the presence or absence of 3MA and 
were trypsinized, stained with LysoTracker green, and analyzed 
by FACS. (A–D) Representative FACS profi les obtained after Lyso-
Tracker staining of wild-type and CAPNS1−/− MEFs before and 
after rapamycin treatment. The gate set between 101 and 102 
separates the cells with high fl uorescence from the background 
population. (E–G) The histograms report the percentage of cells 
with high LysoTracker staining and represent the mean values 
 obtained in four independent experiments. (H and I) Wild-type 
and CAPNS1−/− MEFs were grown for 4 h in amino acid–free 
medium (H) or in serum-free medium (I) in the presence or absence 
of the autophagy inhibitor 3MA, and, subsequently, long-lived 
protein degradation was scored as the percentage of TCA-soluble 
counts on total radioactivity in a standard protein degradation 
 assay. The histograms report the mean values obtained in four inde-
pendent experiments. Error bars represent SD. SSC, side scatter.
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after autophagy induction by means of LysoTracker staining 
and FACS analysis. Wild-type and CAPNS1−/− MEFs were 
 incubated with rapamycin for 24 h, trypsinized, stained with 
LysoTracker green, and analyzed by FACS. The results ob-
tained in a typical experiment are reported in Fig. 3 (A–D). 
A net increase in the percentage of cells that are highly labeled 
with LysoTracker occurs after rapamycin treatment of wild- 
type MEFs (Fig. 3 C) as compared with control untreated cells 
(Fig. 3 A), clearly showing that rapamycin results in an increase 
in lysosomal activity. On the contrary, in CAPNS1−/− MEFs, 
rapamycin is ineffective in inducing an increase in LysoTracker 
" uorescence intensity (Fig. 3, compare B with D). The mean 
values of the percentage of cells highly labeled by LysoTracker 
obtained in four independent experiments are reported in Fig. 3 E. 
To determine whether the increase in lysosomal activity was 
dependent on macroautophagy induction, 3-methyladenine (3MA) 
was added just before stimulation with rapamycin. 3MA clearly 
inhibits the increase in LysoTracker staining, indicating the 
speci! city of the induction (Fig. 3 E). Next, other autophagic 
stimuli, namely etoposide, starvation in Earle’s balanced salt 
solution (EBSS) or serum-free medium, and ceramide, were 
used to induce autophagy in wild-type and CAPNS1−/− MEFs 
using the same type of assay. As shown in Fig. 3 F, all four 
stimuli induce autophagy-dependent lysosomal activation 
after 3 h in wild-type MEFs but not in CAPNS1−/− MEFs; 
moreover, the increase in LysoTracker labeling is dramati-
cally reduced upon the addition of 3MA just before  induction 
(Fig. 3 G).
To further investigate the requirement of calpain in auto-
phagy, we monitored long-lived protein degradation upon amino 
acid starvation both in wild-type and CAPNS1−/− MEFs ac-
cording to standard protocols (Pattingre et al., 2003). Amino 
acid starvation induces an increase in bulk protein degradation 
in both cell lines. However, such an increase is considerably 
lower in calpain-de! cient cells as compared with wild-type 
cells (Fig. 3 H). A reduction in protein degradation occurs in the 
presence of the inhibitor 3MA in both cell lines, indicating that 
although considerably reduced, autophagy may still occur in 
CAPNS1−/− MEFs as a consequence of amino acid starvation. 
Alternatively, this result might be caused by an effect of 3MA 
on alternative degradation pathways, as a similar effect is also 
observed in autophagy-defective ATG5−/− cells (Mizushima 
et al., 2001). Similar results were obtained by studying long-lived 
protein degradation upon serum starvation (Fig. 3 I), con! rming 
the importance of calpain in activating protein degradation 
through the autophagic process.
Calpain is required for autophagosome 
formation in response to rapamycin
Electron microscopy was used to directly analyze and quantify 
autophagosomes in wild-type and CAPNS1−/− MEFs grown in 
control serum-containing medium and after autophagy induc-
tion with rapamycin or amino acid–free medium (EBSS). The 
morphology of early autophagic vacuole (AV [AVi]) and late AV 
(AVd) pro! les of wild-type MEFs are shown in Fig. 4 (A and B, 
respectively). The quantitative results obtained are represented 
in Fig. 4 C.
These electron microscopy experiments demonstrate that 
in CAPNS1−/− MEFs, autophagosome formation is completely 
abolished in response to rapamycin. In the case of EBSS-
 induced autophagy, CAPNS1−/− MEFs do show autophagosome 
formation but at a substantially reduced level compared with 
wild-type MEFs. In this last case, as shown in Fig. S2 (available 
at http://www.jcb.org/cgi/content/full/jcb.200601024/DC1), 
the morphology of the autophagosomes is not altered in 
CAPNS1−/− MEFs with respect to wild-type MEFs. This led 
us to conclude that the mechanics of autophagosome forma-
tion are still functional in CAPNS1−/− MEFs, however severely 
impaired in their ef! ciency. The diminished accumulation of 
autophagosomes in CAPNS1−/− MEFs maintained in EBSS 
medium may therefore suggest that the dramatic reprogram-
ming of cell functions occurring upon amino acid deprivation 
may also involve the activation of some autophagic pathways 
not strictly requiring calpain function. Alternatively, because 
EBSS possibly represents a stronger and broader stimulus in 
respect to rapamycin, residual calpain activity caused by some 
other calpain isoforms may be suf! cient to trigger autophagy, 
albeit at a reduced level.
This evidence prompted us to monitor Tor activity in both 
cell lines before and after rapamycin treatment using S6 kinase 
phosphorylation as readout. The results shown in Fig. S3 (avail-
able at http://www.jcb.org/cgi/content/full/jcb.200601024/DC1) 
clearly indicate that Tor is active in both cell lines, where it 
is inhibited with similar ef! ciency upon rapamycin addition. 
Figure 4. Autophagosome formation is hampered in CAPNS1−/− MEFs. 
(A and B) The electron micrographs show the ultrastructure of early (A) 
and late autophagosomes (B) in wild-type MEFs. The cell area on the 
grid squares was estimated by point counting using negatives taken at 
600×. (C) Quantifi cation of autophagosomes in wild-type and CAPNS1−/− 
MEFs (knockout) grown in control serum-containing medium (FCS) or 
 induced for 3 h with EBSS (EBS) or rapamycin (Rap). Error bars indi-
cate the SEM. The number of AVi and AVd profi les was counted 
under the  microscope at 12,000× from four to fi ve grid squares for 
each sample.
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Further studies are required to de! ne the key regulatory ele-
ments targeted by  calpain for the ef! cient induction of auto-
phagosome formation.
Ectopic LC3 constitutively forms discrete 
bodies in calpain-defi cient MEFs
A widely used method to study autophagy is monitoring the re-
distribution of the overexpressed autophagosome marker LC3 
from a mostly diffused localization to a punctuated pattern 
upon the addition of an autophagic stimulus. Therefore, in par-
allel to the studies on endogenous LC3, we monitored autopha-
gosome formation after overexpressed GFP-LC3 localization 
in wild-type and CAPNS1−/− MEFs. 16 h after transfection, 
the cells were preincubated with the macroautophagy  inhibitor 
3MA or solvent alone, and ceramide was added for 3 h to 
 induce autophagy (Scarlatti et al., 2004). The cells were sub-
sequently ! xed to analyze overexpressed LC3 by " uorescence 
microscopy. As shown in Fig. 5 A, in wild-type MEFs, LC3 
produces a mostly diffuse staining in the absence of stimulus 
and after 3MA treatment. After induction with ceramide, LC3 
accumulates in the autophagosomes, whose formation is pre-
vented by 3MA pretreatment, indicating the speci! city of 
autophagy induction. However, in CAPNS1−/− MEFs, LC3 
accumulates in speci! c bodies even under basal conditions; 
 incubation with the autophagy inhibitor 3MA in this case does 
not prevent the formation of LC3 spots. In addition, the num-
ber of cells with intensely stained bodies does not substantially 
increase after the addition of ceramide (Fig. 5 B). Each exper-
iment was repeated at least four times, obtaining  reproducible 
results. For each experiment, the percentage of cells with LC3 
bodies was counted, and the mean value ± SD is reported in 
the ! gure. At least 200 cells were analyzed for each indepen-
dent experiment.
To further monitor autophagy induction, wild-type and 
CAPNS1−/− MEFs overexpressing GFP-LC3 were challenged 
with several stimuli that were previously used to induce auto-
phagy, namely rapamycin (Noda and Ohsumi, 1998), amino 
acid–free medium (Neely et al., 1977), serum starvation (Pfeifer, 
1973), and etoposide (Shimizu et al., 2004). All of the treat-
ments triggered autophagosome formation in wild-type MEFs 
(Fig. 5 C) while leaving unchanged the LC3 staining pattern in 
CAPNS1−/− MEFs (not depicted). Altogether, these results fur-
ther suggest that autophagy is impaired in cells lacking calpain 
activity, where overexpressed LC3 constitutively accumulates 
into speci! c bodies.
Calpain silencing is coupled 
to the accumulation of overexpressed 
LC3 in human cells
To verify whether the constitutive accumulation of ectopic LC3 
into the observed speci! c bodies in CAPNS1−/− MEFs was 
a peculiarity of the cell line used or a consequence of calpain in-
activation, we monitored the effect of calpain silencing by siRNA 
on autophagosome formation in the human osteosarcoma cell 
line U2OS. An ATG5-speci! c siRNA that has been previously 
described (Boya et al., 2005) was used as a tool to prevent auto-
phagy, allowing the distinction between true autophagosomes 
and other unde! ned structures containing ectopic LC3. U2OS 
cells were transfected with a scrambled siRNA (siRNA control) 
or with a CAPNS1-speci! c siRNA in combination with ATG5 
siRNA or an ineffective siRNA as a control.
48 h later, the cells were transfected with GFP-LC3, and, 
after an additional 16 h, autophagy was induced by a 3-h incu-
bation with ceramide. The ! xed cells were ! nally analyzed by 
" uorescence microscopy. As shown in Fig. 6 A, LC3 appears 
diffuse in control U2OS cells and, after induction with cera-
mide, becomes associated with autophagosomes, which are not 
formed by speci! cally inhibiting autophagy through ATG5 
siRNA. On the other hand, CAPNS1-silenced U2OS cells show 
LC3-positive bodies in the absence of stimulation, and the 
 distribution of GFP-LC3 is not altered by ATG5 silencing. In 
 addition, the LC3 staining pattern is not considerably affected 
by ceramide (Fig. 6 B).
To mark and analyze the LC3 pattern speci! cally in the 
cells where CAPNS1 is silenced, we developed an siCAPNS1-
GFP p-superior plasmid (siCAPNS1-GFP) allowing the simul-
taneous expression of CAPNS1 siRNA and GFP. In parallel, we 
produced a U2OS-derivative cell line expressing HcRed-LC3 
(U2OS-LC3) as a tool to study autophagy induction. U2OS-
LC3 cells were transfected with a control vector (sicontrol-GFP) 
or with siCAPNS1-GFP plasmid; after 48 h, they were stimu-
lated or left unstimulated with ceramide for 3 h and were ! xed 
and analyzed by " uorescence microscopy.
As shown in Fig. 6 C, in the cells transfected with the 
control plasmid, HcRed-LC3 appears diffuse before induc-
tion and forms autophagosomes after ceramide treatment as 
 expected. However, siCAPNS1-GFP–transfected cells show a 
punctuated LC3 pattern both in the presence and absence of ce-
ramide stimulation. Collectively, the data obtained in U2OS cells 
are in agreement with the data obtained comparing wild-type 
Figure 5. Ectopic LC3 constitutively accumulates in vesicles in CAPNS1−/− 
MEFs. (A–C) Wild-type (A and C) and CAPNS1−/− MEFs (B) were trans-
fected with GFP-rLC3, and, 16 h later, the cells were treated for 3 h with 
the stimuli indicated. Afterward, the cells were fi xed and analyzed by fl uo-
rescence microscopy. Representative fi elds are shown. The different pat-
terns of GFP-LC3 distribution were scored in 250 transfected cells for at 
least three independent experiments. The mean of the percentage of cells 
with intensely stained bodies and relative SD are indicated beneath each 
image. Bar, 20 μm.
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with CAPNS1−/− MEFs, demonstrating that in CAPNS1-
 depleted cells, overexpressed LC3 accumulates in speci! c 
bodies independently of autophagy induction.
Ectopic LC3 bodies constitutively present 
in CAPNS1-depleted cells are enriched 
in endosome markers
To investigate the identity of LC3-containing structures in 
CAPNS1-depleted cells, we analyzed whether overexpressed 
LC3 would eventually colocalize with speci! c endosomal mark-
ers both in control and in CAPNS1-silenced U2OS-LC3 cells. 
48 h after silencing with control or CAPNS1 siRNA, autophagy 
was induced by ceramide together with pepstatin to inhibit lyso-
somal activity and freeze any eventual transient colocalization 
event. Thereafter, the cells were ! xed and subjected to immuno-
" uorescence against the markers LAMP-2, EEA1, and trans-
ferrin receptor and were analyzed by a confocal microscope. 
Representative images are shown in Fig. 7. The colocalization 
of LC3 with the endosomal markers was quanti! ed using ImageJ 
software (colocalizer plug-in). The Pearson correlation coef! -
cient (R) is reported near each merged image. Altogether, the 
data indicate that overexpressed LC3 bodies are enriched in 
 endosome markers speci! cally in calpain-depleted cells.
To precisely de! ne the identity of the LC3-positive bod-
ies that accumulate in calpain-de! cient cells, immunoelectron 
 microcopy studies were performed. U2OS cells were trans-
fected with GFP-LC3 and siRNA speci! c for CAPNS1 as 
 described in the ! rst section of Results and were ! xed in PFA. 
Double labeling with GFP and LAMP-2 antibodies allowed 
us to detect GFP-LC3 bodies and also mark endosomes in the 
same experiment. As expected, GFP-LC3 partly accumulates in 
speci! c bodies, as shown in Fig. 8 (A and B). The gold par-
ticles indicating the presence of GFP-LC3 bodies (Fig. 8, large 
gold dots) were associated with endosome-like structures, 
some of which were also positive for LAMP-2 (Fig. 8; small 
gold dots are indicated by arrowheads). The morphology and 
LAMP-2 labeling pattern of GFP-LC3 structures corresponded 
to that of early endosome-like vesicles, clearly con! rming that 
GFP-LC3 bodies accumulating in CAPNS1-depleted cells are 
not autophagosomes.
Figure 6. Ectopic LC3 forms specifi c bodies in CAPNS1-depleted human 
cells. (A and B) U2OS cells were silenced with a control siRNA (A) or with 
a CAPNS1 siRNA (B) in combination with a control siRNA or ATG5 siRNA 
as indicated. After 48 h, the cells were transfected with GFP-hLC3 and, 16 h 
later, were incubated for 3 h with ceramide or solvent alone as a negative 
control. They were subsequently fi xed and analyzed by fl uorescence 
 microscopy. Representative fi elds are shown. (C and D) A U2OS-derivative 
cell line stably expressing HcRed-hLC3 (U2OS-LC3) was established. 
U2OS-LC3 cells were transfected with si-control-GFP (C) or siCAPNS1-GFP (D) 
expression vectors and, 48 h later, were either treated with ceramide 
or with solvent alone for 3 h as indicated. Finally, the cells were fi xed and 
analyzed by fl uorescence microscopy. The different patterns of GFP-LC3 
distribution were scored in 250 transfected cells for at least three indepen-
dent experiments. Bar, 20 μm.
Figure 7. Ectopic LC3 bodies are enriched with endosome markers in 
CAPNS1-depleted cells. (A–C) U2OS-LC3 cells were silenced with a control 
siRNA or a CAPNS1 siRNA as indicated and, 48 h later, were stimulated 
for 3 h with ceramide to induce macroautophagy. Pepstatin A was added 
to inhibit lysosomal activity and freeze any colocalization event between 
LC3 vesicles and lysosomes. Subsequently, the cells were fi xed, decorated 
with anti–LAMP-2 (A), anti-EEA1 (B), and antitransferrin receptor (TR; C), 
and analyzed by confocal microscopy. Images of representative fi elds 
were taken. The Pearson’s correlation coeffi cient, R, is reported for each 
merge image. Bars, 20 μm.
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The calpain-dependent impairment 
of autophagy sensitizes cells to apoptosis
We have previously reported that ceramide triggers apoptosis 
and induces an NF-κB–dependent prosurvival pathway through 
calpain. Accordingly, in calpain-de! cient cells, apoptosis is 
 enhanced (Demarchi et al., 2005). In this study, we have demon-
strated that calpain is required to induce autophagy in response 
to ceramide, etoposide, and amino acid or serum starvation. 
 Recent studies indicate the existence of a negative cross-regulation 
between autophagy and apoptosis (Yu et al., 2004; Boya et al., 
2005; Takacs-Vellai et al., 2005). However, there are examples 
of a mutual requirement between the two pathways (Camougrand 
et al., 2003; Martin and Baehrecke, 2004). Therefore, we 
 decided to de! ne the effect of the calpain-related autophagy 
block on apoptosis induction in the cellular systems used for 
this study.
Wild-type and CAPNS1−/− MEFs were incubated with 
the autophagy inducers etoposide, ceramide, serum-free me-
dium, EBSS, or vinblastine for 20 h. Afterward, the cells were 
double labeled with annexin V and propidium iodide (PI) and 
were analyzed by FACS. The results obtained in a typical ex-
periment of EBSS induction are reported in Fig. 9 (A–D). The 
histogram presented in Fig. 9 E summarizes the results of four 
independent experiments for each speci! c stimulus. A dramatic 
increase in apoptosis can be seen in calpain-de! cient cells after 
induction with all of the stimuli, with the exception of vinblastine. 
Vinblastine is a microtubule-depolymerizing agent, and, although 
it can trigger an autophagic response, it has inhibitory functions 
on late autophagic events (Punnonen and Reunanen, 1990). 
 Interestingly, we have previously reported that the toxicity of 
taxol, an indirect inhibitor of autophagy by virtue of its block of 
microtubule depolymerization, is almost comparable in wild-type 
and CAPNS1−/− MEFS (Demarchi et al., 2005). Collectively, 
the aforementioned data highlight the cytoprotective potential 
of autophagy in MEFs and strongly argue for a strict correlation 
between the impairment of autophagy in  calpain-de! cient cells 
and induction of the apoptotic switch.
To further con! rm this hypothesis, a similar approach was 
followed using human U2OS cells silenced either with ATG5, 
CAPNS1-speci! c siRNA, or a combination of the two. 48 h af-
ter silencing, the cells were shifted to amino acid–free medium 
and incubated for a further 20 h to trigger autophagy. Cell death 
was then quanti! ed by means of PI and annexin staining fol-
lowed by FACS analysis. Fig. 10 (A–F) presents the results of 
a representative experiment and indicates that both ATG5 and 
CAPNS1 silencing sensitize U2OS cells to apoptosis induced 
by amino acid starvation. The mean values obtained in four in-
dependent experiments are reported in Fig. 10 G. The effect of 
CAPNS1 silencing is the most severe, suggesting that CAPNS1 
depletion in addition to the block of autophagy also prevents 
other antiapoptotic mechanisms such as NF-κB activation 
(Demarchi et al., 2005).
Discussion
In this study, we demonstrate that calpain regulates macroauto-
phagy in two cellular systems lacking calpain activity: MEFs 
derived from CAPNS1 knockout mice and CAPNS1-silenced 
Figure 8. GFP-LC3 bodies in CAPNS1-depleted cells are 
 endosome-like structures. Representative immunoelectron micro-
scopy micro photographs showing the ultrastructure of GFP-LC3 
bodies in CAPNS1-depleted U2OS cells. Large gold dots mark 
GFP-positive structures, whereas small gold dots (indicated by 
arrowheads) are labeled with anti–LAMP-2.
Figure 9. CAPNS1−/− MEFs are more sensitive to apoptosis. (A–D) Wild-
type and CAPNS1−/− MEFs were treated with etoposide (ET), ceramide 
(cera), EBSS, serum-free medium (sf), and vinblastine (vin) or left in control 
medium (cont) for 20 h and stained with PI and annexin V–FITC. A set of 
representative experiments with EBSS is shown. The cells in the bottom right 
quadrant were scored as apoptotic. (E) The mean values obtained in four 
independent experiments with all of the stimuli. Error bars represent SD.
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human cells. In addition, we shed some light on the relationship 
between apoptosis and autophagy.
Calpains are activated by several stimuli that trigger macro-
autophagy, including starvation (Gomez-Vicente et al., 2005), 
ceramide (Tanabe et al., 1998; Demarchi et al., 2005), etoposide 
(Varghese et al., 2001), and arsenic trioxide ( Karlsson et al., 
2004). Milli- and microcalpain, which both require CAPNS1 for 
activity, are localized at the endoplasmic reticulum and Golgi, 
where the autophagic machinery works (Kihara et al., 2001; 
Pattingre et al., 2005).
In both calpain-null systems used in this study, de! cient 
autophagy was shown by four different approaches: analysis of 
exogenous and endogenous LC3 by immuno" uorescence and 
Western blotting, quanti! cation of lysosomal induction, long-
lived protein degradation assays, and electron microscopy. 
 Altogether, the data presented indicate that in CAPNS1-de! cient 
cells, the autophagic program is not ef! ciently activated. As a 
result of this defect, CAPNS1-de! cient cells are more sensitive 
to apoptosis induced by several autophagic stimuli, including 
ceramide, etoposide, and starvation.
In light of our ! ndings connecting calpain and auto phagy, 
it will be interesting to investigate this relationship in vivo 
under physiological and pathological conditions as well as in 
response to chemotherapy. Previously reported data lend sup-
port to such a possibility. The dual role of autophagy has been 
seen during cancer progression, where, at the initial stages, auto-
phagy prevents tumor growth (Liang et al., 1999), whereas at 
advanced stages, it might favor tumor cell survival (Paglin et al., 
2001). An example of this is calpain 9, which appears to be a 
 tumor suppressor of gastric cancer, whereas calpain activation 
has been shown to be involved in cell transformation and invasion 
(Carragher and Frame, 2002; Xu and Deng, 2004).
Most interestingly, this parallel is maintained in other 
 degenerative pathologies. Autophagy is protective during the 
initial stages of neurodegeneration (Webb et al., 2003; Ravikumar 
et al., 2004), whereas it becomes deleterious at later stages (Yue 
et al., 2002). A similar dual role could be played by calpain in 
neuronal diseases, where it may be protective at the initial stages 
of neurodegeneration (Kim et al., 2003) and  hyperactivated and 
detrimental at advanced stages (Park and Ferreira, 2005). A de-
tailed investigation of the molecular cross talk between these 
two systems in living organisms might be instrumental for per-
forming appropriate strategies of mole cular intervention.
The precise molecular network linking autophagy, apop-
tosis, and other types of cell death is still unresolved (Assuncao 
Guimaraes and Linden, 2004; Kroemer and Jaattela, 2005). 
 Autophagy is protective against low radiation damage (Paglin 
et al., 2001) and against mutant huntingtin-induced cell death 
(Bjorkoy et al., 2005); it is essential for maintaining cell 
 survival after growth factor withdrawal in Bax−/−Bak−/− cells 
(Lum et al., 2005). Furthermore, the inhibition of macroauto-
phagy triggers apoptosis (Boya et al., 2005; Gonzalez-Polo 
et al., 2005). On the other hand, autophagy is coupled to cell 
death in Bax−/−Bak−/− MEFs (Shimizu et al., 2004) and in 
tamoxifen-treated MCF7 cells (Bursch et al., 2000). In addition, 
autophagy and apoptosis are positively interconnected in sev-
eral systems, including Drosophila development (Baehrecke, 
2003), rat retinal tissue development (Guimaraes et al., 2003), 
and peripheral nerves of adult rats after damage (Xue et al., 
1999). Collectively, our data further support the argument that 
macroautophagy is a survival strategy activated both in response 
to serum and amino acid deprivation. In addition, we have 
shown that macroautophagy is activated and also plays a protec-
tive role upon treatment with speci! c drugs, such as etoposide 
and ceramide; thus, the knockdown of autophagy could be a 
strategy for improving chemotherapy protocols.
Ectopic LC3 is a powerful tool to study autophagy 
 (Kabeya et al., 2000). In this study, we con! rmed that in MEFs 
and U2OS human osteosarcoma cells, the formation of LC3 
 autophagosomes is ef! ciently inhibited by treatment with the 
 autophagy inhibitor 3MA and by siRNA-mediated depletion of 
the essential autophagy gene ATG5, respectively. However, in 
CAPNS1−/− MEFs and siCAPNS1-depleted cells, we observed 
that ectopic LC3 constitutively accumulates in the absence of 
any speci! c autophagic stimulus into cytoplasmic endosome-
like bodies enriched with endosomal markers. Therefore, we 
hypothesize that such LC3 bodies could represent a default 
or salvage lysosomal pathway for protein degradation with 
slower clearance kinetics, which becomes manifest in a calpain-
 de! cient cellular context. A similar pathway may be predicted 
for the endogenous proteins that accumulate in diseases coupled 
to autophagy defects.
Figure 10. Depletion of CAPNS1 results in increased apoptosis in human 
cells. U2OS cells were transfected with a siRNA specifi c for CAPNS1, 
ATG5, or a combination of the two. An ineffective siRNA was used as a 
negative control. 48 h later, the cells were shifted to amino acid–free me-
dium for an additional 20 h, stained with PI and annexin-FITC, and ana-
lyzed by FACS. (A–F) Results of a set of representative experiments. (G) The 
mean of the values obtained in four independent experiments. Bars indi-
cate the percentage of annexin-positive cells with high (h) PI staining (top 
right quadrant in A–F) and low (l) PI staining (bottom right quadrant in A–F). 
Error bars represent SEM.
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Further studies are required to analyze the detailed mech-
anisms involving calpains in the formation of autophagosomes 
and in lysosomal-mediated protein degradation pathways. 
Given the strategic localization of milli- and microcalpain at 
the endoplasmic reticulum, it would be tempting to speculate 
that calpain may play a role in the delivery of membranes to 
the autophagosome. Alternatively, calpain could modulate one 
or more key components of the signaling networks, ultimately 
leading to autophagosome formation. The complete block 
of autophagosome formation occurring in rapamycin-treated 
CAPNS1−/− MEFs favors such a possibility.
Materials and methods
Chemicals and reagents
C2 ceramide, bafi lomycin, pepstatin A, 3MA, rapamycin, and etoposide 
were purchased from Sigma-Aldrich. LipofectAMINE reagent and Oligo-
fectamine were purchased from Invitrogen. SMARTpool for CAPNS1 si-
lencing was obtained from Dharmacon. Micro- and millicalpain siRNAs 
were purchased from Santa Cruz Biotechnology, Inc.
Plasmids and constructs
HcRed-hLC3 and pGFP-hLC3 were constructed by inserting human LC3 in 
HcRed and pGFP plasmid, respectively. The plasmid pGFP-rLC3 was a gift 
from T. Yoshimori (National Institute of Genetics, Shizuoka, Japan). The 
plasmid siCapns1-GFP was obtained by subcloning a double-stranded 
 oligonucleotide containing a sequence complementary to CAPNS1 siRNA 
into commercial p-superior–GFP plasmid according to the manufacturer’s 
instructions. All constructs were checked by sequence analysis.
Cell culture
Wild-type and CAPNS1−/− MEFs (Dourdin et al., 2001) were gifts from 
P.A. Greer (Queen’s University, Kingston, Ontario, Canada). U2OS cells 
and the aforementioned mouse fi broblasts were grown in DME supple-
mented with 10% FCS.
Immunological procedures and quantifi cations
Standard protocols for immunoblotting and immunofl uorescence were 
used. Rabbit serum raised against LC3 was provided by T. Yoshimori. 
Monoclonal antibody against LAMP-2 was purchased from BD  Biosciences. 
LAMP-1–specifi c antibody was purchased from Santa Cruz  Biotechnology, 
Inc., and monoclonal anti-CAPNS1 was purchased from Sigma-Aldrich. 
Monoclonal antitransferrin receptor (OKT9) was previously described 
(Sutherland et al., 1981). Band quantifi cation from Western blots was 
performed using the Image 1.63.sea program (Scion). Secondary anti-
bodies for immunofl uorescence were FITC conjugated, and the cells were 
mounted using Mowiol medium. Analysis and acquisition were performed 
using a confocal laser-scanning microscope (Axiovert 100 M; Carl Zeiss 
MicroImaging, Inc.) with a 63× NA 1.25 or 100× NA 1.30 oil objec-
tive (Leica) at room temperature. Images were imported using LSM-510 
software (Carl Zeiss MicroImaging, Inc.). ImageJ software (National 
 Institutes of Health) was used to quantify the colocalization observed 
by immunofl uorescence.
Transfection
Stable transfections of U2OS cells with HcRed-LC3 were performed by the 
calcium phosphate method using standard procedures. U2OS, CAPNS1−/−, 
and control mouse fi broblasts at 60–80% confl uency were transiently 
transfected or oligofected using FuGene (Roche) or Oligofectamine (Life 
Technologies) according to the manufacturer’s instructions.
Statistical analysis
Results are expressed as means ± SD of at least three independent experi-
ments performed in triplicate or quadruplicate unless indicated otherwise. 
Statistical analysis was performed using a t test, with the level of signifi -
cance set at P < 0.05.
LysoTracker labeling and quantifi cation
To label lysosomes, LysoTracker green (Invitrogen) was used at a fi nal con-
centration of 75 nM. The cells induced for 3 or 24 h with the stimuli were 
trypsinized, resuspended in phenol-free DME, 10% FCS, and 75 nM Lyso-
Tracker green, incubated for 30 min at 37°C, and analyzed with the Cell-
Quest program (BD Biosciences) by FacsCalibur (Becton Dickinson).
Protein degradation assay
Cells were labeled in complete medium in the presence of [14C]valine for 
18 h, washed, and incubated with cold medium for 1 h to allow the degra-
dation of short-lived proteins. Then, after extensive washing, the medium 
was replaced with EBSS for 4 h in the presence or absence of 10 mM 
3MA. Finally, the proteins were precipitated with TCA, and radioactivity 
was measured. Protein degradation was calculated as the percentage of 
TCA-soluble counts on total radioactivity.
Electron microscopy
Monolayers were fi xed in 2% glutaraldehyde in 0.2 M Hepes, pH 7.4, for 
2 h and were scraped off the dish during fi xation. The pellets were embed-
ded in Epon using routine procedures. Approximately 60-nm sections were 
cut and stained using uranyl acetate and lead citrate and were examined 
with an electron microscope (JEM 1200EXII; JEOL). The number of AVi and 
AVd profi les was counted under the microscope by systematically screen-
ing the sections at 12,000× using grid squares as sampling units, as previ-
ously described (Eskelinen et al., 2004).
All AVs occurring in the grid were recorded. The area of cells on 
each grid square was estimated by point counting using photographic 
negatives taken at 600×. Four to fi ve grid squares were screened for each 
sample. The number of vacuoles per cell area was then counted for each 
grid square separately.
For immunogold electron microscopy, U2OS cells were fi xed in 4% 
PFA in 0.2 M Hepes, pH 7.4, for 2 h at room temperature and were further 
processed as previously described (Eskelinen et al., 2002). The cell sec-
tions were analyzed by immunogold electron microscopy with rabbit 
anti-GFP and mouse anti–LAMP-2 antibodies followed by the secondary 
antibodies goat anti–rabbit conjugated to 10 nm gold and goat anti–mouse 
coupled to 5 nm gold.
Annexin V and PI staining and FACS analysis
Translocation of phosphatidylserine to the cell surface was monitored by 
using an annexin V–FITC apoptosis detection kit (Sigma-Aldrich). Cells 
were trypsinized, washed in PBS, and resuspended in binding buffer 
(10 mM Hepes/NaOH, pH 7.4, 140 mM NaCl, and 2.5 mM CaCl2). Cell 
density was adjusted to 2–5 × 105 cells/ml. 1 μl of recombinant human 
annexin V–FITC/a and 2 μl PI were added to 100 μl of cell suspension; 
the mixture was briefl y mixed and incubated for 10 min at room tempera-
ture in the dark. Afterward, 400 μl of binding buffer was added to the cells 
that were then analyzed by FACScan (Becton Dickinson). 15,000 events 
were collected in list mode fashion, stored, and analyzed by CellQuest 
software (BD Biosciences).
Online supplemental material
Fig. S1 shows that the depletion of microcalpain impairs  macroauto phagy. 
Fig. S2 shows that the fi ne ultrastructure of autophagosomes is not al-
tered in CAPNS1−/− MEFs. Fig. S3 shows that rapamycin inhibits Tor 
activity in wild-type and CAPNS1−/− MEFs. Fig. S4 shows that LC3II is 
associated with membranes in CAPNS1−/− MEFs. Fig. S5 shows that 
the induction of LysoTracker-labeled bodies is reduced in CAPNS1−/− MEFs. 
Online supplemental material is available at http://www.jcb.org/cgi/
content/full/jcb.200601024/DC1.
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ABSTrACT
Ubiquitously expressed m- and m-calpain proteases consist of 80-kDa catalytic subunits 
encoded by the Capn1 and Capn2 genes, respectively, and a common 28-kDa regula-
tory subunit encoded by the calpain small 1 (Capns1) gene.
The m- and m-calpain proteases have been implicated in both pro- or anti-apoptotic 
functions. We have found that Capns1 depletion is coupled to increased sensitivity to 
apoptosis triggered by a number of autophagy-inducing stimuli in mammalian cells. 
Therefore we investigated the involvement of calpains in autophagy using MEFs derived 
from Capns1 knockout mice and Capns1 depleted human cells as model systems.
We found that autophagy is impaired in Capns1-deficient cells by immunostaining 
of the endogenous autophagosome marker LC3 and electron microscopy experiments. 
Accordingly, the enhancement of lysosomal activity and long-lived proteins degradation, 
normally occurring upon starvation, are also reduced.
In Capns1-depleted cells ectopic LC3 accumulates in early endosome-like vesicles that 
might represent a salvage pathway for protein degradation when autophagy is defective.
BACKgrounD
Calpains	 constitute	 a	 family	 of	 sixteen	 intracellular	 nonlysosomal	 Ca2+-regulated	
cysteine	 proteases,	 mediating	 regulatory	 cleavages	 of	 specific	 substrates	 involved	 in	 a	
number	of	processes	during	differentiation,	life	and	death	of	the	cell.1	Their	most	studied	
involvement	is	in	the	regulation	of	the	dynamic	rearrangements	of	cytoskeletal	architec-
ture	during	cell	migration2:	depending	on	the	cellular	context,	a	range	of	stemming	effects	
have	been	shown	to	be	controlled	by	calpains	 such	as	 synaptic	 function/remodelling	 in	
neurons3	or	angiogenesis	in	endothelial	cells.4
m-calpain	and	m-calpain,	encoded	by	Capn1	and	Capn2,	respectively,	are	ubiquitously	
expressed	and	require	a	common	28-kDa	regulatory	subunit	encoded	by	the	Capns1 gene	
for	stability	and	activity.	Targeted	disruption	of	Capns1	is	embryonic	lethal	at	day	10–11,	
due	to	severe	defects	in	vascular	development.5	Both	m-calpain	and	m-calpain	are	specifically	
inhibited	by	 calpastatin,	which	binds	 them	 in	 a	 substrate	 competitive	manner1	 and	by	
Gas2,6	a	component	of	the	microfilament	network	system,	specifically	induced	at	growth	
arrest.7
The	 calpain/calpastatin	 system	 associates	 with	 the	 membranes	 of	 the	 endoplasmic	
reticulum,	 Golgi	 apparatus,	 and	 plasma	 membrane,	 as	 well	 as	 lipid	 rafts,	 through	
hydrophobic	 interactions.	 Such	 specific	 compartmentalization	 of	 the	 calpain	 network	
seems	 to	 regulate	 the	 access	 to	Ca(2+)-rich	microdomains	 and	 to	membrane-associated	
phosphoinositides8	both	involved	in	the	activation	of	calpain	enzymatic	activity.
We	have	shown	that	inhibition	of	m-calpain	throught	Gas2	binding	increases	suscep-
tibility	 to	 p53-dependent	 apoptosis6	 and	 the	 free	 transcriptional	 competent	 b-catenin	
pool.9	 In	addition,	 calpain	 is	 required	 for	NF-kB	activation	 in	 response	 to	ceramide.10	
Interference	with	calpain	activity	indeed	strengthens	the	pro-apoptotic	effect	of	ceramide.	
This	finding	led	us	to	explore	the	involvement	of	calpain	in	autophagy.	We	discovered	that	
in	calpain-deficient	cells	autophagy	is	impaired,	thus	contributing	to	the	apoptotic	switch.	
The	 involvement	of	calpain	 in	necrosis	and	apoptosis	 is	well	established.1	Very	recently	
Yousefi	et	al.	reported	that	calpain	could	cleave	the	autophagy	protein	Atg5,	determining	
a	switch	from	autophagy	to	apoptosis.11	Altogether	these	data	could	indicate	that	calpain	
is	 active	 at	 all	 subsequent	 stages	 of	 the	 stress	 response	 leading	 to	 divergent	 biological	
outcomes	 depending	 on	 the	 specific	 timing,	 the	 compartment	 where	 the	 enzyme	 is	
activated	and	the	endogenous	substrates	with	respect	to	the	specialized	functions	of	the	
responding	cells.
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IS CALpAIn InvoLvED In AuTophAgy?
To	directly	tackle	the	question	of	the	role	of	calpain	in	autophagy	
we	 compared	 endogenous	LC3	upon	 autophagy	 induction	 in	wild	
type	versus	Capns1-/-	MEFs	and	in	human	U2OS	osteosarcoma	cells	
versus	calpain-depleted	U2OS.
In	both	cellular	systems	autophagic	stimuli	trigger	an	increase	of	
membrane-bound	 LC3II	with	 respect	 to	 uncleaved	 LC3I,	 whereas	
the	ratio	between	the	two	LC3	forms	is	not	significantly	altered	upon	
autophagy	 induction	 in	 Capns1-/-	 MEFs	 and	 in	 Capns1-depleted	
U2OS.
The	final	result	of	the	autophagic	process	is	protein	degradation	
in	the	lysosome.	Therefore	we	monitored	long-lived	proteins	degra-
dation	 as	well	 as	 induction	 of	 lysosomal	 activity	 upon	 amino	 acid	
starvation	in	wild	type	and	Capns1-/-	MEFs.	Both	readouts	allowed	
us	 to	 further	 underscore	 the	 requirement	 of	 calpain	 for	 efficient	
autophagy.
Although	 immunocytochemistry	 and	protein	degradation	 assays	
are	 increasingly	 accepted	 as	 reliable	 tools	 to	 investigate	 autophagy,	
electron	microscopy	 still	 remains	 the	 gold	 standard	 technique.	We	
demonstrated	that	in	Capns1-/-	MEFs	autophagosome	formation,	as	
followed	by	electron	microscopy,	is	completely	abolished	in	response	
to	 rapamycin.	 In	 the	 case	 of	 EBSS-induced	 autophagy,	 Capns1-/-	
MEFs	do	show	autophagosome	formation,	however,	at	a	significantly	
reduced	level	compared	to	wild	type	MEFs.
Further	 studies	 are	 required	 to	analyze	 the	detailed	mechanisms	
involved	 in	 the	 specific	 interference	of	 calpain	 in	 the	 formation	of	
autophagosomes	 and	 the	 consequent	 effects	 in	 lysosomal-mediated	
protein	degradation	pathways.
how DoES CALpAIn moDuLATE AuTophAgy?
Interestingly	we	have	found	that	ectopic	GFP-LC3	constitutively	
forms	 discrete	 bodies	 in	 calpain-deficient	 MEFs.	 Accordingly,	
Capns1-silenced	U2OS	cells	 show	GFP-LC3	positive	bodies	 in	 the	
absence	 of	 stimulation,	 and	 the	 distribution	 of	 GFP-LC3	 is	 not	
altered	by	Atg5	silencing.	Ectopic	LC3	bodies	constitutively	present	
in	 Capns1-/-	 MEFs	 and	 in	 Capns1-depleted	 U2OS	 cells	 have	 an	
endosome-like	 ultrastructure	 and	 are	 enriched	 in	 the	 endosome	
marker	LAMP1.
Given	the	strategic	localization	of	m-	and	m-calpain	at	the	endo-
plasmic	 reticulum,	 it	 would	 be	 tempting	 to	 speculate	 that	 calpain	
might	play	a	role	in	the	delivery	of	membranes	to	the	phagophore.	
Interestingly	Rim13,	the	calpain-like	protease	of	yeast,	interacts	with	
Vid22,	a	plasma	membrane	protein	involved	in	vacuole	import	and	
degradation.	It	also	interacts	with	Snf7,	a	protein	recruited	from	the	
cytoplasm	to	the	endosomal	membrane,	which	works	in	the	sorting	
of	transmembrane	proteins	into	the	multivesicular	body	pathway.12
Mammalian	calpain	could	modulate	one	or	more	key	components	
of	the	signalling	and	trafficking	networks	involved	in	autophagosome	
formation.	The	complete	block	of	autophagosome	formation	occur-
ring	 in	rapamycin	treated	Capns1-/-	MEFs	favors	 such	a	possibility.	
In	particular	calpain	could	have	a	broad	interfering	effect	on	phos-
phoinositide	signalling,	eventually	regulating	phosphatases	localized	
at	 specific	 membrane	 compartments.	 Indeed	 very	 recent	 studies	
demonstrated	 that	 calpain	 deficiency	 is	 coupled	 to	 alterations	 in	
Akt13	and	JNK	signalling.14
A	 second,	 non	 exclusive,	mechanism	 could	 be	 the	 requirement	
of	 calpain	 in	 the	 processing	 of	 cytoskeletal	 connections,	 possibly	
organized	 through	 the	 microtubule	 network,	 which	 prevent/block	
the	maturation	of	the	isolation	membrane	to	an	autophagosome.	A	
candidate	substrate	could	be	spectrin	that	was	shown	to	recruit	the	
dynactin-dynein	complex	to	membrane	phospholipids,	thus	playing	
an	 essential	 role	 in	 the	 retrograde	 axonal	 transport	 of	 a	 number	
of	 vesicular	 cargoes.15	 Interestingly,	 a	 recent	 study	 showed	 that	
microtubules	 support	production	of	 starvation-induced	autophago-
somes	 and	 not	 their	 targeting	 and	 fusion	 with	 lysosomes.16	 The	
authors	of	these	findings	propose	that	microtubules	serve	to	deliver	
only	 mature	 autophagosomes	 for	 degradation	 providing	 a	 spatial	
barrier	between	phagophores	and	lysosomes.
It	 is	 well	 established	 that	 calpain	 is	 essential	 for	 microfilament	
dynamics	 at	 the	 leading	 edge	 of	 a	migrating	 cell.2	We	hypothesize	
that	it	could	play	a	similar	role	in	orchestrating	the	dynamic	changes	
of	the	cytoskeleton	coupled	to	autophagosome	formation.
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Figure 1. Calpain may act at two possible regulatory steps of autophago-
some formation. Calpain resides in the endoplasmic reticulum and can 
orchestrate membrane delivery to the isolation membrane. Alternatively 
calpain may be required to remove some block regulating the formation of 
the autophagosome from the isolation membrane.
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